Document and Entity Information
Document and Entity Information | 6 Months Ended |
Jun. 30, 2022 | |
Document and Entity Information [Abstract] | |
Document Type | POS AM |
Entity Registrant Name | SmartKem, Inc. |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity Central Index Key | 0001817760 |
Amendment Flag | true |
Amendment Description | AMENDMENT NO. 1 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Current assets: | |||||||
Cash and cash equivalents | $ 7,757 | $ 12,226 | $ 764 | ||||
Accounts receivable | 4 | 18 | |||||
Research and development tax credit receivable | 1,505 | 1,070 | 982 | ||||
Prepaid expenses and other current assets | 1,815 | 802 | 259 | ||||
Total current assets | 11,081 | 14,098 | 2,023 | ||||
Property, plant equipment, net of accumulated depreciation of $1,090 and $1,102 | 677 | 802 | 682 | ||||
Right-of-use assets, net | 549 | 154 | 236 | ||||
Other assets | 6 | 6 | 8 | ||||
Total assets | 12,313 | 15,060 | 2,949 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Accounts payable and accrued expenses | 1,190 | 1,423 | 861 | ||||
Current lease liabilities | 208 | 87 | 217 | ||||
Total current liabilities | 1,398 | 1,510 | 1,078 | ||||
Non-current lease liabilities | 320 | 28 | 20 | ||||
Total liabilities | 1,718 | 1,538 | 1,098 | ||||
Commitments and contingencies (Note 8) | |||||||
Stockholders' Equity: | |||||||
Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 26,949,282 and 25,554,309 shares issued and outstanding, at June 30, 2022 and December 31, 2021, respectively | 3 | 3 | 1 | ||||
Additional paid-in capital | 92,612 | 89,954 | 61,276 | ||||
Accumulated other comprehensive loss | (485) | (1,363) | (1,480) | ||||
Accumulated deficit | (81,535) | (75,072) | (57,946) | ||||
Total Stockholders' equity | 10,595 | $ 12,897 | 13,522 | $ 18,564 | $ 20,825 | 1,851 | $ (5,083) |
Total Liabilities and Stockholders' Equity | $ 12,313 | $ 15,060 | $ 2,949 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Condensed Consolidated Balance Sheets | |||
Property, plant equipment, net of accumulated depreciation | $ 1,090 | $ 1,102 | $ 908 |
Common shares, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 |
Common Stock, Shares Authorized | 300,000,000 | 300,000,000 | 300,000,000 |
Common Stock, Shares Issued | 26,949,282 | 25,554,309 | 13,627,887 |
Common Stock, Shares Outstanding | 26,949,282 | 25,554,309 | 13,627,887 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss $ in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||
Jun. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2022 USN ($) shares | Mar. 31, 2022 USD ($) | Jun. 30, 2021 USD ($) $ / shares shares | Jun. 30, 2021 USN ($) shares | Mar. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2022 USN ($) shares | Jun. 30, 2021 USD ($) $ / shares shares | Jun. 30, 2021 USN ($) shares | Dec. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2021 USN ($) shares | Dec. 31, 2020 USD ($) $ / shares shares | Dec. 31, 2020 USN ($) shares | |
Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||
Revenue | $ 4 | $ 34 | $ 18 | $ 94 | ||||||||||
Cost of revenue | 2 | 25 | 8 | 55 | ||||||||||
Gross profit | 2 | 9 | 10 | 39 | ||||||||||
Other operating income | 294 | $ 256 | 578 | $ 688 | 1,285 | 1,437 | ||||||||
Operating Expenses: | ||||||||||||||
Research and development | 1,344 | 1,355 | 2,802 | 5,369 | 8,199 | 4,319 | ||||||||
Selling, general and administrative | 1,370 | 1,345 | 2,611 | 5,328 | 8,069 | 1,707 | ||||||||
Transaction expenses | 16 | 1,329 | 1,329 | $ 1,329 | ||||||||||
Total operating expenses | 2,714 | 2,716 | 5,413 | 12,026 | 17,597 | 6,026 | ||||||||
Loss from operations | (2,418) | (2,460) | (4,826) | (11,338) | (16,302) | (4,550) | ||||||||
Non-operating (Expense)/Income | ||||||||||||||
(Loss)/Gain on foreign currency transactions | (1,284) | $ (1,284) | 57 | $ (57) | (1,638) | $ (1,638) | (412) | $ (412) | (808) | |||||
Other income | 1 | |||||||||||||
Interest expense | (19) | (19) | (6,835) | |||||||||||
Interest income | 1 | 2 | 1 | 2 | 3 | 3 | ||||||||
Change in fair value of derivative asset | (6,282) | |||||||||||||
Loss on conversion of convertible notes payable | (5,470) | |||||||||||||
Total non-operating (expense)/income | (1,283) | 59 | (1,637) | (429) | (824) | (18,583) | ||||||||
Loss before income taxes | (3,701) | (2,401) | (6,463) | (11,767) | (17,126) | $ (17,126) | (23,133) | $ (23,133) | ||||||
Net loss | (3,701) | $ (2,762) | (2,401) | $ (9,366) | (6,463) | (11,767) | (17,126) | (23,133) | ||||||
Other comprehensive loss: | ||||||||||||||
Foreign currency translation | 722 | $ 156 | 15 | $ 17 | 878 | 33 | 117 | (284) | ||||||
Total comprehensive loss | $ (2,979) | $ (2,386) | $ (5,585) | $ (11,734) | $ (17,009) | $ (23,417) | ||||||||
Basic net loss per common share | $ / shares | $ (0.13) | $ (0.09) | $ (0.23) | $ (0.52) | $ (0.68) | $ (1.80) | ||||||||
Diluted net loss per common share | $ / shares | $ (0.13) | $ (0.09) | $ (0.23) | $ (0.52) | $ (0.68) | $ (1.80) | ||||||||
Basic weighted average shares outstanding | shares | 28,751,365 | 28,751,365 | 27,066,385 | 27,066,385 | 28,595,550 | 28,595,550 | 22,733,033 | 22,733,033 | 25,233,384 | 25,233,384 | 12,821,748 | 12,821,748 | ||
Diluted weighted average shares outstanding | shares | 28,751,365 | 28,751,365 | 27,066,385 | 27,066,385 | 28,595,550 | 28,595,550 | 22,733,033 | 22,733,033 | 25,233,384 | 25,233,384 | 12,821,748 | 12,821,748 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Common stock | Additional Paid-in Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Total |
Beginning Balance at Dec. 31, 2019 | $ 30,926 | $ (1,196) | $ (34,813) | $ (5,083) | |
Beginning Balance (in shares) at Dec. 31, 2019 | 2,183,885 | ||||
Issuance of common shares due to exercise of stock-options (in shares) | 0 | ||||
Foreign currency translation adjustment | (284) | $ (284) | |||
Net loss | (23,133) | (23,133) | |||
Issuance of common stock | 4,592 | 4,592 | |||
Issuance of common stock (in shares) | 2,548,877 | ||||
Conversion of notes and interest | $ 1 | 25,758 | 25,759 | ||
Conversion of notes and interest (in shares) | 8,895,125 | ||||
Ending Balance at Dec. 31, 2020 | $ 1 | 61,276 | (1,480) | (57,946) | 1,851 |
Ending Balance (in shares) at Dec. 31, 2020 | 13,627,887 | ||||
Issuance of common shares due to exercise of stock-options | $ 1 | 19 | 20 | ||
Issuance of common shares due to exercise of stock-options (in shares) | 1,404,813 | ||||
Stock-based compensation expense | 6,020 | 6,020 | |||
Repurchase of common stock (in shares) | (2,307,700) | ||||
Effect of reverse capitalization (in shares) | 2,500,000 | ||||
Issuance of common shares to vendor | 99 | 99 | |||
Issuance of common shares to vendor (in shares) | 50,000 | ||||
Issuance of common stock and warrants in private placement | $ 1 | 24,637 | 24,638 | ||
Issuance of common stock and warrants in private placement (in shares) | 10,162,000 | ||||
Issuance costs related to common stock and warrants in private placement | (2,454) | (2,454) | |||
Foreign currency translation adjustment | 17 | 17 | |||
Net loss | (9,366) | (9,366) | |||
Ending Balance at Mar. 31, 2021 | $ 3 | 89,597 | (1,463) | (67,312) | 20,825 |
Ending Balance (in shares) at Mar. 31, 2021 | 25,437,000 | ||||
Beginning Balance at Dec. 31, 2020 | $ 1 | 61,276 | (1,480) | (57,946) | 1,851 |
Beginning Balance (in shares) at Dec. 31, 2020 | 13,627,887 | ||||
Issuance costs related to common stock and warrants in private placement | (2,454) | ||||
Foreign currency translation adjustment | 33 | ||||
Net loss | (11,767) | ||||
Ending Balance at Jun. 30, 2021 | $ 3 | 89,722 | (1,448) | (69,713) | 18,564 |
Ending Balance (in shares) at Jun. 30, 2021 | 25,462,000 | ||||
Beginning Balance at Dec. 31, 2020 | $ 1 | 61,276 | (1,480) | (57,946) | 1,851 |
Beginning Balance (in shares) at Dec. 31, 2020 | 13,627,887 | ||||
Issuance of common shares due to exercise of stock-options | $ 1 | 19 | $ 20 | ||
Issuance of common shares due to exercise of stock-options (in shares) | 1,424,622 | 1,424,622 | |||
Stock-based compensation expense | 6,196 | $ 6,196 | |||
Repurchase of common stock (in shares) | (2,307,700) | ||||
Effect of reverse capitalization (in shares) | 2,500,000 | ||||
Issuance of common shares to vendor | 280 | 280 | |||
Issuance of common shares to vendor (in shares) | 147,500 | ||||
Issuance of common stock and warrants in private placement | $ 1 | 24,637 | 24,638 | ||
Issuance of common stock and warrants in private placement (in shares) | 10,162,000 | ||||
Issuance costs related to common stock and warrants in private placement | (2,454) | (2,454) | |||
Foreign currency translation adjustment | 117 | 117 | |||
Net loss | (17,126) | (17,126) | |||
Ending Balance at Dec. 31, 2021 | $ 3 | 89,954 | (1,363) | (75,072) | 13,522 |
Ending Balance (in shares) at Dec. 31, 2021 | 25,554,309 | ||||
Beginning Balance at Mar. 31, 2021 | $ 3 | 89,597 | (1,463) | (67,312) | 20,825 |
Beginning Balance (in shares) at Mar. 31, 2021 | 25,437,000 | ||||
Stock-based compensation expense | 75 | 75 | |||
Issuance of common shares to vendor | 50 | 50 | |||
Issuance of common shares to vendor (in shares) | 25,000 | ||||
Foreign currency translation adjustment | 15 | 15 | |||
Net loss | (2,401) | (2,401) | |||
Ending Balance at Jun. 30, 2021 | $ 3 | 89,722 | (1,448) | (69,713) | 18,564 |
Ending Balance (in shares) at Jun. 30, 2021 | 25,462,000 | ||||
Beginning Balance at Dec. 31, 2021 | $ 3 | 89,954 | (1,363) | (75,072) | 13,522 |
Beginning Balance (in shares) at Dec. 31, 2021 | 25,554,309 | ||||
Stock-based compensation expense | 98 | 98 | |||
Issuance of common shares to vendor | 43 | 43 | |||
Issuance of common shares to vendor (in shares) | 12,500 | ||||
Issuance of common stock in private placement | 2,000 | 2,000 | |||
Issuance of common stock in private placement (in shares) | 1,000,000 | ||||
Issuance costs related to common stock and warrants in private placement | (160) | (160) | |||
Foreign currency translation adjustment | 156 | 156 | |||
Net loss | (2,762) | (2,762) | |||
Ending Balance at Mar. 31, 2022 | $ 3 | 91,935 | (1,207) | (77,834) | 12,897 |
Ending Balance (in shares) at Mar. 31, 2022 | 26,566,809 | ||||
Beginning Balance at Dec. 31, 2021 | $ 3 | 89,954 | (1,363) | (75,072) | 13,522 |
Beginning Balance (in shares) at Dec. 31, 2021 | 25,554,309 | ||||
Issuance costs related to common stock and warrants in private placement | (170) | ||||
Foreign currency translation adjustment | 878 | ||||
Net loss | (6,463) | ||||
Ending Balance at Jun. 30, 2022 | $ 3 | 92,612 | (485) | (81,535) | 10,595 |
Ending Balance (in shares) at Jun. 30, 2022 | 26,949,282 | ||||
Beginning Balance at Mar. 31, 2022 | $ 3 | 91,935 | (1,207) | (77,834) | 12,897 |
Beginning Balance (in shares) at Mar. 31, 2022 | 26,566,809 | ||||
Stock-based compensation expense | 97 | 97 | |||
Issuance of common shares to vendor | 590 | 590 | |||
Issuance of common shares to vendor (in shares) | 382,473 | ||||
Issuance costs related to common stock and warrants in private placement | (10) | (10) | |||
Foreign currency translation adjustment | 722 | 722 | |||
Net loss | (3,701) | (3,701) | |||
Ending Balance at Jun. 30, 2022 | $ 3 | $ 92,612 | $ (485) | $ (81,535) | $ 10,595 |
Ending Balance (in shares) at Jun. 30, 2022 | 26,949,282 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows $ in Thousands, $ in Thousands | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 USN ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2021 USN ($) | Dec. 31, 2020 USD ($) | |
Cash flows from operating activities: | ||||||
Net loss | $ (6,463) | $ (11,767) | $ (23,133) | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation | 105 | 95 | 197 | |||
Common shares issued to vendor for services | 633 | 107 | ||||
Amortization of right of use asset | 131 | 96 | 176 | |||
Stock-based compensation | 195 | 6,095 | ||||
Loss on foreign currency transactions | 1,638 | 412 | ||||
Non-cash interest expense | 6,835 | |||||
Change in fair value of embedded conversion feature | 6,282 | |||||
Loss on conversion of convertible notes payable | 5,470 | |||||
Change in operating assets and liabilities: | ||||||
Accounts receivable, net | (6) | 19 | (17) | |||
Research & development tax credit receivable | (578) | (499) | 551 | |||
Prepaid expenses and other current assets | (1,057) | (901) | (70) | |||
Accounts payable and accrued expenses | (134) | 435 | (214) | |||
Lease liabilities | (115) | (120) | (157) | |||
Other assets | (1) | (2) | ||||
Net cash used in operating activities | (5,651) | (6,029) | (4,082) | |||
Cash flows from investing activities: | ||||||
Purchases of property, plant and equipment | (58) | (121) | (118) | |||
Net cash used by investing activities | (58) | (121) | (118) | |||
Cash flows from financing activities: | ||||||
Proceeds from term loan payable | 738 | |||||
Repayment of term loan payable | (738) | |||||
Proceeds from the issuance of common stock | 4,592 | |||||
Proceeds from the issuance of common stock and warrants in private placement | 24,638 | |||||
Proceeds from the issuance of common stock in private placement | 2,000 | |||||
Payment of issuance costs | (170) | (2,454) | ||||
Proceeds from the exercise of stock options | 20 | |||||
Net cash provided by financing activities | 1,830 | 22,204 | 4,592 | |||
Effect of exchange rate changes on cash | (590) | (387) | (40) | |||
Net change in cash | (4,469) | 15,667 | 352 | |||
Cash, beginning of period | 12,226 | 764 | $ 764 | 412 | ||
Cash, end of period | 7,757 | 16,431 | 12,226 | 764 | ||
Supplemental disclosure of cash and non-cash investing and financing activities | ||||||
Cash paid for interest | 19 | |||||
Right of use asset and lease liability additions | 539 | 86 | 136 | |||
Conversion of debt and accrued interest into common shares | 25,759 | |||||
As restated | ||||||
Cash flows from operating activities: | ||||||
Net loss | (17,126) | |||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation | 209 | |||||
Common shares issued to vendor for services | 263 | |||||
Amortization of right of use asset | 234 | |||||
Stock-based compensation | 6,196 | |||||
Loss on foreign currency transactions | 808 | |||||
Change in operating assets and liabilities: | ||||||
Accounts receivable, net | 19 | |||||
Research & development tax credit receivable | (104) | |||||
Prepaid expenses and other current assets | (532) | |||||
Accounts payable and accrued expenses | 579 | |||||
Lease liabilities | (276) | |||||
Other assets | 2 | |||||
Net cash used in operating activities | $ (6,029) | (9,728) | $ (9,728) | |||
Cash flows from investing activities: | ||||||
Purchases of property, plant and equipment | (341) | |||||
Net cash used by investing activities | (341) | |||||
Cash flows from financing activities: | ||||||
Proceeds from term loan payable | 738 | |||||
Repayment of term loan payable | (738) | |||||
Proceeds from the issuance of common stock in private placement | 24,638 | |||||
Payment of issuance costs | (2,454) | |||||
Proceeds from the exercise of stock options | 20 | |||||
Net cash provided by financing activities | 22,204 | |||||
Effect of exchange rate changes on cash | $ (387) | (673) | $ (673) | |||
Net change in cash | 11,462 | |||||
Cash, beginning of period | $ 12,226 | $ 764 | 764 | |||
Cash, end of period | 12,226 | $ 764 | ||||
Supplemental disclosure of cash and non-cash investing and financing activities | ||||||
Cash paid for interest | 19 | |||||
Right of use asset and lease liability additions | $ 136 |
BUSINESS AND LIQUIDITY
BUSINESS AND LIQUIDITY | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
BUSINESS AND BASIS OF PREPARATION | ||
BUSINESS AND LIQUIDITY | 1. BUSINESS AND BASIS OF PREPARATION SmartKem Inc. (“SmartKem” or the “Company”) a Delaware corporation, formerly known as Parasol Investments Corporation (“Parasol”), was formed on May 13, 2020 and is the successor, as discussed below, of SmartKem Limited, which was formed under the Laws of England and Wales. The Company was founded as a “shell” company registered under the Exchange Act, with no specific business plan or purpose until it began operating the business of SmartKem Limited following the closing of the Exchange described below. SmartKem is seeking to reshape the world of electronics with a revolutionary semiconductor platform that enables a new generation of displays, sensors and logic. SmartKem’s patented TRUFLEX ® Restatement of previously filed financial statements The Company has determined that it made an error in the presentation and accounting of its consolidated statement of cash flows in the Company’s annual and interim consolidated financial statements during 2021 and 2022. The management of the company has assessed its accounting policies as well as the presentation and accounting for the gain and loss on foreign currency and has concluded that it was necessary to restate its previously issued financial statements for the correction of this error related to incorrect classification of gain and loss on foreign currency in effect of exchange rate changes on cash instead of including such non-cash unrealized gains and losses in cash flows from operating activities. The effect of this error was to overstate net cash used in operating activities and effect of exchange rate changes on cash by $412 thousand for the six months ended June 30, 2021, respectively. The errors and the required restatement had no effect on the Company’s cash flows from investing activities, financing activities, net changes in cash or cash and cash equivalents as of June 30, 2021 and had no impact on the Company’s consolidated balance sheet, statements of operations and comprehensive loss and statements of stockholders’ equity as of and for the three- and six-month periods ended June 30, 2021. The changes are presented below (in thousands): For the Six Months Ended June 30, 2021 Net cash used in operating activities as previously reported $ (6,441) Adjustment for (Loss)/Gain on foreign currency transactions 412 Net cash used in operating activities as restated $ (6,029) Effect of exchange rate changes on cash as previously reported $ 25 Adjustment for (Gain)/Loss on foreign currency transactions (412) Effect of exchange rate changes on cash as restated $ (387) Basis for Presentation These unaudited interim condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting and are presented in thousands, except number of shares and per share data. Accordingly, certain notes or other information that are normally required by U.S. GAAP have been omitted if they substantially duplicate the disclosures contained in the Company’s annual audited consolidated financial statements. Accordingly, the unaudited interim condensed consolidated financial statements should be read in connection with the Company’s audited financial statements and related notes as of and for the year ended December 31, 2021. The accompanying interim condensed consolidated financial statements are unaudited; however, in the opinion of management, they include all normal and recurring adjustments necessary for a fair presentation of the Company’s unaudited interim condensed consolidated financial statements for the periods presented. Results of operations reported for interim periods are not necessarily indicative of results for the entire year. Comprehensive loss of all periods presented is comprised primarily of net loss and foreign currency translation adjustments. Going Concern The accompanying unaudited interim condensed consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the ordinary course of business. Since inception, we have incurred recurring losses including net losses of $3.7 million and $6.5 million for the three and six months ended June 30, 2022, respectively. As of June 30, 2022 we had an accumulated deficit of $81.5 million. The Company’s cash as of June 30, 2022 was $7.8 million. We anticipate operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, further development of our technology and products and expenses related to the commercialization of our products. Management believes that the Company’s existing cash as of June 30, 2022 will be sufficient to fund the operations of the Company through to April 2023 and that the Company will require additional capital to continue its operations and research and development activity thereafter. There can be no assurance, however, that such financing will be available when needed, if at all, or on acceptable terms and conditions. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including the market demand for the Company’s products, the quality of product development efforts, management of working capital, and the continuation of normal payment terms and conditions for purchase of services. In order to address its capital needs, including its planned research and development activities and other expenditures, the Company is assessing options for financing our working capital requirements through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Adequate financing opportunities might not be available to the Company, when and if needed, on acceptable terms or at all. If the Company is unable to obtain additional financing in sufficient amounts or on acceptable terms, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs and product portfolio expansion, which could adversely affect its operating results or business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. After considering the uncertainties, management consider it is appropriate to continue to adopt the going concern basis in preparing the consolidated financial statements. The accompanying unaudited interim condensed consolidated financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. Reverse Recapitalization On February 23, 2021 Parasol entered into a Securities Exchange Agreement (“the Exchange Agreement”), with SmartKem Limited. Pursuant to the Exchange Agreement all of the equity interests in SmartKem Limited, except certain deferred shares which had no economic or voting rights (the “Deferred Shares”) and which were purchased by Parasol for an aggregate purchase price of $1.40, were exchanged for shares of Parasol common stock, par value $0.0001 per share (“common stock”), and SmartKem Limited became a wholly owned subsidiary of Parasol (the “Exchange”). As a result of the Exchange, Parasol acquired the business of SmartKem Limited, and continues as the existing business operations of SmartKem Limited as a public reporting company under the name SmartKem, Inc. Under ASC 805, Business Combinations, SmartKem Limited was deemed the accounting acquirer based on the following predominate factors: Parasol was created as a “shell” company to effect a business combination and had no operations, the former shareholders of SmartKem Limited own more than a majority of the outstanding voting stock of the Company, the Company’s board of directors and management consists of the former board of directors and management of SmartKem Limited, SmartKem Limited was the largest entity by assets at the time of the Exchange, and the principal operating location of the Company is SmartKem Limited’s premises which are located in Manchester, United Kingdom. The Exchange was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with U.S. GAAP. Under this method of accounting, Parasol was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Exchange was treated as the equivalent of SmartKem Limited issuing stock for the net assets of Parasol, accompanied by a recapitalization. The net assets of Parasol are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities, and results of operations prior to the Exchange are those of SmartKem Limited. Reported shares and earnings per share available to holders of the Company’s common stock, prior to the Exchange, have been retroactively restated as shares reflecting the exchange ratios established in the Exchange. At the closing of the Exchange (the “Closing”), each SmartKem Limited ordinary share issued and outstanding immediately prior to the Closing (other than the Deferred Shares) was exchanged for 0.0111907 of a share of the Company’s common stock and each SmartKem Limited A ordinary share issued and outstanding immediately prior to the Closing was exchanged for 0.0676668 of a share of the Company’s common stock, with the maximum number of shares of our common stock issuable to the former holders of SmartKem Limited’s ordinary shares and A ordinary shares equal to 12,725,000. This includes enterprise management incentive options to purchase 124,497,910 SmartKem Limited ordinary shares (the “SmartKem Limited EMI Options”) issued and outstanding immediately prior to the Closing that were accelerated and exercised by the holders thereof for a like number of ordinary shares and exchanged for shares of the Company’s common stock pursuant to the Exchange. In aggregate 1,127,720,477 SmartKem Limited shares were exchanged for 12,725,000 of the Company’s common stock, an average exchange ratio of 0.011283825. Immediately prior to the Closing, an aggregate of 2,500,000 shares of the Company’s common stock owned by the stockholders of Parasol prior to the Exchange were forfeited and cancelled (the “Stock Forfeiture”). The consolidated entity presented is referred to herein as “SmartKem”, “we”, “us”, “our”, or the “Company”, as the context requires and unless otherwise noted. | 1. BUSINESS AND LIQUIDITY Restatement of previously issued financial statements The Company has determined that it made an error in the presentation and accounting of its consolidated statement of cash flows in the Company’s annual and interim consolidated financial statements during 2021 and 2022. The management of the company has assessed its accounting policies as well as the presentation and accounting for the gain and loss on foreign currency and has concluded that it was necessary to restate its previously issued financial statements for the correction of this error related to incorrect classification of gain and loss on foreign currency in effect of exchange rate changes on cash instead of including such non-cash unrealized gains and losses in cash flows from operating activities. The effect of this error was to overstate net cash used in operating activities and effect of exchange rate changes on cash by $808 thousand for the year ended December 31, 2021. The errors and the required restatement had no effect on the Company’s cash flows from investing activities, financing activities, net changes in cash or cash and cash equivalents as of December 31, 2021 and had no impact on the Company’s consolidated balance sheet, the Company’s consolidated statements of operations and comprehensive loss and stockholders’ equity as of and for year ended December 31, 2021. The changes are presented below (in thousands): For the year ended December 31, 2021 Net cash used in operating activities as previously reported $ (10,536) Adjustment for Loss/(Gain) on foreign currency transactions 808 Net cash used in operating activities as restated $ (9,728) Effect of exchange rate changes on cash as previously reported $ 135 Adjustment for (Gain)/Loss on foreign currency transactions (808) Effect of exchange rate changes on cash as restated $ (673) Organization & Reverse Recapitalization SmartKem Inc. (“SmartKem” or the “Company”) a Delaware corporation, formerly known as Parasol Investments Corporation (“Parasol”), was formed on May 13, 2020 and is the successor, as discussed below, of SmartKem Limited, which was formed under the Laws of England and Wales. The Company was founded as a “shell” company registered under the Exchange Act, with no specific business plan or purpose until it began operating the business of SmartKem Limited following the closing of the Exchange described below. On February 23, 2021 Parasol entered into a Securities Exchange Agreement (“the Exchange Agreement”), with SmartKem Limited. Pursuant to the Exchange Agreement all of the equity interests in SmartKem Limited, except certain deferred shares which had no economic or voting rights (the “Deferred Shares”) and which were purchased by Parasol for an aggregate purchase price of $1.40, were exchanged for shares of Parasol common stock, par value $0.0001 per share (“common stock”), and SmartKem Limited became a wholly owned subsidiary of Parasol (the “Exchange”). As a result of the Exchange, Parasol legally acquired the business of SmartKem Limited, and continues as the existing business operations of SmartKem Limited as a public reporting company under the name SmartKem, Inc. Under ASC 805, Business Combinations, SmartKem Limited was deemed the accounting acquirer based on the following predominate factors: Parasol was created as a “shell” company to effect a business combination and had no operations, the former shareholders of SmartKem Limited own more than a majority of the outstanding voting stock of the Company, the Company’s board of directors and management consists of the former board of directors and management of SmartKem Limited, SmartKem Limited was the largest entity by assets at the time of the Exchange, and the principal operating location of the Company is SmartKem Limited’s premises which are located in Manchester, United Kingdom. The Exchange was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). Under this method of accounting, Parasol was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Exchange was treated as the equivalent of SmartKem Limited issuing stock for the net assets of Parasol, accompanied by a recapitalization. The net assets of Parasol are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities, and results of operations prior to the Exchange are those of SmartKem Limited. Reported shares and earnings per share available to holders of the Company’s common stock, prior to the Exchange, have been retroactively restated as shares reflecting the exchange ratios established in the Exchange. At the closing of the Exchange (the “Closing”), each SmartKem Limited ordinary share issued and outstanding immediately prior to the Closing (other than the Deferred Shares) was exchanged for 0.0111907 of a share of the Company’s common stock and each SmartKem Limited A ordinary share issued and outstanding immediately prior to the Closing was exchanged for 0.0676668 of a share of the Company’s common stock, with the maximum number of shares of our common stock issuable to the former holders of SmartKem Limited’s ordinary shares and A ordinary shares equal to 12,725,000. This includes enterprise management incentive options to purchase 124,497,910 SmartKem Limited ordinary shares (the “SmartKem Limited EMI Options”) issued and outstanding immediately prior to the Closing that were accelerated and exercised by the holders thereof for a like number of ordinary shares and exchanged for shares of the Company’s common stock pursuant to the Exchange. In aggregate 1,127,720,477 SmartKem Ltd shares were exchanged for 12,725,000 of the Company’s common stock, an average exchange ratio of 0.011283825. Immediately prior to the Closing, an aggregate of 2,500,000 shares of the Company’s common stock owned by the stockholders of Parasol prior to the Exchange were forfeited and cancelled (the “Stock Forfeiture”). Business SmartKem, Inc. is seeking to reshape the world of electronics with a revolutionary semiconductor platform that enables a new generation of displays, sensors and logic. SmartKem’s patented TRUFLEX ® COVID-19 Pandemic In March 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic (the “Pandemic”). The Pandemic has had a widespread and detrimental effect on the global economy and has adversely impacted the Company’s business and results of operations. The Company has experienced travel bans, states of emergency, quarantines, lockdowns, “shelter in place” orders, business restrictions and shutdowns in the countries where it operates. The Company’s containment measures have impacted its day-to-day operations and disrupted its business. Because the severity, magnitude and duration of the Pandemic and its economic consequences are highly uncertain, rapidly changing and difficult to predict, the ultimate impact of the Pandemic on the Company’s business, financial condition and results of operations is currently unknown. The additional costs incurred by the Company related to COVID-19 for the year ended December 31, 2021 were deemed to be immaterial to the consolidated financial statements. The Company anticipates there may be additional costs relating to the Pandemic incurred in the upcoming months that will be attributable to fiscal year 2022 and thereafter. These costs are not expected to be material. The consolidated entity presented is referred to herein as “SmartKem”, “we”, “us”, “our”, or the “Company”, as the context requires and unless otherwise noted. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of SmartKem, Inc. and its wholly-owned subsidiaries, SmartKem Delaware, Inc. and SmartKem Limited. The Company does not have any nonconsolidated subsidiaries. All intercompany balances and transactions have been eliminated on consolidation, including unrealized gains and losses on transactions between the companies. The Company's formerly wholly-owned subsidiary, SmartKem Delaware Inc. was dissolved on May 13, 2021. Comprehensive loss Comprehensive loss of all periods presented is comprised primarily of net loss and foreign currency translation adjustments. Management’s Use of Estimates The preparation of interim condensed consolidated financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company’s unaudited interim condensed consolidated financial statements relates to the valuation of common share, fair value of share options, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. As of June 30, 2022 and December 31, 2021, the Company did not have any cash equivalents. Accounts Receivable Accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of non-collection. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required. There was no allowance for doubtful accounts recorded as of June 30, 2022 and December 31, 2021. Impairment of Long-Lived Assets Management continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. If the carrying amount is greater than the undiscounted cash flows, the carrying amount of the asset is reduced to the asset’s fair value. An impairment loss is recognized immediately as an operating expense in the condensed consolidated statements of operations. Reversal of previously recorded impairment losses are prohibited. As of June 30, 2022 and December 31, 2021, Company’s management believed that no revision to the remaining useful lives or impairment of the Company’s long-lived assets was required. Warrants The accounting treatment of warrants issued is determined pursuant to the guidance provided by ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging Leases Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the unaudited condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. The Company has elected not to present short-term leases as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the Company’s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments. Revenue The Company applies the provisions of ASC 606 Revenue from Contracts with Customers The Company’s current contracts with customers do not contain significant estimates or judgments. All of the Company’s revenue contains a single performance obligation that is recognized upon fulfilment of the sales order. The Company derives its revenues primarily from sales of TRUFLEX ® Other Operating Income The Company’s other operating income is related to government grant incentives received for qualifying research and development projects, and research and development tax credits related to the United Kingdom’s Research and Development Expenditure Credit scheme, which is a government tax incentive designed to reward innovative companies for investing in research and development. Such incentives are recorded as other income when it is probable the amounts are collectible and can be reasonably estimated. For the three months ended June 30, 2022 and 2021, the Company recorded grant income and research & development tax credits of $294 thousand and $256 thousand, respectively, and $578 thousand and $688 thousand for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, and December 31, 2021, the Company had receivables related to research & development tax credits for payments not yet received of $1,505 thousand and $1,070 thousand, respectively. Share-based compensation All share-based payments, including grants of stock options, are measured based on the fair value of the share-based awards at the grant date and recognized over their respective vesting periods. Outstanding options generally expire 10 years after the grant date. The Company has issued options that vest based on service requirements and options become exercisable when service requirements are met. Due to the Exchange, all options outstanding immediately prior to the event with a performance obligation requirement became vested and exercisable. The estimated fair value of stock options at the grant date is determined using the Black-Scholes pricing model. The Black-Scholes option pricing model requires inputs such as the fair value of common stock on date of grant, expected term, expected volatility, dividend yield, and risk-free interest rate. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The Company records forfeitures when they occur. Functional Currency and Operations Prior to the Exchange, SmartKem Limited’s (“the predecessor’s”) functional currency was the British Pound Sterling (“GBP”), and the consolidated financial statements were presented in United States dollars (“USD”). The predecessor’s functional currency was the respective local currency of the primary economic environment in which an entity’s operations are conducted. The predecessor translated the financial statements into the presentation currency using exchanges rates in effect on the balance sheet date for assets and liabilities and average exchanges rates for the period for statement of operations accounts, with the difference recognized in accumulated other comprehensive income /(loss). From the date of the Exchange forward, the Company’s functional currency is the U.S. dollar (“USD”). The functional currency of the Company’s foreign operation is the respective local currency. Assets and liabilities of foreign operation denominated in local currencies are translated at the spot rate in effect at the applicable reporting date. The condensed consolidated statements of operations and comprehensive loss are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized gain/loss is recognized as foreign currency translation as a component of other comprehensive income. Foreign Currency Transactions The company measures foreign currency denominated monetary assets and liabilities using exchange rates in effect at the end for the period. Transaction gains and losses are included in net loss. Foreign exchange losses, primarily driven by foreign exchange revaluation of our dollar borrowings held by non-dollar group undertakings, were $1,284 thousand and $1,638 thousand for the three- and six-month periods ended June 30, 2022, respectively. Foreign exchange gains were $57 thousand and foreign exchanges losses were $412 thousand for the three-and six-month periods ended June 30, 2021, respectively. Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. As of June 30, 2022 and December 31, 2021, there were no accruals for uncertain tax positions. Contingent Liabilities A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of June 30, 2022, the Company does not expect that such matters will have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows. Offering Costs Direct and incremental legal and accounting costs associated with the Company’s issuance of common stock and warrants are deferred and classified as a component of other assets on the condensed consolidated balance sheet until completion of the issuance. Upon completion of the issuance, deferred offering costs are reclassified from other assets to equity and recorded against the net proceeds received in the issuance. For the six months ended June 30, 2022 and 2021 respectively, $170 thousand and $2,454 thousand of offering costs were recorded in additional paid-in capital. No offering costs were deferred as of both June 30, 2022 and December 31, 2021. Segment Information The Company has determined that it operates and reports in one segment Basic and Diluted Loss Per Share Basic and diluted net loss per share is determined by dividing net loss by the weighted average ordinary shares outstanding during the period. For all periods presented with a net loss, the shares underlying the ordinary share options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per share are the same for periods with a net loss. The loss per share information in these unaudited interim condensed consolidated financial statements is reflected and calculated as if the Company had existed since January 1, 2020. Accordingly, loss per share for all periods was calculated based on the number of shares retroactively adjusted for the exchange ratio determined in the reverse recapitalization (see also note 1). The Company has 2,168,000 pre-funded common stock warrants outstanding as of June 30, 2022, which became exercisable on April 24, 2021 based on terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $0.01, these shares are considered outstanding common shares and included in computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions were met on April 24, 2021. The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: June 30, 2022 2021 Options 1,937,382 1,596,562 Warrants 985,533 985,533 Total 2,922,915 2,582,095 Recent Accounting Pronouncements Adopted In May 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2021-04, Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity Classified Written Call Options In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) Recent Accounting Pronouncements Not Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments: Credit Losses (Topic 326) Reclassifications Certain amounts in prior periods' interim condensed consolidated financial statements have been reclassified to conform to the current period’s presentation. | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis for Presentation These consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and accounting principles generally accepted in the United States of America ( “US GAAP”) as defined by the Financial Accounting Standards Board (FASB) within the FASB Accounting Standards Codification (“ASC”) and are presented in thousands, except number of shares and per share data . Going Concern The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities, and commitments in the ordinary course of business. Since inception, we have incurred recurring losses including net losses of $17.1 million and $23.1 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $75.1 million. We anticipate operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, further development of our technology and products and expenses related to the commercialization of our products. We expect that our cash and cash equivalents of $12.2 million as of December 31, 2021 will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the issuance date of these consolidated financial statements through the first quarter of 2023. It is possible this period could be shortened if there are any significant increases in planned spending or development programs or more rapid progress of development programs than anticipated. Our future viability is dependent on our ability to raise additional capital to fund our operations. In the long-term, we will need to obtain additional funds to satisfy our operational needs and to fund our sales and marketing efforts, research and development expenditures, and business development activities. Until such time, if ever, as we can generate sufficient cash through revenue, we expect to finance our working capital requirements through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. There can be no assurance however that such financing will be available in sufficient amounts, when and if needed, on acceptable terms or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including the market demand for the Company’s products and services, the quality of product development efforts, management of working capital, and continuation of normal payment terms and conditions for purchase of services. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows for operations, then the Company will need to raise additional funding to continue as a going concern. Basis of Consolidation The consolidated financial statements include the accounts of SmartKem, Inc. and its wholly-owned subsidiaries, SmartKem Delaware, Inc. and SmartKem Limited. The Company does not have any nonconsolidated subsidiaries. All intercompany balances and transactions have been eliminated on consolidation, including unrealized gains and losses on transactions between the companies. The Company's formerly wholly-owned subsidiary, SmartKem Delaware Inc. was dissolved on May 13, 2021. Comprehensive loss Comprehensive loss of all periods presented is comprised primarily of net loss and foreign currency translation adjustments. Management’s Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relates to the valuation of common share, fair value of share options, fair value of embedded conversion features in the convertible notes, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Certain Risk and Uncertainties The Company’s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the growth stage, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements. See Item 1a of this Form 10-K/A for a fuller discussion of the Company’s risk factors. The Company has access under a framework agreement to equipment which is used in the manufacturing of demonstrator products employing the Company’s inks. If the Company lost access to this fabrication facility, it would materially and adversely affect the Company’s ability to manufacture prototypes and demonstration products for potential customers. The loss of this access could significantly impede the Company’s ability to engage in product development and process improvement activities. Alternative providers of similar services exist, but would take effort and time to bring into the Company’s operations. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. As of December 31, 2021 and 2020, the Company did not have any cash equivalents. Accounts Receivable Accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of non-collection. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required. There was no allowance for doubtful accounts recorded as of December 31, 2021 and 2020. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. Property, Plant and Equipment Property, plant and equipment is stated at cost, less accumulated depreciation. Maintenance and repairs are expensed when incurred. Additions and improvements that extend the economic useful life of the asset are capitalized and depreciated over the remaining useful lives of the assets. The cost and accumulated depreciation of assets sold or retired are removed from the respective accounts, and any resulting gain or loss is reflected in current earnings. Depreciation and amortization are provided using the accelerated declining balance method in amounts considered to be sufficient to amortize the cost of the assets to operations over their estimated useful lives. Property, plant and equipment is depreciated at 25 percent of net book value on an annual basis, resulting in an estimated useful life of approximately 15 years. Impairment of Long-Lived Assets Management continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. If the carrying amount is greater than the undiscounted cash flows, the carrying amount of the asset is reduced to the asset’s fair value. An impairment loss is recognized immediately as an operating expense in the consolidated statements of operations. Reversal of previously recorded impairment losses are prohibited. As of December 31, 2021 and 2020, Company’s management believed that no revision to the remaining useful lives or impairment of the Company’s long-lived assets was required. Derivative Asset for Embedded Conversion Features The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates convertible notes to determine if those contracts or embedded components of those contracts qualify as derivatives to be accounted for separately. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The result of this accounting treatment is that the fair value of the embedded derivative is recorded as a liability and marked-to-market each balance sheet date, with the change in fair value recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The fair value of the embedded conversion features are estimated using a Monte Carlo simulation model, in which possible outcomes and their values are simulated repeatedly and randomly. Under the Monte Carlo method the Company estimated the fair value of the convertible notes conversion feature at the time of issuance and subsequent remeasurement dates, utilizing the with-and without method, where the value of the derivative feature is the difference in values between a note simulated with the embedded conversion feature and the value of the same note simulated without the embedded conversion feature. Estimating fair values of embedded conversion features requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. Fair Value of Financial Instruments ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2021 and 2020. The carrying value of the Company’s cash, accounts receivable, other receivables, prepaid expenses and other current assets, accounts payable and accrued expenses approximate fair value because of the short-term maturity of these financial instruments. The carrying value of derivative asset is displayed at fair value. See Note 8 for additional information regarding fair value measurements. Convertible Notes The Company accounts for its convertible notes in accordance with ASC 470-20, Debt with Conversion and Other Options Debt discount created by the bifurcation of embedded feature in the convertible notes are reflected as a reduction to the related debt liability. The discount is amortized to interest expense over the term of the debt using the effective-interest method. Warrants The accounting treatment of warrants issued is determined pursuant to the guidance provided by ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging Leases Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the consolidated balance sheets as of December 31, 2021 and 2020. The Company has elected not to present short-term leases as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the Company’s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments. Revenue The Company applies the provisions of ASC 606, Revenue from Contracts with Customers The Company’s current contracts with customers do not contain significant estimates or judgments. All of the Company’s revenue contains a single performance obligation that is recognized upon fulfilment of the sales order. The Company derives its revenues primarily from sales of demonstrator units to customers evaluating organic semiconductor technology. The transaction price is stated in each customer agreement and is allocated to a single performance obligation. Revenue is recognized upon shipment of each demonstrator, at a point in time. The Company does not have any significant financing components as payment is received at or shortly after the point of sale. Costs incurred to obtain a contract will be expensed as incurred when the amortization period is less than a year. Research and Development Expenses The Company expenses research and development costs as incurred. Research and development costs include salaries, employee benefit costs, direct project costs, supplies and other related costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. Patent and Licensing Costs Patent and licensing costs are expensed as incurred because their realization is uncertain. These costs are classified as research and development expenses in the accompanying consolidated statements of operations and comprehensive loss. Other Operating Income The Company’s other operating income is related to government grant incentives received for qualifying research and development projects, and research and development tax credits related to the United Kingdom’s Research and Development Expenditure Credit scheme, which is a government tax incentive designed to reward innovative companies for investing in research and development. Such incentives are recorded as other income when it is probable the amounts are collectible and can be reasonably estimated. For the year ended December 31, 2021 and 2020, the Company recorded grant income and research & development tax credits of $1,285 thousand and $1,437 thousand, respectively, which are recorded as other operating income in the accompanying consolidated statements of operations. As of December 31, 2021, and December 31, 2020, the Company had receivables related to research & development tax credits for payments not yet received of $1,070 thousand and $982 thousand, respectively. Ordinary Shares Valuation Due to the absence of an active market for the Company’s ordinary shares, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its ordinary shares. In determining the exercise prices for options to be issued, the estimated fair value of the Company’s ordinary shares on each grant date was estimated based upon a variety of factors, including: ● the issuance prices of ordinary shares; ● the rights and preferences of preferred shareholders; ● the progress of the Company’s research and development programs; ● the Company’s stage of development and business strategy; ● external market conditions affecting the technology industry and trends within the technology industry; ● the Company’s financial position, including cash on hand; ● the Company’s historical and forecasted performance and operating results; ● the lack of active public market for the Company’s ordinary shares; ● the likelihood of achieving a liquidity event, such as a securities offering, initial public offering or a sale of the Company’s shares. Significant changes to the key assumptions underlying the factors used could result in different fair values of ordinary shares at each valuation date. Ordinary shares are classified in shareholders’ equity and represent issued share capital. Share-based compensation All share-based payments, including grants of stock options, are measured based on the fair value of the share-based awards at the grant date and recognized over their respective vesting periods. Outstanding options generally expire 10 years after the grant date. The Company has issued options that vest based on service requirements and issued options that vest based on performance requirements. Options become exercisable when service requirements are met. In the case of performance based options, options become exercisable when there is a liquidity event, such as a change in control or sale or admission (listing as a public company or initial public offering (“IPO”)), and the employee, or consultant, must be providing services to the Company at the time of the event. Due to the Exchange, all options outstanding immediately prior to the event with a performance obligation requirement became vested and exercisable. Non-cash stock-based compensation expense for the year ended December 31, 2021 was The estimated fair value of stock options at the grant date is determined using the Black-Scholes pricing model. The Black-Scholes option pricing model requires inputs such as the fair value of common stock on date of grant, expected term, expected volatility, dividend yield, and risk-free interest rate. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The Company records forfeitures when they occur. Functional Currency and Operations Prior to the Exchange, SmartKem Limited’s (“the predecessor’s”) functional currency was the British Pound Sterling (“GBP”), and the consolidated financial statements were presented in United States dollars (“USD”). The predecessor’s functional currency was the respective local currency of the primary economic environment in which an entity’s operations are conducted. The predecessor translated the consolidated financial statements into the presentation currency using exchanges rates in effect on the balance sheet date for assets and liabilities and average exchanges rates for the period for statement of operations accounts, with the difference recognized in accumulated other comprehensive income/ (loss). The Company’s functional currency is the U.S. dollar (“USD”). The functional currency of the Company’s foreign operation is the respective local currency. Assets and liabilities of foreign operations denominated in local currencies are translated at the spot rate in effect at the applicable reporting date. The consolidated statements of operations and comprehensive loss are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized gain/loss is recognized as foreign currency translation as a component of other comprehensive income. Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. As of December 31, 2021 and 2020, there were no material uncertain tax positions. Contingent Liabilities A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of December 31, 2021, the Company does not expect that such matters will have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows. Offering Costs Direct and incremental legal and accounting costs associated with the Company’s issuance of common stock and warrants are deferred and classified as a component of other assets on the consolidated balance sheet until completion of the issuance. Upon completion of the issuance, deferred offering costs are reclassified from other assets to equity in additional paid-in capital and recorded against the net proceeds received in the issuance. The deferred offering costs incurred as of December 31, 2020 were immaterial and no offering costs were capitalized. For the year ended December 31, 2021 $2,454 thousand of offering costs were recorded in additional paid-in capital. For the year ended December 31, 2021, $1.329 million of direct and incremental costs associated with the Exchange were recorded as Transaction Expenses in the Consolidated Statement of Operations and Comprehensive Loss. Segment Information The Company has determined that it operates and reports in one segment Basic and Diluted Loss Per Share Basic and diluted net loss per share is determined by dividing net loss by the weighted average ordinary shares outstanding during the period. For all periods presented with a net loss, the shares underlying the ordinary share options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per share are the same for periods with a net loss. The loss per share information in these consolidated financial statements is reflected and calculated as if the Company had existed since January 1, 2020. Accordingly, loss per share for all periods was calculated based on the number of shares retroactively adjusted for the exchange ratio determined in the reverse recapitalization (see also note 1). The Company has 2,168,000 pre-funded common stock warrants outstanding as of December 31, 2021, which became exercisable on April 23, 2021 based on terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $0.01, these shares are considered outstanding common shares and included in computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions were met on April 23, 2021. The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: December 31, 2021 2020 Options 1,953,882 1,810,749 Warrants 985,533 — Total 2,939,415 1,810,749 Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments: Credit Losses (Topic 326) annual and interim periods beginning after December 15, 2022. Management is currently evaluating the impact of these changes on the consolidated financial statements. In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40). The amendments in this update affect all entities that issue freestanding written call options (for example warrants) that are classified in equity. Specifically, the amendments affect those entities when a freestanding equity-classified written call option is modified or exchanged and remains equity classified after the modification or exchange. The amendments that relate to the recognition and measurement of EPS for certain modifications or exchanges of freestanding equity-classified written call options affect entities that present EPS in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Management is currently evaluating the impact of this guidance but does not expect this update to have a material impact on the Company's consolidated financial statements. In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance. The amendments in this update affect all business entities that account for a transaction with a government by applying a grant or contribution accounting model by analogy to other accounting guidance. The amendments in this Update require annual disclosures about: (1) Information about the nature of the transactions and the related accounting policy used to account for the transactions; (2) The line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and (3) Significant terms and conditions of the transactions, including commitments and contingencies. The amendments in this update are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. Management is currently evaluating the impact of this guidance but does not expect this update to have a material impact on the Company's consolidated financial statements. Reclassifications Certain amounts in prior years' consolidated financial statements have been recast and reclassified to conform to the current year's presentation |
PREPAID EXPENSES AND OTHER CURR
PREPAID EXPENSES AND OTHER CURRENT ASSETS | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
PREPAID EXPENSES AND OTHER CURRENT ASSETS | ||
PREPAID EXPENSES AND OTHER CURRENT ASSETS | 3. PREPAID EXPENSES AND OTHER CURRENT ASSETS: Prepaid expenses and other current assets consist of the following: June 30, December 31, 2022 2021 Prepaid service charges and property taxes $ 83 $ 58 Prepaid utilities 31 51 Prepaid insurance 633 412 Prepaid administrative expenses 55 63 Prepaid technical fees 212 141 Prepaid consulting fees 629 27 VAT receivable 141 50 Other Receivable and other prepaid expenses 31 — Total prepaid expenses and other current assets $ 1,815 $ 802 As of June 30, 2022 and December 31, 2021, there was $191 thousand and $217 thousand respectively, of non-current prepaid insurance related to directors’ and officers’ liability insurance that was included in the amounts above. | 3. PREPAID EXPENSES AND OTHER CURRENT ASSETS: Prepaid expenses and other current assets consist of the following: December 31, 2021 2020 Prepaid rent $ 58 $ 65 Prepaid utilities 51 30 Prepaid insurance 412 41 Prepaid administrative expenses 63 61 Prepaid technical fees 141 8 Prepaid consulting fees 27 — VAT receivable 50 54 Total prepaid expenses and other current assets $ 802 $ 259 As of December 31, 2021 and 2020, there was $217 thousand and $0 , respectively, of non-current prepaid insurance related to directors’ and officers’ liability insurance that was included in the amounts above. |
PROPERTY, PLANT AND EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
PROPERTY, PLANT AND EQUIPMENT | ||
PROPERTY, PLANT AND EQUIPMENT | 4. PROPERTY, PLANT AND EQUIPMENT: Property, plant and equipment consist of the following: June 30, December 31, 2022 2021 Plant and equipment $ 1,523 $ 1,633 Furniture and fixtures 220 245 Computer hardware and software 24 26 1,767 1,904 Less: Accumulated depreciation (1,090) (1,102) Property, plant and equipment, net $ 677 $ 802 Depreciation expense was $51 thousand and $47 thousand for the three months ended June 30, 2022 and 2021, respectively, and $105 thousand and $95 thousand for the six months ended June 30, 2022 and 2021, respectively and is classified as research and development expense. | 4. PROPERTY, PLANT AND EQUIPMENT: Property, plant and equipment consist of the following: December 31, 2021 2020 Plant and equipment $ 1,633 $ 1,316 Furniture and fixtures 245 248 Computer hardware and software 26 26 1,904 1,590 Less: Accumulated depreciation (1,102) (908) Property, plant and equipment, net $ 802 $ 682 Depreciation expense was $209 thousand and $197 thousand for the year ended December 31, 2021 and 2020, respectively, and is classified as research and development expense. |
ACCOUNTS PAYABLE AND ACCRUED EX
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | ||
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | 5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES: Accounts payable and accrued expenses consist of the following: June 30, December 31, 2022 2021 Accounts payable $ 457 $ 510 Accrued expenses – lab refurbishments 118 131 Accrued expenses – technical fees 58 66 Accrued expenses – variable rent & utilities 9 20 Accrued expenses – audit & accounting fees 167 191 Accrued expenses – other 67 112 Credit card liabilities 34 10 Payroll and social security liabilities 280 383 Total accounts payable and accrued expenses $ 1,190 $ 1,423 | 5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES: Accounts payable and accrued expenses consist of the following: December 31, 2021 2020 Accounts payable $ 510 $ 227 Accrued expenses – lab refurbishments 131 132 Accrued expenses – technical fees 66 45 Accrued expenses – variable rent & utilities 20 67 Accrued expenses – audit & accounting fees 191 250 Accrued expenses – other 112 6 Credit card liabilities 10 6 Payroll and social security liabilities 383 128 Total accounts payable and accrued expenses $ 1,423 $ 861 |
LEASES
LEASES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
LEASES | ||
LEASES | 6. LEASES: The Company has operating leases consisting of office space, lab space, and equipment with remaining lease terms of 1 to 3 years, subject to certain renewal options as applicable. In April 2022, the Company renewed its lease for research & development, engineering, testing and corporate offices in Manchester. The renewed lease term expires in 2025 with an option for the Company to end the lease in 2024. There was no sublease rental income for the three and six months ended June 30, 2022 and 2021. The Company is not the lessor in any lease agreement, and no related party transactions for lease arrangements have occurred. The table below presents certain information related to the lease costs for the Company’s operating and finance leases for the periods ended: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Operating lease cost $ 68 $ 52 $ 131 $ 99 Short-term lease cost 2 13 4 26 Variable lease cost 41 64 95 98 Total lease cost $ 111 $ 129 $ 230 $ 223 The total lease cost is included in the unaudited condensed consolidated statements of operations as follows: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 105 $ 120 $ 218 $ 207 Selling, general and administrative 6 9 12 16 Total lease cost $ 111 $ 129 $ 230 $ 223 Right of use lease assets and lease liabilities for our operating leases were recorded in the unaudited condensed consolidated balance sheet as follows: June 30, December 31, 2022 2021 Assets Operating lease right of use assets $ 549 $ 154 Total lease assets $ 549 $ 154 Liabilities Current liabilities: Operating lease liability – current portion $ 208 $ 87 Noncurrent liabilities: Operating lease liability, net of current portion 320 28 Total lease liabilities $ 528 $ 115 The Company had no right of use lease assets and lease liabilities for financing leases as of June 30, 2022 and December 31, 2021. The table below presents certain information related to the cash flows for the Company’s operating leases for the periods ended: For the Six Months Ended June 30, 2022 2021 Operating cash outflows from operating leases $ 115 $ 120 Supplemental non-cash amounts of operating lease liabilities arising from obtaining right of use assets $ 539 $ 86 The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s operating and finance leases as of the period ended: For the Six Months Ended June 30, 2022 2021 Weighted average remaining lease term (in years) – operating leases 2.66 1.10 Weighted average discount rate – operating leases 7.64 % 6.12 % Undiscounted operating lease liabilities as of June 30, 2022, by year and in the aggregate, having non-cancelable lease terms in excess of one year were as follows: As of June 30, 2022 2022 $ 137 2023 220 2024 219 2025 9 2026 — Thereafter — Total undiscounted lease payments 585 Less imputed interest (57) Total net lease liabilities $ 528 | 6. LEASES: The Company has operating leases consisting of office space, lab space, and equipment with remaining lease terms of 1 There was no sublease rental income for the year ended December 31, 2021 and 2020. The Company is not the lessor in any lease agreement, and no related party transactions for lease arrangements have occurred. The table below presents certain information related to the lease costs for the Company’s operating and finance leases for the periods ended: For the Year Ended December 31, 2021 2020 Operating lease cost $ 225 $ 175 Short-term lease cost 32 48 Variable lease cost 140 401 Total lease cost $ 397 $ 624 The total lease cost is included in the consolidated statements of operations as follows: For the Year Ended December 31, 2021 2020 Research and development $ 373 $ 562 Selling, general and administrative 24 62 Total lease cost $ 397 $ 624 Right of use lease assets and lease liabilities for our operating leases were recorded in the consolidated balance sheets as follows: December 31, 2021 2020 Assets Operating lease right of use assets $ 154 $ 236 Total lease assets $ 154 $ 236 Liabilities Current liabilities: Operating lease liability – current portion $ 87 $ 217 Noncurrent liabilities: Operating lease liability, net of current portion 28 20 Total lease liabilities $ 115 $ 237 The Company had no right of use lease assets and lease liabilities The table below presents certain information related to the cash flows for the Company’s operating leases for the periods ended: For the Year Ended December 31, 2021 2020 Operating cash outflows from operating leases $ 276 $ 157 Supplemental non-cash amounts of operating lease liabilities arising from obtaining right of use assets $ 136 $ — The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s operating and finance leases as of the period ended: For the Year Ended December 31, 2021 2020 Weighted average remaining lease term (in years) – operating leases 1.40 1.35 Weighted average discount rate – operating leases 6.07 % 6.30 % Undiscounted operating lease liabilities as of December 31, 2021, by year and in the aggregate, having non-cancelable lease terms in excess of one year were as follows: As of December 31, 2021 2022 $ 93 2023 22 2024 7 2025 — 2026 — Thereafter — Total undiscounted lease payments 122 Less future minimum short-term lease payments (3) Less imputed interest (4) Total net lease liabilities $ 115 |
CONVERTIBLE NOTES AND NOTES PAY
CONVERTIBLE NOTES AND NOTES PAYABLE | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
CONVERTIBLE NOTES AND NOTES PAYABLE. | ||
CONVERTIBLE NOTES AND NOTES PAYABLE | 7. NOTES PAYABLE: On January 26, 2021, the Company entered into a term loan facility agreement for the amount of $739 thousand. The funds were available to be drawn on from the effective date of the agreement through January 27, 2021. The Company drew down the full loan amount on January 26, 2021. The Company’s research and development tax credit was to be utilized as collateral. The Lender was to be paid immediately following payment of research and development tax credit from the United Kingdom’s HM Revenue and Customs. The final repayment was due six months from the agreement date, if the loan and any interest was not repaid in full prior to this date. The loan carried a monthly interest rate of 1.25%. The interest accrued daily and compounded monthly on the monthly anniversary of the draw down date of the loan. The Company repaid the note payable in full on March 2, 2021. For six months ended June 30, 2021, the Company incurred an effective interest rate of 26.20% relating to notes payable. The interest expense recognized based on the debt’s effective interest rate for six months ended June 30, 2021, was $19 thousand. There were no notes payable outstanding during the six months ended June 30, 2022 and no associated interest expense during the period. | 7. CONVERTIBLE NOTES AND NOTES PAYABLE: Convertible Notes The activity for the Company’s convertible notes during the years ended December 31, 2021 and 2020 was as follows: For the Year Ended December 31, 2021 2020 Balance, beginning of year $ — $ 7,280 Amortization of debt discount — 25 Extinguishment of debt discount — 6,767 Loss on conversion of note — 9,344 Conversion of notes to equity — (23,630) Foreign currency translation — 214 Balance, end of year $ — $ — On January 24, 2020, a Qualified Financing Event (as defined below) occurred when the Company received cumulative investment proceeds in excess of $4,600 thousand from the sale and issuance of common shares. The fair value of the Company’s common shares were $1.807011 per share. The 2018 BASF Venture Capital and Entrepreneurs Fund L.P. Notes (as defined below), 2018 Octopus Investment Limited Notes (as defined below), and the 2019 Octopus, EF, and Other Notes (as defined below) in the aggregate principal amount of $11,796 thousand were converted into 8,159,977 of common shares (at the discounted price of $1.45 per share), and the related unpaid and accrued interest totaling $1,063 thousand were also converted into 735,148 of A Ordinary common shares of the Company (at the discounted price of $1.45 per share). The Company recognized a loss on conversion of $5,470 thousand for the year ended December 31, 2020 related to the conversion of notes measured as the difference in carrying value of debt and accrued interest and the fair value of shares converted on the conversion date. As a result of the conversion, the Company also recognized the unamortized debt discount related to the beneficial conversion feature of $6,767 thousand as interest expense for the year ended December 31, 2020. For the year ended December 31, 2020, the Company incurred an effective interest rate of 13.5% relating to convertible notes. There were no convertible notes outstanding as of December 31, 2021 and 2020. There was interest expense recognized based on the debt’s stated interest for the year ended December 31, 2021 and 2020 of zero and $43 thousand, respectively, relating to convertible notes. Additional interest expense related to the amortization of debt issuance cost was zero and $25 thousand for the year ended December 31, 2021 and 2020, respectively, for convertible notes. Loss on the conversion of notes is included on the consolidated statements of operations and other comprehensive loss as loss on conversion of convertible notes payable. The amount displayed in the statements of operations and other comprehensive loss for the year ended December 31, 2020 is inclusive of the loss on notes in the amount of $9,344 thousand, loss on accrued interest in the amount of $1,046 thousand and offset by the gain on the extinguishment of derivative liability in the amount of $4,920 thousand (Note 8). 2018 BASF Venture Capital and Entrepreneurs Fund L.P. Notes On April 18, 2018, the Company entered into a convertible note agreement (the “2018 BASF Venture Capital and Entrepreneurs Fund L.P. Notes”), with BASF Venture Capital (“BASF”) and Entrepreneurs Fund L.P. (“EF”) with an aggregate principal of $5,862 thousand. The 2018 BASF/EF Convertible Note was issued in three separate tranches on April 18, 2018, July 20, 2018 December 28, 2018 The 2018 BASF Venture Capital and Entrepreneurs Fund L.P. Notes and accrued but unpaid interest were convertible into the common share based on (i) fund raising at a price paid per Senior Share equal to the price paid per Senior Share by the investors on a Fund Raising at a discount to the per share price in the Fund Raising, (ii) sale of the company at a price per Senior Share of $16.39, or (iii) listing of the company on a publicly traded market at a price per Senior Share of $16.39. The principal amount shall accrue interest at a rate of 8% per annum, from the Issue Date up until the first anniversary of the Issue Date. Interest shall accrue on the principal amount at a rate of 15% per annum from, and including, the first anniversary of the Issue Date up until the notes are (i) converted, cancelled, repaid or redeemed or (ii) the longstop date. Accrued interest was to be calculated on the basis of a 365-day year for the actual number of days elapsed. 2018 Octopus Notes On July 20, 2018 the Company entered into a convertible note agreement (the “2018 Octopus Investment Limited Notes”) with Octopus Investment Limited (“Octopus”) with an aggregate nominal amount of $2,622 thousand. The 2018 Octopus Convertible Note was issued in two separate tranches on July 20, 2018 and December 28, 2018 The 2018 Octopus Notes and accrued but unpaid interest were convertible into the common shares based on (i) fund raising at a price paid per Senior Share equal to the price paid per Senior Share by the investors on a Fund Raising at a discount, (ii) sale of the company at a price per Senior Share of $15.10, or (iii) listing of the company on a publicly traded market at a price per Senior Share of $15.10. The principal amount shall accrue interest at a rate of 8% per annum, from the Issue Date up until the first anniversary of the Issue Date. Interest shall accrue on the principal amount at a rate of 12% per annum from, and including, the first anniversary of the Issue Date up until the notes are (i) converted, cancelled, repaid or redeemed or (ii) the longstop date. Accrued interest was to be calculated on the basis of a 365-day year for the actual number of days elapsed. 2019 Octopus, EF, and Other Notes On June 26, 2019 the Company entered into a convertible note agreement (the “2019 Octopus, EF, and Other Notes”) with Octopus, EF, and various private investors with an aggregate nominal amount of $3,681 thousand. The 2019 Octopus Convertible Note was issued in two separate tranches on June 26, 2019 and September 23, 2019 The 2018 Octopus, EF, and Other Notes and accrued but unpaid interest were convertible into the common shares based on (i) fund raising at a price paid per Senior Share equal to the price paid per Senior Share by the investors on a Fund Raising at a discount, (ii) sale of the company at a price per Senior Share of $0.001861, (iii) listing of the company on a publicly traded market at a price per Senior Share of $14.61, or (ii) any date following the first anniversary of the date the of the Instrument at a price per Senior Share of $11.19. The principal amount shall accrue interest at a rate of 10% per annum, from the Issue Date up until the notes are (i) converted, cancelled, repaid or redeemed or (ii) the longstop date. Accrued interest was to be calculated on the basis of a 365-day year for the actual number of days elapsed. The issuance of convertible notes with a beneficial redemption feature resulted in a debt discount of $2,608 thousand. Notes Payable On January 26, 2021, the Company entered into a term loan facility agreement for the amount of $738 Customs. The final repayment was due six months from the agreement date, if the loan and any interest was not repaid in full prior to this date. The loan carried a monthly interest rate of 1.25%. The interest accrued daily and compounded monthly on the monthly anniversary of the draw down date of the loan. For year ended December 31, 2021, the Company incurred an effective interest rate of 26.20% relating to notes payable. There were no notes payable outstanding during for the year ended December 31, 2020. The interest expense recognized based on the debt’s effective interest rate for year ended December 31, 2021 and 2020, was $19 thousand and zero, respectively, relating to notes payable. The Company repaid the note payable in full on March 2, 2021. There were no notes payable outstanding as of December 31, 2021 and 2020. |
DERIVATIVE ASSET
DERIVATIVE ASSET | 12 Months Ended |
Dec. 31, 2021 | |
DERIVATIVE ASSET [Abstract] | |
DERIVATIVE ASSET | 8. DERIVATIVE ASSET: The table below provides a summary of the changes in fair value of the derivative asset measured on a recurring basis using significant unobservable inputs (Level 3) during the years ended December 31, 2021: For the Year Ended December 31, 2021 2020 Balance, beginning of year $ — $ 1,407 Loss on fair value of derivative asset included in earnings — (6,282) Gain on extinguishment of derivative asset upon conversion — 4,920 Foreign currency translation — (45) Balance, end of year $ — $ — The Embedded Conversion Features are separately measured at fair value, with changes in fair value recognized in current operations. The original values of the Embedded Conversion Features were recorded as a derivative asset with the offset as a debt premium to the Convertible Notes which is being amortized over the term of the Convertible Notes. During the year ended December 31, 2020, all outstanding convertible notes were converted into equity. The derivative asset was marked to market on the date of conversion and derecognized at conversion. The change in fair value of derivative asset included in earnings was $6,282 thousand for the year ended December 31, 2020. The gain on extinguishment of derivative asset upon conversion is $4,920 thousand and is recorded as an offset within the loss on conversion of convertible notes payable on the consolidated statements of operations and comprehensive loss. There were no convertible notes outstanding during the year ended December 31, 2021, and no associated derivative asset during the year. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
COMMITMENTS AND CONTINGENCIES. | ||
COMMITMENTS AND CONTINGENCIES | 8. COMMITMENTS AND CONTINGENCIES: Legal proceedings In the normal course of business, the Company may become involved in legal disputes regarding various litigation matters. In the opinion of management, any potential liabilities resulting from such claims would not have a material effect on the financial statements. Capital expenditure commitments and unconditional purchase obligations contracted for but not yet incurred as of June 30, 2022, totaled $1,087 thousand and primarily consists of purchase commitments in the normal course of business for research & development services, communications infrastructure and administrative services. | 9. COMMITMENTS AND CONTINGENCIES: Legal proceedings In the normal course of business, the Company may become involved in legal disputes regarding various litigation matters. In the opinion of management, any potential liabilities resulting from such claims would not have a material effect on the consolidated financial statements. Capital expenditure commitments contracted for but not yet incurred totaled $1,422 thousand and primarily consists of purchase commitments in the normal course of business for research & development services, communications infrastructure and administrative services. |
STOCKHOLDERS' EQUITY
STOCKHOLDERS' EQUITY | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
STOCKHOLDERS' EQUITY | ||
STOCKHOLDERS' EQUITY | 9. STOCKHOLDERS’ EQUITY: Common Stock Voting Rights Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. The Company’s amended and restated certificate of incorporation and the Company’s amended and restated bylaws do not provide for cumulative voting rights. The holders of one-third of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. Dividends The Company has never paid any cash dividends to shareholders and do not anticipate paying any cash dividends to shareholders in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our board of directors and will be dependent upon financial condition, results of operations, capital requirements and such other factors as the board of directors deems relevant. Market Information Quotations on our common stock on the OTC Market Group’s OTCQB ® Common shares issued to vendor for services On May 27, 2022, the Company issued 22,473 shares of common stock as payment for investor relations services. On June 29, 2022, the Company issued 360,000 shares of common stock as payment for a one-year internet advertising contract. Preferred Stock The Company currently has no shares of preferred stock outstanding, and the Company has no present plan to issue any shares of preferred stock. The board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. Common Stock Warrants On February 23, 2021, a total of 985,533 fully vested common stock warrants were issued to a vendor for financial advisory services provided in connection with the sale of the Company’s common stock. The common stock warrants are exercisable at a per share price of $2.00 until they expire on February 23, 2026. During the six months ended June 30, 2022 and 2021, respectively, no warrants issued to vendors for financial advisory services were exercised. The grant date fair value for these warrants of $0.91 per warrant for a total fair value of $896 thousand, was determined using the Black-Scholes options valuation model. The Company recorded the warrants at fair value, as both an increase and decrease in additional paid-in capital during the six months ended June 30, 2021. There were no warrants issued during the three and six months ended June 30, 2022. A summary of the Company’s warrants to purchase common stock activity is as follows: Weighted- Average Weighted- Remaining Average Contractual Number of Exercise Term Shares Price (Years) Warrants outstanding at January 1, 2022 985,533 $ 2.00 4.15 Exercised — — — Forfeited or Expired — — — Granted — — — Warrants outstanding at June 30, 2022 985,533 $ 2.00 3.65 On February 23, 2021, a total of 2,168,000 pre-funded common stock warrants were issued to investors with an exercise price of $0.01 per share for total proceeds to the Company of $4,314 thousand. During the three and six months ended June 30, 2022, no warrants A summary of the Company’s pre-funded warrants to purchase common stock activity is as follows: Weighted- Average Number of Exercise Shares Price Pre-funded warrants outstanding at January 1, 2022 2,168,000 $ 0.01 Exercised — — Forfeited or Expired — — Granted — Pre-funded warrants outstanding at June 30, 2022 2,168,000 $ 0.01 The grant date fair value of common stock warrants is determined using the Black Scholes option-pricing model. There was no public trading market for our shares before February 2022 and the Company estimates its expected stock volatility based on historical volatility of publicly traded peer companies. The Company did not issue any warrants in the six months ended June 30, 2022. | 10. STOCKHOLDERS’ EQUITY: Common Stock Voting Rights Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. The Company’s amended and restated certificate of incorporation and the Company’s amended and restated bylaws do not provide for cumulative voting rights. The holders of one-third of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. Dividends The Company has never paid any cash dividends to shareholders and do not anticipate paying any cash dividends to shareholders in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our board of directors and will be dependent upon financial condition, results of operations, capital requirements and such other factors as the board of directors deems relevant. Market Information Quotations on our common stock on the OTC Market Group’s OTCQB ® Preferred Stock The Company currently has no shares of preferred stock outstanding, and the Company has no present plan to issue any shares of preferred stock. The board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. Common Stock Warrants On February 23, 2021, a total of 985,533 fully vested common stock warrants were issued to a vendor for financial advisory services provided in connection with the sale of the Company’s common stock . The common stock warrants are exercisable at a per share price of $2.00 until they expire on February 23, 2026. During the year ended December 31, 2021, no warrants issued to vendors for financial advisory services were exercised. The grant date fair value for these warrants of $0.91 per warrant for a total fair value of $896 thousand, was determined using the Black-Scholes options valuation model. The Company recorded the warrants at fair value, as both an increase and decrease in additional paid-in capital during the year ended December 31, 2021. A summary of the Company’s warrants to purchase common stock activity is as follows: Weighted- Average Weighted- Remaining Average Contractual Number of Exercise Term Shares Price (Years) Warrants outstanding at January 1, 2021 — $ — — Exercised — — — Forfeited or Expired — — — Granted 985,533 2.00 5.00 Warrants outstanding at December 31, 2021 985,533 $ 2.00 4.15 On February 23, 2021, a total of 2,168,000 pre-funded common stock warrants were issued to investors with an exercise price of $0.01 per share for total proceeds to the Company of $4,314 thousand. During the year ended December 31, 2021, no warrants issued to investors were exercised. The grant date fair value for these warrants of $1.99 is based on the stock price at issuance date of $2.00 less the exercise price of $0.01. The pre-funded common stock warrants have no expiration date and terminate upon exercise. A summary of the Company’s pre-funded warrants to purchase common stock activity is as follows: Weighted- Average Number of Exercise Shares Price Pre-funded warrants outstanding at January 1, 2021 — $ — Exercised — — Forfeited or Expired — — Granted 2,168,000 0.01 Pre-funded warrants outstanding at December 31, 2021 2,168,000 $ 0.01 The grant date fair value of common stock warrants is determined using the Black-Scholes option-pricing model. There was no public trading market for our shares before February 2022 and the Company estimates its expected stock volatility based on historical volatility of publicly traded peer companies. The following assumptions were used during the year ended December 31, 2021: Year Ended December 31, 2021 Expected term (years) 5 years Risk-free interest rate 0.60% Expected volatility 54% Expected dividend yield 0% There were no common stock warrants issued during the year ended December 31, 2020. |
SHARE-BASED COMPENSATION
SHARE-BASED COMPENSATION | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SHARE-BASED COMPENSATION | ||
SHARE-BASED COMPENSATION | 10. SHARE-BASED COMPENSATION: Prior to the Exchange discussed in Note 1, SmartKem Limited had stock option plans. SmartKem Limited had issued Enterprise Management Incentive options (“EMI Options”) and non-tax-advantaged options (“Unapproved Options”) to eligible employees, officers, non-employee directors and other individual service providers as a means for them to develop a sense of proprietorship and personal involvement in the development and financial success of SmartKem Limited. The options generally expired the Company at the time of the event. As of December 31, 2020, there were 1,810,749 options outstanding. These options were either exercised or cancelled as a result of the reverse merger and recapitalization. On February 23, 2021, the Company approved the 2021 Equity Incentive Plan (“2021 Plan”), in which a maximum aggregate number of shares of common stock that may be issued under the 2021 Plan is 2,275,000 shares. Subject to the adjustment provisions of the 2021 Plan, the number of shares of the Company’s common stock available for issuance under the 2021 Plan will also include an annual increase on the first day of each fiscal year beginning with 2022 fiscal year and ending on the Company’s 2031 fiscal year in an amount equal to the least of: 1) 2,275,000 shares of the Company’s common stock; 2) four percent (4%) of the outstanding shares of the Company’s common stock on the last day of the immediately preceding fiscal year; or 3) such number of shares of the Company’s common stock as the administrator may determine. As a result of the reverse merger and recapitalization, an aggregate of 402,586 options were issued during February 2021 under the 2021 Plan in consideration for the cancellation of the SmartKem Limited options that were outstanding. Of these options, 336,557 had an exercise price of $0.001 per share and 66,029 had an exercise price of $2.00 per share and all expire on the ten year anniversary of the grant date. These options were fully vested on the grant date. No options were awarded during the three and six months ended June 30, 2022. Determining the appropriate fair value of share-based awards requires the input of subjective assumptions, including the fair value of the Company’s common shares, and for share options, the expected life of the option, and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its share option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involves inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, the share-based compensation expense could be materially different for future awards. In the absence of a public trading market of the common share, on each grant date, the Company develops an estimate of the fair value of the common shares underlying the option grants. The Company estimated the fair value of the common shares by referencing arms-length transactions inclusive of the common shares underlying which occurred on or near the valuation date(s). From February 2022, the Company’s common shares are publicly traded and the Company will no longer have to estimate the fair value of the common share, rather the value will be determined based on quoted market prices. The Company determined the fair value of common share using methodologies, approaches and assumptions consistent with the AICPA Practice Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation and based in part on input from an independent third-party valuation firm. The Company estimates its expected volatility by using a combination of historical share price volatilities of similar companies within our industry. The risk-free interest rate assumption is based on observed interest rates for the appropriate term of the Company’s options on a grant date. The expected option term assumption is the contractual term, as the service period is implied under the practical expedient since the Company does not have sufficient exercise history to estimate expected term of its historical option awards. The following table reflects share activity under the share option plans for six months ended June, 2022: Weighted- Average Weighted- Remaining Weighted- Aggregate Average Contractual Average Intrinsic Number of Exercise Term Fair Value at Value Shares Price (Years) Grant Date (in thousands) Options outstanding at January 1, 2022 1,953,882 $ 1.72323 9.31 $ 1.12355 Exercised — — Cancelled — — Forfeited (16,500) 2.00000 Granted — — Options outstanding at June 30, 2022 1,937,382 $ 1.72087 8.81 $ 1.12553 Options exercisable at June 30, 2022 708,624 $ 1.23685 8.71 $ 541 Vested and expected to vest after June 30, 2022 1,937,382 $ 1.72087 8.81 $ 541 As of June 30, 2022, there were 708,624 exercisable options outstanding. Stock-based compensation, including stock options and warrants is included in the unaudited interim condensed consolidated statements of operations as follows: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 38 $ 24 $ 78 $ 2,931 Selling, general and administrative 59 51 117 3,164 Total $ 97 $ 75 $ 195 $ 6,095 Total compensation cost related to non-vested stock option awards not yet recognized as of June 30, 2022 was $1,122 thousand and will be recognized on a straight-line basis through the end of the vesting periods in September 2025. The amount of future stock option compensation expense could be affected by any future option grants or by any forfeitures. | 11. SHARE-BASED COMPENSATION: Prior to the Exchange discussed in Note 1, SmartKem Limited had stock option plans. SmartKem Limited stock options discussed below have been retroactively restated as options reflecting the exchange ratios established in the Exchange. SmartKem Limited had issued Enterprise Management Incentive options (“EMI Options”) and non-tax-advantaged options ( “Unapproved Options”) to eligible employees, officers, non-employee directors and other individual service providers as a means for them to develop a sense of proprietorship and personal involvement in the development and financial success of SmartKem Limited and to encourage them to devote their best efforts to the business of SmartKem Limited, thereby advancing the interests of SmartKem Limited and its shareholders. Options were issued to certain employees and service providers under the investment agreement dated July 15, 2014, which provided for the grant of up to 175,292 options. On December 14, 2018, the Company entered into a written resolution, which allowed SmartKem Limited to grant up to 458,316 options. SmartKem Limited adopted a new Investment Agreement (the “Agreement”) dated January 24, 2020, SmartKem Limited, by means of the Agreement, seeks to retain the services of such eligible persons and to provide incentives for such persons to exert maximum efforts for the success of SmartKem Limited. The Agreement commenced on the January 24, 2020 and the Agreement is administered by Board of Directors. The maximum aggregate number of shares of common shares which may be issued under all Awards granted to Participants under the Agreement shall be 15% of SmartKem Limited’s issued capital shares. In the event of a termination of continuous service (other than as a result of a change of control, as defined in the Agreement), unvested share options generally shall terminate and, with regard to vested share options, the exercise period shall be the lesser of the original expiration date or six months from the date continuous service terminates. The Company has granted these share option awards to employees and consultants. Outstanding options generally expire 10 years after the grant date. Options are subject to vesting and, grantees become fully vested and exercisable when there is a liquidity event, such as a change in control or sale or admission (listing as a public company or initial public offering (“IPO”)), and the employee, or consultant, must be providing services to the Company at the time of the event. During the year ended December 31, 2020, the Company granted 1,828,128 SmartKem Limited share options to employees and consultants. These options were either exercised or cancelled as a result of the reverse merger and recapitalization. On February 23, 2021, the Company approved the 2021 Equity Incentive Plan (“2021 Plan”), in which a maximum aggregate number of shares of common stock that may be issued under the 2021 Plan is 2,275,000 shares. Subject to the adjustment provisions of the 2021 Plan, the number of shares of the Company’s common stock available for issuance under the 2021 Plan will also include an annual increase on the first day of each fiscal year beginning with 2022 fiscal year and ending on the Company’s 2031 fiscal year in an amount equal to the least of: 1) 2,275,000 shares of the Company’s common stock; 2) four percent (4%) of the outstanding shares of the Company’s common stock on the last day of the immediately preceding fiscal year; or 3) such number of shares of the Company’s common stock as the administrator may determine. As a result of the reverse merger and recapitalization, an aggregate of 402,586 options were issued during February 2021 under the 2021 Plan in consideration for the cancellation of the SmartKem Limited options that were outstanding. Of these options, 336,557 had an exercise price of $0.001 per share and 66,029 had an exercise price of $2.00 per share and all expire on the ten year anniversary of the grant date. These options were fully vested on the grant date. During the year ended December 31, 2021, the Company has issued a further 1,707,326 options for employees, directors and consultants. The options vest over a period of four years, have an exercise price of $2.00 per share and expire on the ten year anniversary of the grant date. Determining the appropriate fair value of share-based awards requires the input of subjective assumptions, including the fair value of the Company’s common shares, and for share options, the expected life of the option, and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its share option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involves inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, the share-based compensation expense could be materially different for future awards. Options granted under the 2021 Plan for year ended December 31, 2021 were valued using the Black-Scholes option-pricing model with the following assumptions: Year Ended December 31, 2021 December 31, 2020 Expected term (years) 5 years – 6 years 0.46 years Risk-free interest rate 0.3% – 1.2% (0.7%) – 0.2% Expected volatility 54% – 58% 58% Expected dividend yield 0% 0% In the absence of a public trading market of the common share, on each grant date, the Company develops an estimate of the fair value of the common shares underlying the option grants. The Company estimated the fair value of the common shares by referencing arms-length transactions inclusive of the common shares underlying which occurred on or near the valuation date(s). From February 2022, the Company’s common shares are publicly traded and the Company will no longer have to estimate the fair value of the common share, rather the value will be determined based on quoted market prices. The Company determined the fair value of common share using methodologies, approaches and assumptions consistent with the AICPA Practice Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation and based in part on input from an independent third-party valuation firm. The Company estimates its expected volatility by using a combination of historical share price volatilities of similar companies within our industry. The risk-free interest rate assumption is based on observed interest rates for the appropriate term of the Company’s options on a grant date. The expected option term assumption is the contractual term, as the service period is implied under the practical expedient since the Company does not have sufficient exercise history to estimate expected term of its historical option awards. The following table reflects share activity under the share option plans for the years ended December 31, 2021 and 2020: Weighted- Average Weighted- Remaining Weighted- Aggregate Average Contractual Average Intrinsic Number of Exercise Term Fair Value at Value Shares Price (Years) Grant Date (in thousands) Options outstanding at January 1, 2020 160,317 1.18311 7.31 8.57245 Exercised — — Cancelled (86,967) 0.65226 Forfeited (90,729) 1.25578 Granted 1,828,128 0.05051 Options outstanding at December 31, 2020 1,810,749 $ 0.06143 9.70 $ 3.46867 $ Exercised (1,424,622) 0.01447 Cancelled (405,936) 0.06452 Forfeited (136,221) 0.00100 Granted 2,109,912 1.68113 Options outstanding at December 31, 2021 1,953,882 $ 1.72323 9.31 $ 1.12355 $ 465 Options exercisable at December 31, 2021 336,556 $ 0.39318 9.15 $ 465 Vested and expected to vest after December 31, 2021 1,953,882 $ 1.72323 9.31 $ 465 The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of our common shares at the end of the year for those options that had exercise prices lower than the fair value of our common shares. The aggregate intrinsic value of options exercised during the years ended December 31, 2021 was $2.4 million. No options were exercised in the year end December 31, 2020. The total fair value of options vesting in the year to December 31, 2021 was $6.6 million. No options vested in the year to December 31, 2020. The weighted-average grant-date fair value per share option granted for the year ended December 31, 2021 and 2020 was $1.14. and $0.04 respectively. Stock-based compensation, including stock options and warrants is included in the consolidated statements of operations as follows: For the Year Ended December 31, 2021 2020 Research and development $ 2,982 $ — Selling, general and administrative 3,214 — Total $ 6,196 $ — As of December 31, 2021 there was $1.3 million of compensation cost related to non-vested stock option awards not yet recognized that will be recognized on a straight-line basis through the end of the vesting periods in September 2025. The amount of future stock option compensation expense could be affected by any future option grants or by any forfeitures. |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2021 | |
INCOME TAXES | |
INCOME TAXES | 12. INCOME TAXES United States and foreign loss from operations before income taxes was as follows: For the Year Ended December 31, 2021 2020 United States $ (5,039) $ — Foreign (12,087) (23,133) Loss before income taxes $ (17,126) $ (23,133) A reconciliation of the statutory income tax rate to the Company’s effective tax rate consists of the following: For the Year Ended December 31, 2021 2020 Taxes at domestic rate 21.0 % 19.0 % Non-US statutory rates (0.8) % — % Permanent items (7.3) % (1.9) % Change in valuation allowance (22.4) % (9.4) % Loss on conversion of note and associated interest — % (8.4) % Statutory Rate Change 9.6 % — % Other (0.1) % 0.7 % Effective tax rate — % — % Prior to the reorganization, domestic refers to UK tax jurisdiction and foreign refers to all non-UK tax jurisdictions. The components of income tax provision/(benefit) are as follows: December 31, 2021 2020 Current Federal — — State — — Foreign — — Total Current $ — $ — Deferred Federal — — State — — Foreign — — Total Deferred — — Total $ — $ — Deferred income taxes reflect the net tax effects of temporary differences between the carrying value of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. The temporary differences that give rise to deferred tax assets and liabilities are as follows: December 31, 2021 2020 Deferred tax assets/(liabilities): Net operating loss carryforwards $ 7,506 $ 3,931 Convertible notes payable discount and embedded derivative — — Property plant and equipment (190) (129) Other 229 14 7,545 3,816 Valuation allowance (7,545) (3,816) Deferred tax assets, net of allowance $ — $ — The Company recorded a full valuation allowance against its net deferred tax assets as of December 31, 2021 and 2020. The Company considered the positive and negative evidence bearing upon its ability to realize the deferred tax assets. In addition to the Company’s history of cumulative losses, the Company cannot be certain that future taxable income will be sufficient to realize its deferred tax assets. Accordingly, a full valuation allowance has been provided against its net deferred tax assets. When the Company changes its determination as to the amount of its deferred tax assets that can be realized, the valuation allowance is adjusted with a corresponding impact to the provision for income taxes in the period in which such determination is made. As of December 31, 2021 and 2020, the Company had net operating loss carry-forwards of approximately $30,674 thousand and $20,691 thousand, respectively. The net operating loss carry-forwards were generated in the tax years from 2009 to 2021 with an unlimited carry-forward period. The Company has no uncertain tax positions, or penalties and interest accrued, that if recognized would reduce net operating loss carry-forwards or effect tax expense. The Company files tax returns as prescribed by the tax laws in the Unites States and United Kingdom in which they operate. In the normal course of business, the Company is subject to examination by the federal jurisdiction based on the statute of limitations. As of December 31, 2021, open years related to the United Kingdom are 2020 and 2019. The Company has no open tax audits with any taxing authority as of December 31, 2021. |
SELLING, GENERAL AND ADMINISTRA
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | ||
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | 11. SELLING, GENERAL AND ADMINISTRATIVE EXPENSES: Selling, general and administrative expenses are comprised of the following items: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Salaries and benefits $ 504 $ 507 $ 1,005 $ 4,242 Rent and property tax (benefit)/expense (12) 3 16 16 Insurance 165 172 331 253 Utilities 1 1 2 2 Sales and marketing 247 83 434 105 Legal and professional fees 449 569 738 691 Other selling, general, and administrative expenses 16 10 85 19 Total $ 1,370 $ 1,345 $ 2,611 $ 5,328 | 13. SELLING, GENERAL AND ADMINISTRATIVE EXPENSES: Selling, general and administrative expenses are comprised of the following items: For the Years End December 31, 2021 2020 Salaries and benefits $ 5,366 $ 908 Rent and property tax expense 24 62 Insurance 486 — Utilities 4 1 Sales and marketing 749 96 Legal and professional fees 1,132 625 Other selling, general, and administrative expenses 308 15 Total $ 8,069 $ 1,707 |
DEFINED CONTRIBUTION PENSION
DEFINED CONTRIBUTION PENSION | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
DEFINED CONTRIBUTION PENSION | ||
DEFINED CONTRIBUTION PENSION | 12. DEFINED CONTRIBUTION PENSION: The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund. Pension cost is included in the unaudited interim condensed consolidated statements of operations as follows: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 26 $ 24 $ 53 $ 48 Selling, general and administrative 13 9 27 17 Total pension cost $ 39 $ 33 $ 80 $ 65 As of June 30, 2022 and December 31, 2021 there were no amounts owed to the pension scheme. | 14. DEFINED CONTRIBUTION PENSION: The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund. Pension cost is included in the consolidated statements of operations as follows: For the Years End December 31, 2021 2020 Research and development $ 98 $ 83 Selling, general and administrative 42 31 Total pension cost $ 140 $ 114 As of December 31, 2021 and December 31, 2020 there were no amounts owed to the pension scheme. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
RELATED PARTY TRANSACTIONS | ||
RELATED PARTY TRANSACTIONS | 13. RELATED PARTY TRANSACTIONS: In addition to transactions and balances related share-based compensation to officers and directors, the Company incurred expenses of $29 thousand and $18 thousand, for the three months ended June 30, 2022 and 2021, respectively, and $47 thousand and $25 thousand, for the six months ended June 30, 2022 and 2021 due to reimbursement of expenses and compensation for members of the Board of Directors. These expenses are recorded in selling, general & administrative in the unaudited interim condensed consolidated statements of operations. As of both June 30, 2022 and December 31, 2021, there was $18 thousand payable to members of the Board of Directors that are recorded in accounts payable and accrued expenses on the unaudited interim condensed consolidated balance sheets. Octopus Share Purchase On January 27, 2022, we sold an aggregate of 1,000,000 shares of our common stock at a purchase price of $2.00 per share to Octopus Titan VCT plc and Octopus Investments Nominees Limited in accordance with the Letter Agreement, dated as of February 23, 2021, between the Company and Octopus Titan VCT plc and certain related parties. | 15. RELATED PARTY TRANSACTIONS: On May 14, 2020, the Company issued a promissory note (the “Note”) to a stockholder of the Company pursuant to which the Company agreed to repay the sum of any and all amounts advanced to the Company, on or before the date that the Company consummated a business combination with a private company or reverse takeover transaction or other transaction after which the Company would cease to be a shell company. The Note was non-interest bearing unless an event of default occurred. As of December 31, 2020, the amount due under the note payable was $20,000 . The maximum amount due under the note payable in the year ended December 31, 2021, was Prior to the closing of the Exchange, we used the office space and equipment of our management at no cost. In addition to transactions and balances related share-based compensation to officers and directors, the Company incurred expenses of $65 thousand and $7 thousand, for the year ended December 31, 2021 and 2020, respectively, due to reimbursement of expenses and compensation for members of the Board of Directors. These expenses are recorded in selling, general & administrative in the consolidated statements of operations. As of December 31, 2021 and December 31, 2020, there was $18 thousand and zero, respectively, payable to members of the Board of Directors that are recorded in accounts payable and accrued expenses on the consolidated balance sheets. During the year ended December 31, 2021, the Company reimbursed an owner for legal fees and other expenses as a result of the Exchange (see Note 1). The reimbursement of these fees for services resulted in an expense of $66 thousand for the year ended December 31, 2021 and there was zero payable as of December 31, 2021. The Company obtained consulting services from an individual who is a family member of a Director of the Company. The consulting services resulted in an expense of $35 thousand for the year ended December 31, 2021 and there was zero payable as of December 31, 2021. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SUBSEQUENT EVENTS. | ||
SUBSEQUENT EVENTS | 14. SUBSEQUENT EVENTS: During July 2022, the Company issued a further 225,700 EMI options, 150,000 ISO options and 92,300 NQSO options to employees and directors under the 2021 plan. The options vest over a period of four years, expire on the ten | 16. SUBSEQUENT EVENTS: Under the adjustment provisions of the 2021 Plan, on January 1, 2022 the number of shares of the Company’s common stock available for issuance under the 2021 Plan was increased by 1,022,172 or four percent (4%) of the total number of shares of Common Stock outstanding on December 31, 2021. After giving effect to the Evergreen Increase, the total number of shares of Common Stock that may be issued under Plan will be 3,297,172. On January 27, 2022, we sold 1,000,000 shares of our common stock at a purchase price of $2.00 per share to Octopus Investors in accordance with the Octopus Letter Agreement, dated as of February 23, 2021, among the Company and Octopus Titan VCT plc and certain related parties. In February 2022, 12,500 shares of our common stock were issued to a vendor in consideration for services to be provided. Quotations on our common stock on the OTC Market Group’s OTCQB ® |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
Restatement of previously filed financial statements | Restatement of previously issued financial statements The Company has determined that it made an error in the presentation and accounting of its consolidated statement of cash flows in the Company’s annual and interim consolidated financial statements during 2021 and 2022. The management of the company has assessed its accounting policies as well as the presentation and accounting for the gain and loss on foreign currency and has concluded that it was necessary to restate its previously issued financial statements for the correction of this error related to incorrect classification of gain and loss on foreign currency in effect of exchange rate changes on cash instead of including such non-cash unrealized gains and losses in cash flows from operating activities. The effect of this error was to overstate net cash used in operating activities and effect of exchange rate changes on cash by $808 thousand for the year ended December 31, 2021. The errors and the required restatement had no effect on the Company’s cash flows from investing activities, financing activities, net changes in cash or cash and cash equivalents as of December 31, 2021 and had no impact on the Company’s consolidated balance sheet, the Company’s consolidated statements of operations and comprehensive loss and stockholders’ equity as of and for year ended December 31, 2021. The changes are presented below (in thousands): For the year ended December 31, 2021 Net cash used in operating activities as previously reported $ (10,536) Adjustment for Loss/(Gain) on foreign currency transactions 808 Net cash used in operating activities as restated $ (9,728) Effect of exchange rate changes on cash as previously reported $ 135 Adjustment for (Gain)/Loss on foreign currency transactions (808) Effect of exchange rate changes on cash as restated $ (673) | |
Basis of Consolidation | Basis of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of SmartKem, Inc. and its wholly-owned subsidiaries, SmartKem Delaware, Inc. and SmartKem Limited. The Company does not have any nonconsolidated subsidiaries. All intercompany balances and transactions have been eliminated on consolidation, including unrealized gains and losses on transactions between the companies. The Company's formerly wholly-owned subsidiary, SmartKem Delaware Inc. was dissolved on May 13, 2021. | Basis of Consolidation The consolidated financial statements include the accounts of SmartKem, Inc. and its wholly-owned subsidiaries, SmartKem Delaware, Inc. and SmartKem Limited. The Company does not have any nonconsolidated subsidiaries. All intercompany balances and transactions have been eliminated on consolidation, including unrealized gains and losses on transactions between the companies. The Company's formerly wholly-owned subsidiary, SmartKem Delaware Inc. was dissolved on May 13, 2021. |
Comprehensive loss | Comprehensive loss Comprehensive loss of all periods presented is comprised primarily of net loss and foreign currency translation adjustments. | Comprehensive loss Comprehensive loss of all periods presented is comprised primarily of net loss and foreign currency translation adjustments. |
Management's Use of Estimates | Management’s Use of Estimates The preparation of interim condensed consolidated financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company’s unaudited interim condensed consolidated financial statements relates to the valuation of common share, fair value of share options, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates. | Management’s Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relates to the valuation of common share, fair value of share options, fair value of embedded conversion features in the convertible notes, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. As of June 30, 2022 and December 31, 2021, the Company did not have any cash equivalents. | Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. As of December 31, 2021 and 2020, the Company did not have any cash equivalents. |
Accounts Receivable | Accounts Receivable Accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of non-collection. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required. There was no allowance for doubtful accounts recorded as of June 30, 2022 and December 31, 2021. | Accounts Receivable Accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of non-collection. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required. There was no allowance for doubtful accounts recorded as of December 31, 2021 and 2020. |
Impairment of Long-Lived Assets | Impairment of Long-Lived Assets Management continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. If the carrying amount is greater than the undiscounted cash flows, the carrying amount of the asset is reduced to the asset’s fair value. An impairment loss is recognized immediately as an operating expense in the condensed consolidated statements of operations. Reversal of previously recorded impairment losses are prohibited. As of June 30, 2022 and December 31, 2021, Company’s management believed that no revision to the remaining useful lives or impairment of the Company’s long-lived assets was required. | Impairment of Long-Lived Assets Management continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. If the carrying amount is greater than the undiscounted cash flows, the carrying amount of the asset is reduced to the asset’s fair value. An impairment loss is recognized immediately as an operating expense in the consolidated statements of operations. Reversal of previously recorded impairment losses are prohibited. As of December 31, 2021 and 2020, Company’s management believed that no revision to the remaining useful lives or impairment of the Company’s long-lived assets was required. |
Warrants | Warrants The accounting treatment of warrants issued is determined pursuant to the guidance provided by ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging | Warrants The accounting treatment of warrants issued is determined pursuant to the guidance provided by ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging |
Leases | Leases Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the unaudited condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. The Company has elected not to present short-term leases as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the Company’s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments. | Leases Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the consolidated balance sheets as of December 31, 2021 and 2020. The Company has elected not to present short-term leases as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the Company’s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments. |
Revenue | Revenue The Company applies the provisions of ASC 606 Revenue from Contracts with Customers The Company’s current contracts with customers do not contain significant estimates or judgments. All of the Company’s revenue contains a single performance obligation that is recognized upon fulfilment of the sales order. The Company derives its revenues primarily from sales of TRUFLEX ® | Revenue The Company applies the provisions of ASC 606, Revenue from Contracts with Customers The Company’s current contracts with customers do not contain significant estimates or judgments. All of the Company’s revenue contains a single performance obligation that is recognized upon fulfilment of the sales order. The Company derives its revenues primarily from sales of demonstrator units to customers evaluating organic semiconductor technology. The transaction price is stated in each customer agreement and is allocated to a single performance obligation. Revenue is recognized upon shipment of each demonstrator, at a point in time. The Company does not have any significant financing components as payment is received at or shortly after the point of sale. Costs incurred to obtain a contract will be expensed as incurred when the amortization period is less than a year. |
Other Operating Income | Other Operating Income The Company’s other operating income is related to government grant incentives received for qualifying research and development projects, and research and development tax credits related to the United Kingdom’s Research and Development Expenditure Credit scheme, which is a government tax incentive designed to reward innovative companies for investing in research and development. Such incentives are recorded as other income when it is probable the amounts are collectible and can be reasonably estimated. For the three months ended June 30, 2022 and 2021, the Company recorded grant income and research & development tax credits of $294 thousand and $256 thousand, respectively, and $578 thousand and $688 thousand for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, and December 31, 2021, the Company had receivables related to research & development tax credits for payments not yet received of $1,505 thousand and $1,070 thousand, respectively. | Other Operating Income The Company’s other operating income is related to government grant incentives received for qualifying research and development projects, and research and development tax credits related to the United Kingdom’s Research and Development Expenditure Credit scheme, which is a government tax incentive designed to reward innovative companies for investing in research and development. Such incentives are recorded as other income when it is probable the amounts are collectible and can be reasonably estimated. For the year ended December 31, 2021 and 2020, the Company recorded grant income and research & development tax credits of $1,285 thousand and $1,437 thousand, respectively, which are recorded as other operating income in the accompanying consolidated statements of operations. As of December 31, 2021, and December 31, 2020, the Company had receivables related to research & development tax credits for payments not yet received of $1,070 thousand and $982 thousand, respectively. |
Share-based compensation | Share-based compensation All share-based payments, including grants of stock options, are measured based on the fair value of the share-based awards at the grant date and recognized over their respective vesting periods. Outstanding options generally expire 10 years after the grant date. The Company has issued options that vest based on service requirements and options become exercisable when service requirements are met. Due to the Exchange, all options outstanding immediately prior to the event with a performance obligation requirement became vested and exercisable. The estimated fair value of stock options at the grant date is determined using the Black-Scholes pricing model. The Black-Scholes option pricing model requires inputs such as the fair value of common stock on date of grant, expected term, expected volatility, dividend yield, and risk-free interest rate. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The Company records forfeitures when they occur. | Share-based compensation All share-based payments, including grants of stock options, are measured based on the fair value of the share-based awards at the grant date and recognized over their respective vesting periods. Outstanding options generally expire 10 years after the grant date. The Company has issued options that vest based on service requirements and issued options that vest based on performance requirements. Options become exercisable when service requirements are met. In the case of performance based options, options become exercisable when there is a liquidity event, such as a change in control or sale or admission (listing as a public company or initial public offering (“IPO”)), and the employee, or consultant, must be providing services to the Company at the time of the event. Due to the Exchange, all options outstanding immediately prior to the event with a performance obligation requirement became vested and exercisable. Non-cash stock-based compensation expense for the year ended December 31, 2021 was The estimated fair value of stock options at the grant date is determined using the Black-Scholes pricing model. The Black-Scholes option pricing model requires inputs such as the fair value of common stock on date of grant, expected term, expected volatility, dividend yield, and risk-free interest rate. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The Company records forfeitures when they occur. |
Functional currency and operations | Functional Currency and Operations Prior to the Exchange, SmartKem Limited’s (“the predecessor’s”) functional currency was the British Pound Sterling (“GBP”), and the consolidated financial statements were presented in United States dollars (“USD”). The predecessor’s functional currency was the respective local currency of the primary economic environment in which an entity’s operations are conducted. The predecessor translated the financial statements into the presentation currency using exchanges rates in effect on the balance sheet date for assets and liabilities and average exchanges rates for the period for statement of operations accounts, with the difference recognized in accumulated other comprehensive income /(loss). From the date of the Exchange forward, the Company’s functional currency is the U.S. dollar (“USD”). The functional currency of the Company’s foreign operation is the respective local currency. Assets and liabilities of foreign operation denominated in local currencies are translated at the spot rate in effect at the applicable reporting date. The condensed consolidated statements of operations and comprehensive loss are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized gain/loss is recognized as foreign currency translation as a component of other comprehensive income. | Functional Currency and Operations Prior to the Exchange, SmartKem Limited’s (“the predecessor’s”) functional currency was the British Pound Sterling (“GBP”), and the consolidated financial statements were presented in United States dollars (“USD”). The predecessor’s functional currency was the respective local currency of the primary economic environment in which an entity’s operations are conducted. The predecessor translated the consolidated financial statements into the presentation currency using exchanges rates in effect on the balance sheet date for assets and liabilities and average exchanges rates for the period for statement of operations accounts, with the difference recognized in accumulated other comprehensive income/ (loss). The Company’s functional currency is the U.S. dollar (“USD”). The functional currency of the Company’s foreign operation is the respective local currency. Assets and liabilities of foreign operations denominated in local currencies are translated at the spot rate in effect at the applicable reporting date. The consolidated statements of operations and comprehensive loss are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized gain/loss is recognized as foreign currency translation as a component of other comprehensive income. |
Foreign Currency Transactions | Foreign Currency Transactions The company measures foreign currency denominated monetary assets and liabilities using exchange rates in effect at the end for the period. Transaction gains and losses are included in net loss. Foreign exchange losses, primarily driven by foreign exchange revaluation of our dollar borrowings held by non-dollar group undertakings, were $1,284 thousand and $1,638 thousand for the three- and six-month periods ended June 30, 2022, respectively. Foreign exchange gains were $57 thousand and foreign exchanges losses were $412 thousand for the three-and six-month periods ended June 30, 2021, respectively. | |
Income Taxes | Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. As of June 30, 2022 and December 31, 2021, there were no accruals for uncertain tax positions. | Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. As of December 31, 2021 and 2020, there were no material uncertain tax positions. |
Contingent Liabilities | Contingent Liabilities A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of June 30, 2022, the Company does not expect that such matters will have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows. | Contingent Liabilities A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of December 31, 2021, the Company does not expect that such matters will have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows. |
Offering Costs | Offering Costs Direct and incremental legal and accounting costs associated with the Company’s issuance of common stock and warrants are deferred and classified as a component of other assets on the condensed consolidated balance sheet until completion of the issuance. Upon completion of the issuance, deferred offering costs are reclassified from other assets to equity and recorded against the net proceeds received in the issuance. For the six months ended June 30, 2022 and 2021 respectively, $170 thousand and $2,454 thousand of offering costs were recorded in additional paid-in capital. No offering costs were deferred as of both June 30, 2022 and December 31, 2021. | Offering Costs Direct and incremental legal and accounting costs associated with the Company’s issuance of common stock and warrants are deferred and classified as a component of other assets on the consolidated balance sheet until completion of the issuance. Upon completion of the issuance, deferred offering costs are reclassified from other assets to equity in additional paid-in capital and recorded against the net proceeds received in the issuance. The deferred offering costs incurred as of December 31, 2020 were immaterial and no offering costs were capitalized. For the year ended December 31, 2021 $2,454 thousand of offering costs were recorded in additional paid-in capital. For the year ended December 31, 2021, $1.329 million of direct and incremental costs associated with the Exchange were recorded as Transaction Expenses in the Consolidated Statement of Operations and Comprehensive Loss. |
Segment Information | Segment Information The Company has determined that it operates and reports in one segment | Segment Information The Company has determined that it operates and reports in one segment |
Basic and Diluted Loss Per Share | Basic and Diluted Loss Per Share Basic and diluted net loss per share is determined by dividing net loss by the weighted average ordinary shares outstanding during the period. For all periods presented with a net loss, the shares underlying the ordinary share options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per share are the same for periods with a net loss. The loss per share information in these unaudited interim condensed consolidated financial statements is reflected and calculated as if the Company had existed since January 1, 2020. Accordingly, loss per share for all periods was calculated based on the number of shares retroactively adjusted for the exchange ratio determined in the reverse recapitalization (see also note 1). The Company has 2,168,000 pre-funded common stock warrants outstanding as of June 30, 2022, which became exercisable on April 24, 2021 based on terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $0.01, these shares are considered outstanding common shares and included in computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions were met on April 24, 2021. The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: June 30, 2022 2021 Options 1,937,382 1,596,562 Warrants 985,533 985,533 Total 2,922,915 2,582,095 | Basic and Diluted Loss Per Share Basic and diluted net loss per share is determined by dividing net loss by the weighted average ordinary shares outstanding during the period. For all periods presented with a net loss, the shares underlying the ordinary share options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per share are the same for periods with a net loss. The loss per share information in these consolidated financial statements is reflected and calculated as if the Company had existed since January 1, 2020. Accordingly, loss per share for all periods was calculated based on the number of shares retroactively adjusted for the exchange ratio determined in the reverse recapitalization (see also note 1). The Company has 2,168,000 pre-funded common stock warrants outstanding as of December 31, 2021, which became exercisable on April 23, 2021 based on terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $0.01, these shares are considered outstanding common shares and included in computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions were met on April 23, 2021. The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: December 31, 2021 2020 Options 1,953,882 1,810,749 Warrants 985,533 — Total 2,939,415 1,810,749 |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Adopted In May 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2021-04, Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity Classified Written Call Options In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) Recent Accounting Pronouncements Not Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments: Credit Losses (Topic 326) | Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments: Credit Losses (Topic 326) annual and interim periods beginning after December 15, 2022. Management is currently evaluating the impact of these changes on the consolidated financial statements. In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40). The amendments in this update affect all entities that issue freestanding written call options (for example warrants) that are classified in equity. Specifically, the amendments affect those entities when a freestanding equity-classified written call option is modified or exchanged and remains equity classified after the modification or exchange. The amendments that relate to the recognition and measurement of EPS for certain modifications or exchanges of freestanding equity-classified written call options affect entities that present EPS in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Management is currently evaluating the impact of this guidance but does not expect this update to have a material impact on the Company's consolidated financial statements. In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance. The amendments in this update affect all business entities that account for a transaction with a government by applying a grant or contribution accounting model by analogy to other accounting guidance. The amendments in this Update require annual disclosures about: (1) Information about the nature of the transactions and the related accounting policy used to account for the transactions; (2) The line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and (3) Significant terms and conditions of the transactions, including commitments and contingencies. The amendments in this update are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. Management is currently evaluating the impact of this guidance but does not expect this update to have a material impact on the Company's consolidated financial statements. |
Reclassifications | Reclassifications Certain amounts in prior periods' interim condensed consolidated financial statements have been reclassified to conform to the current period’s presentation. | Reclassifications Certain amounts in prior years' consolidated financial statements have been recast and reclassified to conform to the current year's presentation |
Basis for Preparation | Basis for Presentation These consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and accounting principles generally accepted in the United States of America ( “US GAAP”) as defined by the Financial Accounting Standards Board (FASB) within the FASB Accounting Standards Codification (“ASC”) and are presented in thousands, except number of shares and per share data . | |
Going Concern | Going Concern The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities, and commitments in the ordinary course of business. Since inception, we have incurred recurring losses including net losses of $17.1 million and $23.1 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $75.1 million. We anticipate operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, further development of our technology and products and expenses related to the commercialization of our products. We expect that our cash and cash equivalents of $12.2 million as of December 31, 2021 will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the issuance date of these consolidated financial statements through the first quarter of 2023. It is possible this period could be shortened if there are any significant increases in planned spending or development programs or more rapid progress of development programs than anticipated. Our future viability is dependent on our ability to raise additional capital to fund our operations. In the long-term, we will need to obtain additional funds to satisfy our operational needs and to fund our sales and marketing efforts, research and development expenditures, and business development activities. Until such time, if ever, as we can generate sufficient cash through revenue, we expect to finance our working capital requirements through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. There can be no assurance however that such financing will be available in sufficient amounts, when and if needed, on acceptable terms or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including the market demand for the Company’s products and services, the quality of product development efforts, management of working capital, and continuation of normal payment terms and conditions for purchase of services. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows for operations, then the Company will need to raise additional funding to continue as a going concern. | |
Certain Risk and Uncertainties | Certain Risk and Uncertainties The Company’s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the growth stage, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements. See Item 1a of this Form 10-K/A for a fuller discussion of the Company’s risk factors. The Company has access under a framework agreement to equipment which is used in the manufacturing of demonstrator products employing the Company’s inks. If the Company lost access to this fabrication facility, it would materially and adversely affect the Company’s ability to manufacture prototypes and demonstration products for potential customers. The loss of this access could significantly impede the Company’s ability to engage in product development and process improvement activities. Alternative providers of similar services exist, but would take effort and time to bring into the Company’s operations. | |
Concentrations of Credit Risk | Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. | |
Property, Plant and Equipment | Property, Plant and Equipment Property, plant and equipment is stated at cost, less accumulated depreciation. Maintenance and repairs are expensed when incurred. Additions and improvements that extend the economic useful life of the asset are capitalized and depreciated over the remaining useful lives of the assets. The cost and accumulated depreciation of assets sold or retired are removed from the respective accounts, and any resulting gain or loss is reflected in current earnings. Depreciation and amortization are provided using the accelerated declining balance method in amounts considered to be sufficient to amortize the cost of the assets to operations over their estimated useful lives. Property, plant and equipment is depreciated at 25 percent of net book value on an annual basis, resulting in an estimated useful life of approximately 15 years. | |
Derivative Asset for Embedded Conversion Features | Derivative Asset for Embedded Conversion Features The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates convertible notes to determine if those contracts or embedded components of those contracts qualify as derivatives to be accounted for separately. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The result of this accounting treatment is that the fair value of the embedded derivative is recorded as a liability and marked-to-market each balance sheet date, with the change in fair value recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The fair value of the embedded conversion features are estimated using a Monte Carlo simulation model, in which possible outcomes and their values are simulated repeatedly and randomly. Under the Monte Carlo method the Company estimated the fair value of the convertible notes conversion feature at the time of issuance and subsequent remeasurement dates, utilizing the with-and without method, where the value of the derivative feature is the difference in values between a note simulated with the embedded conversion feature and the value of the same note simulated without the embedded conversion feature. Estimating fair values of embedded conversion features requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. | |
Fair Value of Financial Instruments | Fair Value of Financial Instruments ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2021 and 2020. The carrying value of the Company’s cash, accounts receivable, other receivables, prepaid expenses and other current assets, accounts payable and accrued expenses approximate fair value because of the short-term maturity of these financial instruments. The carrying value of derivative asset is displayed at fair value. See Note 8 for additional information regarding fair value measurements. | |
Convertible Notes | Convertible Notes The Company accounts for its convertible notes in accordance with ASC 470-20, Debt with Conversion and Other Options Debt discount created by the bifurcation of embedded feature in the convertible notes are reflected as a reduction to the related debt liability. The discount is amortized to interest expense over the term of the debt using the effective-interest method. | |
Research and Development Expenses | Research and Development Expenses The Company expenses research and development costs as incurred. Research and development costs include salaries, employee benefit costs, direct project costs, supplies and other related costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. | |
Patent and Licensing Costs | Patent and Licensing Costs Patent and licensing costs are expensed as incurred because their realization is uncertain. These costs are classified as research and development expenses in the accompanying consolidated statements of operations and comprehensive loss. | |
Ordinary Shares Valuation | Ordinary Shares Valuation Due to the absence of an active market for the Company’s ordinary shares, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its ordinary shares. In determining the exercise prices for options to be issued, the estimated fair value of the Company’s ordinary shares on each grant date was estimated based upon a variety of factors, including: ● the issuance prices of ordinary shares; ● the rights and preferences of preferred shareholders; ● the progress of the Company’s research and development programs; ● the Company’s stage of development and business strategy; ● external market conditions affecting the technology industry and trends within the technology industry; ● the Company’s financial position, including cash on hand; ● the Company’s historical and forecasted performance and operating results; ● the lack of active public market for the Company’s ordinary shares; ● the likelihood of achieving a liquidity event, such as a securities offering, initial public offering or a sale of the Company’s shares. Significant changes to the key assumptions underlying the factors used could result in different fair values of ordinary shares at each valuation date. Ordinary shares are classified in shareholders’ equity and represent issued share capital. |
BUSINESS AND LIQUIDITY (Tables)
BUSINESS AND LIQUIDITY (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
BUSINESS AND BASIS OF PREPARATION | ||
Restatement of previously issued financial statements | For the Six Months Ended June 30, 2021 Net cash used in operating activities as previously reported $ (6,441) Adjustment for (Loss)/Gain on foreign currency transactions 412 Net cash used in operating activities as restated $ (6,029) Effect of exchange rate changes on cash as previously reported $ 25 Adjustment for (Gain)/Loss on foreign currency transactions (412) Effect of exchange rate changes on cash as restated $ (387) | For the year ended December 31, 2021 Net cash used in operating activities as previously reported $ (10,536) Adjustment for Loss/(Gain) on foreign currency transactions 808 Net cash used in operating activities as restated $ (9,728) Effect of exchange rate changes on cash as previously reported $ 135 Adjustment for (Gain)/Loss on foreign currency transactions (808) Effect of exchange rate changes on cash as restated $ (673) |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
Schedule of Antidilutive Securities | June 30, 2022 2021 Options 1,937,382 1,596,562 Warrants 985,533 985,533 Total 2,922,915 2,582,095 | December 31, 2021 2020 Options 1,953,882 1,810,749 Warrants 985,533 — Total 2,939,415 1,810,749 |
PREPAID EXPENSES AND OTHER CU_2
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
PREPAID EXPENSES AND OTHER CURRENT ASSETS | ||
Schedule of Prepaid Expenses and Other Current Assets | June 30, December 31, 2022 2021 Prepaid service charges and property taxes $ 83 $ 58 Prepaid utilities 31 51 Prepaid insurance 633 412 Prepaid administrative expenses 55 63 Prepaid technical fees 212 141 Prepaid consulting fees 629 27 VAT receivable 141 50 Other Receivable and other prepaid expenses 31 — Total prepaid expenses and other current assets $ 1,815 $ 802 | December 31, 2021 2020 Prepaid rent $ 58 $ 65 Prepaid utilities 51 30 Prepaid insurance 412 41 Prepaid administrative expenses 63 61 Prepaid technical fees 141 8 Prepaid consulting fees 27 — VAT receivable 50 54 Total prepaid expenses and other current assets $ 802 $ 259 |
PROPERTY, PLANT AND EQUIPMENT (
PROPERTY, PLANT AND EQUIPMENT (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
PROPERTY, PLANT AND EQUIPMENT | ||
Schedule of Property, Plant and Equipment | June 30, December 31, 2022 2021 Plant and equipment $ 1,523 $ 1,633 Furniture and fixtures 220 245 Computer hardware and software 24 26 1,767 1,904 Less: Accumulated depreciation (1,090) (1,102) Property, plant and equipment, net $ 677 $ 802 | December 31, 2021 2020 Plant and equipment $ 1,633 $ 1,316 Furniture and fixtures 245 248 Computer hardware and software 26 26 1,904 1,590 Less: Accumulated depreciation (1,102) (908) Property, plant and equipment, net $ 802 $ 682 |
ACCOUNTS PAYABLE AND ACCRUED _2
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | ||
Schedule of Accounts Payable and Accrued Expenses | June 30, December 31, 2022 2021 Accounts payable $ 457 $ 510 Accrued expenses – lab refurbishments 118 131 Accrued expenses – technical fees 58 66 Accrued expenses – variable rent & utilities 9 20 Accrued expenses – audit & accounting fees 167 191 Accrued expenses – other 67 112 Credit card liabilities 34 10 Payroll and social security liabilities 280 383 Total accounts payable and accrued expenses $ 1,190 $ 1,423 | December 31, 2021 2020 Accounts payable $ 510 $ 227 Accrued expenses – lab refurbishments 131 132 Accrued expenses – technical fees 66 45 Accrued expenses – variable rent & utilities 20 67 Accrued expenses – audit & accounting fees 191 250 Accrued expenses – other 112 6 Credit card liabilities 10 6 Payroll and social security liabilities 383 128 Total accounts payable and accrued expenses $ 1,423 $ 861 |
LEASES (Tables)
LEASES (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
LEASES | ||
Schedule of Lease Costs | For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Operating lease cost $ 68 $ 52 $ 131 $ 99 Short-term lease cost 2 13 4 26 Variable lease cost 41 64 95 98 Total lease cost $ 111 $ 129 $ 230 $ 223 For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 105 $ 120 $ 218 $ 207 Selling, general and administrative 6 9 12 16 Total lease cost $ 111 $ 129 $ 230 $ 223 | For the Year Ended December 31, 2021 2020 Operating lease cost $ 225 $ 175 Short-term lease cost 32 48 Variable lease cost 140 401 Total lease cost $ 397 $ 624 For the Year Ended December 31, 2021 2020 Research and development $ 373 $ 562 Selling, general and administrative 24 62 Total lease cost $ 397 $ 624 |
Schedule of Operating Lease Assets And Liabilities | June 30, December 31, 2022 2021 Assets Operating lease right of use assets $ 549 $ 154 Total lease assets $ 549 $ 154 Liabilities Current liabilities: Operating lease liability – current portion $ 208 $ 87 Noncurrent liabilities: Operating lease liability, net of current portion 320 28 Total lease liabilities $ 528 $ 115 | December 31, 2021 2020 Assets Operating lease right of use assets $ 154 $ 236 Total lease assets $ 154 $ 236 Liabilities Current liabilities: Operating lease liability – current portion $ 87 $ 217 Noncurrent liabilities: Operating lease liability, net of current portion 28 20 Total lease liabilities $ 115 $ 237 |
Schedule of Operating Lease Cash Flow Information | For the Six Months Ended June 30, 2022 2021 Operating cash outflows from operating leases $ 115 $ 120 Supplemental non-cash amounts of operating lease liabilities arising from obtaining right of use assets $ 539 $ 86 | For the Year Ended December 31, 2021 2020 Operating cash outflows from operating leases $ 276 $ 157 Supplemental non-cash amounts of operating lease liabilities arising from obtaining right of use assets $ 136 $ — |
Schedule of Weighted Average Remaining Lease Term and Weighted Average Discount Rate | For the Six Months Ended June 30, 2022 2021 Weighted average remaining lease term (in years) – operating leases 2.66 1.10 Weighted average discount rate – operating leases 7.64 % 6.12 % | For the Year Ended December 31, 2021 2020 Weighted average remaining lease term (in years) – operating leases 1.40 1.35 Weighted average discount rate – operating leases 6.07 % 6.30 % |
Schedule of Operating Lease, Liability, Maturity | As of June 30, 2022 2022 $ 137 2023 220 2024 219 2025 9 2026 — Thereafter — Total undiscounted lease payments 585 Less imputed interest (57) Total net lease liabilities $ 528 | As of December 31, 2021 2022 $ 93 2023 22 2024 7 2025 — 2026 — Thereafter — Total undiscounted lease payments 122 Less future minimum short-term lease payments (3) Less imputed interest (4) Total net lease liabilities $ 115 |
CONVERTIBLE NOTES AND NOTES P_2
CONVERTIBLE NOTES AND NOTES PAYABLE (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
CONVERTIBLE NOTES AND NOTES PAYABLE. | |
Schedule of activity for the Company's convertible notes | For the Year Ended December 31, 2021 2020 Balance, beginning of year $ — $ 7,280 Amortization of debt discount — 25 Extinguishment of debt discount — 6,767 Loss on conversion of note — 9,344 Conversion of notes to equity — (23,630) Foreign currency translation — 214 Balance, end of year $ — $ — |
DERIVATIVE ASSET (Tables)
DERIVATIVE ASSET (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
DERIVATIVE ASSET [Abstract] | |
Summary of the changes in fair value of derivative asset measured on a recurring basis | For the Year Ended December 31, 2021 2020 Balance, beginning of year $ — $ 1,407 Loss on fair value of derivative asset included in earnings — (6,282) Gain on extinguishment of derivative asset upon conversion — 4,920 Foreign currency translation — (45) Balance, end of year $ — $ — |
STOCKHOLDERS' EQUITY (Tables)
STOCKHOLDERS' EQUITY (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Common Stock Warrants | ||
Schedule of Warrants | Weighted- Average Weighted- Remaining Average Contractual Number of Exercise Term Shares Price (Years) Warrants outstanding at January 1, 2022 985,533 $ 2.00 4.15 Exercised — — — Forfeited or Expired — — — Granted — — — Warrants outstanding at June 30, 2022 985,533 $ 2.00 3.65 | Weighted- Average Weighted- Remaining Average Contractual Number of Exercise Term Shares Price (Years) Warrants outstanding at January 1, 2021 — $ — — Exercised — — — Forfeited or Expired — — — Granted 985,533 2.00 5.00 Warrants outstanding at December 31, 2021 985,533 $ 2.00 4.15 |
Schedule of Fair Value of Common Stock Warrants Assumptions | Year Ended December 31, 2021 Expected term (years) 5 years Risk-free interest rate 0.60% Expected volatility 54% Expected dividend yield 0% | |
Pre Funded Warrants | ||
Schedule of Warrants | Weighted- Average Number of Exercise Shares Price Pre-funded warrants outstanding at January 1, 2022 2,168,000 $ 0.01 Exercised — — Forfeited or Expired — — Granted — Pre-funded warrants outstanding at June 30, 2022 2,168,000 $ 0.01 | Weighted- Average Number of Exercise Shares Price Pre-funded warrants outstanding at January 1, 2021 — $ — Exercised — — Forfeited or Expired — — Granted 2,168,000 0.01 Pre-funded warrants outstanding at December 31, 2021 2,168,000 $ 0.01 |
SHARE-BASED COMPENSATION (Table
SHARE-BASED COMPENSATION (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SHARE-BASED COMPENSATION | ||
Schedule of Black Scholes option-pricing model with assumptions used | Year Ended December 31, 2021 December 31, 2020 Expected term (years) 5 years – 6 years 0.46 years Risk-free interest rate 0.3% – 1.2% (0.7%) – 0.2% Expected volatility 54% – 58% 58% Expected dividend yield 0% 0% | |
Summary of non-vested share option activity under the share option plans | Weighted- Average Weighted- Remaining Weighted- Aggregate Average Contractual Average Intrinsic Number of Exercise Term Fair Value at Value Shares Price (Years) Grant Date (in thousands) Options outstanding at January 1, 2022 1,953,882 $ 1.72323 9.31 $ 1.12355 Exercised — — Cancelled — — Forfeited (16,500) 2.00000 Granted — — Options outstanding at June 30, 2022 1,937,382 $ 1.72087 8.81 $ 1.12553 Options exercisable at June 30, 2022 708,624 $ 1.23685 8.71 $ 541 Vested and expected to vest after June 30, 2022 1,937,382 $ 1.72087 8.81 $ 541 | Weighted- Average Weighted- Remaining Weighted- Aggregate Average Contractual Average Intrinsic Number of Exercise Term Fair Value at Value Shares Price (Years) Grant Date (in thousands) Options outstanding at January 1, 2020 160,317 1.18311 7.31 8.57245 Exercised — — Cancelled (86,967) 0.65226 Forfeited (90,729) 1.25578 Granted 1,828,128 0.05051 Options outstanding at December 31, 2020 1,810,749 $ 0.06143 9.70 $ 3.46867 $ Exercised (1,424,622) 0.01447 Cancelled (405,936) 0.06452 Forfeited (136,221) 0.00100 Granted 2,109,912 1.68113 Options outstanding at December 31, 2021 1,953,882 $ 1.72323 9.31 $ 1.12355 $ 465 Options exercisable at December 31, 2021 336,556 $ 0.39318 9.15 $ 465 Vested and expected to vest after December 31, 2021 1,953,882 $ 1.72323 9.31 $ 465 |
Schedule of stock-based compensation | For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 38 $ 24 $ 78 $ 2,931 Selling, general and administrative 59 51 117 3,164 Total $ 97 $ 75 $ 195 $ 6,095 | For the Year Ended December 31, 2021 2020 Research and development $ 2,982 $ — Selling, general and administrative 3,214 — Total $ 6,196 $ — |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
INCOME TAXES | |
Schedule of loss from operations before income taxes | For the Year Ended December 31, 2021 2020 United States $ (5,039) $ — Foreign (12,087) (23,133) Loss before income taxes $ (17,126) $ (23,133) |
Schedule of reconciliation of the statutory income tax rate to company's effective tax rate | For the Year Ended December 31, 2021 2020 Taxes at domestic rate 21.0 % 19.0 % Non-US statutory rates (0.8) % — % Permanent items (7.3) % (1.9) % Change in valuation allowance (22.4) % (9.4) % Loss on conversion of note and associated interest — % (8.4) % Statutory Rate Change 9.6 % — % Other (0.1) % 0.7 % Effective tax rate — % — % |
Schedule of components of income tax provision/(benefit) | December 31, 2021 2020 Current Federal — — State — — Foreign — — Total Current $ — $ — Deferred Federal — — State — — Foreign — — Total Deferred — — Total $ — $ — |
Schedule of deferred tax assets and liabilities | December 31, 2021 2020 Deferred tax assets/(liabilities): Net operating loss carryforwards $ 7,506 $ 3,931 Convertible notes payable discount and embedded derivative — — Property plant and equipment (190) (129) Other 229 14 7,545 3,816 Valuation allowance (7,545) (3,816) Deferred tax assets, net of allowance $ — $ — |
SELLING, GENERAL AND ADMINIST_2
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | ||
Schedule of Selling, general and administrative expenses | For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Salaries and benefits $ 504 $ 507 $ 1,005 $ 4,242 Rent and property tax (benefit)/expense (12) 3 16 16 Insurance 165 172 331 253 Utilities 1 1 2 2 Sales and marketing 247 83 434 105 Legal and professional fees 449 569 738 691 Other selling, general, and administrative expenses 16 10 85 19 Total $ 1,370 $ 1,345 $ 2,611 $ 5,328 | For the Years End December 31, 2021 2020 Salaries and benefits $ 5,366 $ 908 Rent and property tax expense 24 62 Insurance 486 — Utilities 4 1 Sales and marketing 749 96 Legal and professional fees 1,132 625 Other selling, general, and administrative expenses 308 15 Total $ 8,069 $ 1,707 |
DEFINED CONTRIBUTION PENSION (T
DEFINED CONTRIBUTION PENSION (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
DEFINED CONTRIBUTION PENSION | ||
Schedule of pension cost | For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 26 $ 24 $ 53 $ 48 Selling, general and administrative 13 9 27 17 Total pension cost $ 39 $ 33 $ 80 $ 65 | For the Years End December 31, 2021 2020 Research and development $ 98 $ 83 Selling, general and administrative 42 31 Total pension cost $ 140 $ 114 |
BUSINESS AND BASIS OF PREPARATI
BUSINESS AND BASIS OF PREPARATION - Going Concern and Reverse Recapitalization (Details) $ / shares in Units, $ in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||
Feb. 23, 2021 $ / shares shares | Jun. 30, 2022 USD ($) patent $ / shares | Jun. 30, 2022 USN ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 USN ($) | Mar. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) patent $ / shares | Jun. 30, 2022 USN ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 USN ($) | Dec. 31, 2021 USD ($) patent $ / shares | Dec. 31, 2021 USN ($) | Dec. 31, 2020 USD ($) $ / shares | |
Net cash used in operating activities | $ (5,651) | $ (6,029) | $ (4,082) | |||||||||||
Gain (loss) on foreign currency transactions | $ 1,284 | $ 1,284 | $ (57) | $ 57 | 1,638 | $ 1,638 | 412 | $ 412 | $ 808 | |||||
Effect of exchange rate changes on cash | (590) | (387) | (40) | |||||||||||
Adjustment for (Gain)/Loss on foreign currency transactions | (1,284) | $ (1,284) | 57 | $ (57) | (1,638) | $ (1,638) | (412) | (412) | (808) | |||||
Net loss | 3,701 | $ 2,762 | $ 2,401 | $ 9,366 | 6,463 | $ 11,767 | 17,126 | 23,133 | ||||||
Accumulated deficit | 81,535 | 81,535 | 75,072 | 57,946 | ||||||||||
Cash and cash equivalents | $ 7,757 | $ 7,757 | $ 12,226 | $ 764 | ||||||||||
Common shares, par value | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||||
Number of issued patents | patent | 120 | 120 | 120 | |||||||||||
As restated | ||||||||||||||
Net cash used in operating activities | (6,029) | $ (9,728) | $ (9,728) | |||||||||||
Gain (loss) on foreign currency transactions | (412) | 808 | ||||||||||||
Effect of exchange rate changes on cash | (387) | $ (673) | (673) | |||||||||||
Adjustment for (Gain)/Loss on foreign currency transactions | 412 | (808) | ||||||||||||
Previously Reported [Member] | ||||||||||||||
Net cash used in operating activities | (6,441) | (10,536) | ||||||||||||
Effect of exchange rate changes on cash | $ 25 | $ 135 | ||||||||||||
Securities Exchange Agreement, Smartkem Limited | ||||||||||||||
Purchase price (in dollars per share) | $ / shares | $ 1.40 | |||||||||||||
Common shares, par value | $ / shares | $ 0.0001 | |||||||||||||
Share exchange ratio | 0.0676668 | |||||||||||||
Securities Exchange Agreement, Smartkem Limited | Common stock A Shares | ||||||||||||||
Share exchange ratio | 0.0111907 | |||||||||||||
Share exchange, number of shares issued or issuable | shares | 12,725,000 | |||||||||||||
Shares exchange, number of shares exchanged | shares | 1,127,720,477 | |||||||||||||
Management incentive options to purchase | shares | 124,497,910 | |||||||||||||
Average share exchange ratio | 0.011283825 | |||||||||||||
Effect of reverse capitalization (in shares) | shares | 2,500,000 |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||
Jun. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2022 USN ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 USN ($) | Mar. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) segment $ / shares shares | Jun. 30, 2022 USN ($) segment | Jun. 30, 2021 USD ($) | Jun. 30, 2021 USN ($) | Dec. 31, 2021 USD ($) segment $ / shares shares | Dec. 31, 2020 USD ($) | Feb. 23, 2021 $ / shares | |
Class of Warrant or Right [Line Items] | |||||||||||||
Cash equivalents | $ 0 | $ 0 | $ 0 | $ 0 | |||||||||
Allowance for doubtful accounts | 0 | 0 | $ 0 | 0 | |||||||||
Percentage of depreciated of net book value | 25% | ||||||||||||
Estimated useful life | 15 years | ||||||||||||
Other operating income | 294 | $ 256 | 578 | $ 688 | $ 1,285 | 1,437 | |||||||
Uncertain tax positions | 0 | 0 | 0 | ||||||||||
Research & development tax credits | 1,505 | $ 1,505 | $ 1,070 | 982 | |||||||||
Expiration term | 10 years | 10 years | 10 years | ||||||||||
Deferred offering costs | 0 | $ 0 | $ 0 | $ 0 | |||||||||
Number of operating segments | segment | 1 | 1 | 1 | ||||||||||
Number of reportable segments | segment | 1 | 1 | 1 | ||||||||||
Loss on foreign currency transactions | 1,284 | $ 1,284 | $ (57) | $ 57 | $ 1,638 | $ 1,638 | 412 | $ 412 | $ 808 | ||||
Offering costs recorded in additional paid-in capital | $ 10 | $ 160 | $ 2,454 | $ 170 | $ 2,454 | $ 2,454 | |||||||
Pre Funded Warrants | |||||||||||||
Class of Warrant or Right [Line Items] | |||||||||||||
Common stock warrants outstanding | shares | 2,168,000 | 2,168,000 | 2,168,000 | ||||||||||
Warrants exercisable price | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 |
SUMMARY OF SIGNIFICANT ACCOUN_5
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Dilutive Securities (Details) - shares | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of earnings per share | 2,922,915 | 2,582,095 | 2,939,415 | 1,810,749 |
Options | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of earnings per share | 1,937,382 | 1,596,562 | 1,953,882 | 1,810,749 |
Warrants | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of earnings per share | 985,533 | 985,533 | 985,533 |
PREPAID EXPENSES AND OTHER CU_3
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
PREPAID EXPENSES AND OTHER CURRENT ASSETS | |||
Prepaid service charges and property taxes | $ 83 | $ 58 | |
Prepaid rent | 58 | $ 65 | |
Prepaid utilities | 31 | 51 | 30 |
Prepaid insurance | 633 | 412 | 41 |
Prepaid administrative expenses | 55 | 63 | 61 |
Prepaid technical fees | 212 | 141 | 8 |
Prepaid consulting fees | 629 | 27 | |
VAT receivable | 141 | 50 | 54 |
Other Receivable and other prepaid expenses | 31 | ||
Total prepaid expenses and other current assets | 1,815 | 802 | 259 |
Prepaid Insurance Noncurrent | $ 191 | $ 217 | $ 0 |
PROPERTY, PLANT AND EQUIPMENT_2
PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Line Items] | ||||||
Property, plant and equipment, Gross | $ 1,767 | $ 1,767 | $ 1,904 | $ 1,590 | ||
Less: Accumulated depreciation | (1,090) | (1,090) | (1,102) | (908) | ||
Property, plant and equipment, net | 677 | 677 | 802 | 682 | ||
Depreciation | 105 | $ 95 | 197 | |||
Plant and equipment | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Property, plant and equipment, Gross | 1,523 | 1,523 | 1,633 | 1,316 | ||
Furniture and fixtures | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Property, plant and equipment, Gross | 220 | 220 | 245 | 248 | ||
Computer hardware and software | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Property, plant and equipment, Gross | 24 | 24 | 26 | 26 | ||
Research and development | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Depreciation | $ 51 | $ 47 | $ 105 | $ 95 | $ 209 | $ 197 |
ACCOUNTS PAYABLE AND ACCRUED _3
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | |||
Accounts payable | $ 457 | $ 510 | $ 227 |
Accrued expenses - lab refurbishments | 118 | 131 | 132 |
Accrued expenses - technical fees | 58 | 66 | 45 |
Accrued expenses - variable rent & utilities | 9 | 20 | 67 |
Accrued expenses - audit & accounting fees | 167 | 191 | 250 |
Accrued expenses - other | 67 | 112 | 6 |
Credit card liabilities | 34 | 10 | 6 |
Payroll and social security liabilities | 280 | 383 | 128 |
Total accounts payable and accrued expenses | $ 1,190 | $ 1,423 | $ 861 |
LEASES - Lease Costs (Details)
LEASES - Lease Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Operating lease cost | $ 68 | $ 52 | $ 131 | $ 99 | $ 225 | $ 175 |
Short-term lease cost | 2 | 13 | 4 | 26 | 32 | 48 |
Variable lease cost | 41 | 64 | 95 | 98 | 140 | 401 |
Total lease cost | 111 | 129 | 230 | 223 | 397 | 624 |
Research and development | ||||||
Total lease cost | 105 | 120 | 218 | 207 | 373 | 562 |
Selling, general and administrative | ||||||
Total lease cost | $ 6 | $ 9 | $ 12 | $ 16 | $ 24 | $ 62 |
LEASES - Lease Assets And Liabi
LEASES - Lease Assets And Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Assets | |||
Operating lease right of use assets | $ 549 | $ 154 | $ 236 |
Total lease assets | 549 | 154 | 236 |
Current liabilities: | |||
Operating lease liability - current portion | 208 | 87 | 217 |
Noncurrent liabilities: | |||
Operating lease liability, net of current portion | 320 | 28 | 20 |
Total lease liabilities | $ 528 | $ 115 | $ 237 |
LEASES - Operating And Finance
LEASES - Operating And Finance Leases (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
LEASES | ||||
Operating cash flows from operating leases | $ 115 | $ 120 | $ 276 | $ 157 |
Supplemental non-cash amounts of operating lease liabilities arising from obtaining right of use assets | $ 539 | $ 86 | $ 136 |
LEASES - Weighted Average (Deta
LEASES - Weighted Average (Details) | Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2020 |
LEASES | ||||
Weighted average remaining lease term (in years) - operating leases | 2 years 7 months 28 days | 1 year 4 months 24 days | 1 year 1 month 6 days | 1 year 4 months 6 days |
Weighted average discount rate - operating leases | 7.64% | 6.07% | 6.12% | 6.30% |
LEASES - Undiscounted Operating
LEASES - Undiscounted Operating Lease Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Lessee, Operating Lease, Liability, Payment, Due [Abstract] | |||
2022 | $ 137 | ||
2023 | 220 | $ 93 | |
2024 | 219 | 22 | |
2025 | 9 | 7 | |
Total undiscounted lease payments | 585 | 122 | |
Less future minimum short-term lease payments | (3) | ||
Less imputed interest | (57) | (4) | |
Total net lease liabilities | $ 528 | $ 115 | $ 237 |
LEASES - Additional Information
LEASES - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Sublease rental income | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 |
Finance lease, right-of-use assets | 0 | 0 | 0 | |||
Finance lease, liabilities | $ 0 | $ 0 | $ 0 | |||
Minimum | ||||||
Operating leases terms | 1 year | 1 year | 1 year | |||
Maximum | ||||||
Operating leases terms | 3 years | 3 years | 3 years |
CONVERTIBLE NOTES AND NOTES P_3
CONVERTIBLE NOTES AND NOTES PAYABLE - Activity of convertible notes (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
CONVERTIBLE NOTES AND NOTES PAYABLE. | ||
Balance, beginning of period | $ 7,280 | |
Amortization of debt discount | $ 0 | 25 |
Extinguishment of debt discount | 6,767 | |
Loss on conversion of note | 9,344 | |
Conversion of notes to equity | (23,630) | |
Foreign currency translation | $ 214 |
CONVERTIBLE NOTES AND NOTES P_4
CONVERTIBLE NOTES AND NOTES PAYABLE - Additional Information (Details) $ / shares in Units, $ in Thousands | 6 Months Ended | 12 Months Ended | |||||||||||
Jan. 26, 2021 USD ($) | Jan. 24, 2020 USD ($) $ / shares shares | Sep. 23, 2019 tranche | Jun. 26, 2019 USD ($) tranche $ / shares | Dec. 28, 2018 tranche | Jul. 20, 2018 USD ($) tranche $ / shares | Apr. 18, 2018 USD ($) tranche $ / shares | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2021 USN ($) | Dec. 31, 2020 USN ($) | |
Debt Instrument [Line Items] | |||||||||||||
Cumulative investment proceeds, excess limit | $ 4,600 | ||||||||||||
Fair value of common shares | $ / shares | $ 1.807011 | ||||||||||||
Aggregate principal, converted | $ 11,796 | ||||||||||||
Conversion of debt, Shares issued | shares | 8,159,977 | ||||||||||||
Discounted price of conversion (in dollars per share) | $ / shares | $ 1.45 | ||||||||||||
Unpaid interest, converted | $ 1,063 | ||||||||||||
Conversion of debt interest, Shares issued | shares | 735,148 | ||||||||||||
Loss on conversion of note | $ 5,470 | ||||||||||||
Unamortized debt discount due to beneficial conversion feature | $ 6,767 | ||||||||||||
Effective interest rate | 13.50% | 13.50% | |||||||||||
Interest expense, stated interest rate | $ 0 | $ 43 | |||||||||||
Amortization of debt issuance cost | 0 | 25 | |||||||||||
Loss on notes | 9,344 | ||||||||||||
Loss on accrued interest | 1,046 | ||||||||||||
Gain on extinguishment of derivative liability | 4,920 | ||||||||||||
Convertible notes | $ 0 | 0 | |||||||||||
Notes payable | $ 47,500 | $ 20,000 | |||||||||||
2018 BASF Venture Capital and Entrepreneurs Fund L.P. Notes | |||||||||||||
Debt Instrument [Line Items] | |||||||||||||
Aggregate principal | $ 5,862 | ||||||||||||
Number of tranches | tranche | 3 | 3 | 3 | ||||||||||
Share price trigger (in dollars per share) | $ / shares | $ 16.39 | ||||||||||||
Accrued interest rate trigger, first anniversary | 8% | ||||||||||||
Accrued interest rate trigger, conversion period | 15% | ||||||||||||
Threshold number of days for interest calculation | 365 days | ||||||||||||
2018 Octopus Notes | |||||||||||||
Debt Instrument [Line Items] | |||||||||||||
Aggregate principal | $ 2,622 | ||||||||||||
Number of tranches | tranche | 2 | 2 | |||||||||||
Share price trigger (in dollars per share) | $ / shares | $ 15.10 | ||||||||||||
Accrued interest rate trigger, first anniversary | 8% | ||||||||||||
Accrued interest rate trigger, conversion period | 12% | ||||||||||||
Threshold number of days for interest calculation | 365 days | ||||||||||||
2019 Octopus, EF, and Other Notes | |||||||||||||
Debt Instrument [Line Items] | |||||||||||||
Aggregate principal | $ 3,681 | ||||||||||||
Number of tranches | tranche | 2 | 2 | |||||||||||
Share price trigger (in dollars per share) | $ / shares | $ 0.001861 | ||||||||||||
Accrued interest rate trigger, conversion period | 10% | ||||||||||||
Threshold number of days for interest calculation | 365 days | ||||||||||||
Debt instrument price per senior share | $ / shares | $ 11.19 | ||||||||||||
Debt discount - bifurcation of redemption feature | $ 2,608 | ||||||||||||
Term Loan Facility Agreement | |||||||||||||
Debt Instrument [Line Items] | |||||||||||||
Effective interest rate | 26.20% | 26.20% | 26.20% | ||||||||||
Aggregate principal | $ 739 | ||||||||||||
Debt term | 6 months | ||||||||||||
Monthly interest rate | 1.25% | ||||||||||||
Notes payable | $ 0 | $ 0 | 0 | ||||||||||
Interest expense of notes payable | $ 0 | $ 19 | $ 19 | $ 0 | |||||||||
Publicly Traded Market | 2019 Octopus, EF, and Other Notes | |||||||||||||
Debt Instrument [Line Items] | |||||||||||||
Share price trigger (in dollars per share) | $ / shares | $ 14.61 |
DERIVATIVE ASSET (Details)
DERIVATIVE ASSET (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2021 | |
Changes in fair value of the derivative asset | ||
Balance, beginning of period | $ 1,407 | |
Loss on fair value of derivative asset included in earnings | (6,282) | |
Gain on extinguishment of derivative asset upon conversion | 4,920 | |
Foreign currency translation | (45) | |
Convertible notes | $ 0 | $ 0 |
Derivative asset | $ 0 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands, $ in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 USD ($) | Dec. 31, 2021 USN ($) | |
COMMITMENTS AND CONTINGENCIES. | ||
Capital expenditures to be paid in the future | $ 1,087 | $ 1,422 |
STOCKHOLDERS' EQUITY (Details)
STOCKHOLDERS' EQUITY (Details) | 6 Months Ended | 12 Months Ended | ||
Jun. 29, 2022 shares | May 27, 2022 shares | Jun. 30, 2022 Vote shares | Dec. 31, 2021 Vote shares | |
Class of Stock [Line Items] | ||||
Number of votes, common shares | Vote | 1 | 1 | ||
Preferred shares, outstanding (in shares) | 0 | 0 | ||
Preferred stock available for issuance | 10,000,000 | 10,000,000 | ||
Investor relations services | ||||
Class of Stock [Line Items] | ||||
Issuance of common shares to vendor (in shares) | 22,473 | |||
Internet advertisement contract services | ||||
Class of Stock [Line Items] | ||||
Issuance of common shares to vendor (in shares) | 360,000 |
STOCKHOLDERS' EQUITY - Common S
STOCKHOLDERS' EQUITY - Common Stock Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Feb. 23, 2021 | Jun. 30, 2022 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Weighted Average Remaining Contractual Term (years) | ||||||
Warrants outstanding at beginning | 5 years | |||||
Warrants outstanding at end | 5 years | |||||
Common Stock Warrants | ||||||
Number of shares | ||||||
Warrants outstanding beginning (in shares) | 985,533 | |||||
Exercised (in shares) | 0 | 0 | 0 | |||
Warrants outstanding at end (in shares) | 985,533 | 985,533 | 985,533 | |||
Weighted-Average Exercise Price | ||||||
Warrants outstanding beginning (in dollars per share) | $ 2 | |||||
Warrants outstanding at end (in dollars per share) | $ 2 | $ 2 | $ 2 | |||
Weighted Average Remaining Contractual Term (years) | ||||||
Warrants outstanding at end | 3 years 7 months 24 days | 3 years 7 months 24 days | ||||
Warrants issued | 985,533 | 0 | 0 | 0 | ||
Warrants exercisable price | $ 2 | $ 0.91 | $ 0.91 | $ 0.91 | ||
Fair value of warrant | $ 896 | $ 896 | $ 896 | |||
Pre Funded Warrants | ||||||
Number of shares | ||||||
Warrants outstanding beginning (in shares) | 2,168,000 | |||||
Granted (in shares) | 2,168,000 | |||||
Warrants outstanding at end (in shares) | 2,168,000 | 2,168,000 | 2,168,000 | |||
Weighted-Average Exercise Price | ||||||
Warrants outstanding beginning (in dollars per share) | $ 0.01 | |||||
Granted (in dollars per share) | $ 0.01 | |||||
Warrants outstanding at end (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | |||
Weighted Average Remaining Contractual Term (years) | ||||||
Warrants issued | 2,168,000 | 0 | 0 | 0 | ||
Warrants exercisable price | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | ||
Fair value of per warrant | 1.99 | 1.99 | ||||
Exercise less amount | $ 2 | $ 2 | ||||
Proceeds from Warrant | $ 4,314 |
STOCKHOLDERS' EQUITY - Fair val
STOCKHOLDERS' EQUITY - Fair value assumptions (Details) | Dec. 31, 2021 |
Class of Warrant or Right [Line Items] | |
Warrants and Rights Outstanding, Term | 5 years |
Risk-free interest rate | |
Class of Warrant or Right [Line Items] | |
Warrants measurement input | 0.60 |
Expected volatility | |
Class of Warrant or Right [Line Items] | |
Warrants measurement input | 54 |
Expected dividend yield | |
Class of Warrant or Right [Line Items] | |
Warrants measurement input | 0 |
SHARE-BASED COMPENSATION - Assu
SHARE-BASED COMPENSATION - Assumptions (Details) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Black-Scholes option-pricing model, Assumptions: | ||
Expected term (years) | 5 months 15 days | |
Risk-free interest rate, minimum | 0.30% | 0.70% |
Risk-free interest rate, maximum | 1.20% | 0.20% |
Expected volatility | 58% | |
Expected dividend yield | 0% | 0% |
Minimum | ||
Black-Scholes option-pricing model, Assumptions: | ||
Expected term (years) | 5 years | |
Expected volatility | 54% | |
Maximum | ||
Black-Scholes option-pricing model, Assumptions: | ||
Expected term (years) | 6 years | |
Expected volatility | 58% |
SHARE-BASED COMPENSATION - Shar
SHARE-BASED COMPENSATION - Share option activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Number of Shares | ||||
Options outstanding at beginning (in shares) | 1,953,882 | 1,810,749 | 160,317 | |
Exercised (in shares) | (1,424,622) | 0 | ||
Cancelled (in shares) | (405,936) | (86,967) | ||
Forfeited (in shares) | (16,500) | (136,221) | (90,729) | |
Granted (in shares) | 2,109,912 | 1,828,128 | ||
Options outstanding at end (in shares) | 1,937,382 | 1,953,882 | 1,810,749 | 160,317 |
Options exercisable (in shares) | 708,624 | 336,556 | ||
Vested and expected to vest (in shares) | 1,937,382 | 1,953,882 | ||
Weighted-Average Exercise Price | ||||
Options outstanding at beginning (in dollars per share) | $ 1.72323 | $ 0.06143 | $ 1.18311 | |
Exercised (in dollars per share) | 0.01447 | |||
Cancelled (in dollars per share) | 0.06452 | 0.65226 | ||
Forfeited (in dollars per share) | 2 | 0.00100 | 1.25578 | |
Granted (in dollars per share) | 1.68113 | 0.05051 | ||
Options outstanding at end (in dollars per share) | 1.72087 | 1.72323 | $ 0.06143 | $ 1.18311 |
Options exercisable (in dollars per share) | 1.23685 | 0.39318 | ||
Vested and expected to vest (in dollars per share) | $ 1.72087 | $ 1.72323 | ||
Weighted-Average Remaining Contractual Term : | ||||
Weighted-Average Remaining Contractual Term (in Years) | 8 years 9 months 21 days | 9 years 3 months 21 days | 9 years 8 months 12 days | 7 years 3 months 21 days |
Options exercisable weighted average remaining contractual term | 8 years 8 months 15 days | 9 years 1 month 24 days | ||
Vested and expected to vest outstanding weighted average remaining contractual term | 8 years 9 months 21 days | 9 years 3 months 21 days | ||
Weighted- Average Fair Value at Grant Date : | ||||
Weighted- Average Fair Value at Grant Date at beginning (in dollars) | $ 1.12355 | $ 3.46867 | $ 8.57245 | |
Weighted- Average Fair Value at Grant Date at end (in dollars) | $ 1.12553 | $ 1.12355 | $ 3.46867 | $ 8.57245 |
Aggregate Intrinsic Value, Options outstanding (in dollars) | $ 465 | |||
Aggregate Intrinsic Value, Options exercisable | $ 541 | 465 | ||
Aggregate Intrinsic Value, Vested and expected to vest | $ 541 | $ 465 |
SHARE-BASED COMPENSATION - Stoc
SHARE-BASED COMPENSATION - Stock Based Compensation (Details) $ in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USN ($) | Dec. 31, 2021 USD ($) | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Total | $ 97 | $ 75 | $ 195 | $ 6,095 | $ 6,196 | $ 6,196 |
Research and development | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Total | 38 | 24 | 78 | 2,931 | 2,982 | |
Selling, general and administrative | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Total | $ 59 | $ 51 | $ 117 | $ 3,164 | $ 3,214 |
SHARE-BASED COMPENSATION - Addi
SHARE-BASED COMPENSATION - Additional information (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
Feb. 28, 2021 | Feb. 23, 2021 | Jun. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 14, 2018 | Jul. 15, 2014 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Expiration term | 10 years | 10 years | ||||||
Options granted (in shares) | 2,109,912 | 1,828,128 | ||||||
Granted (in dollars per share) | $ 1.68113 | $ 0.05051 | ||||||
Vested shares | 0 | |||||||
Weighted-average grant-date fair value (in dollars per share) | $ 1.14 | $ 0.04 | ||||||
Exercisable options (in shares) | 708,624 | 708,624 | 336,556 | |||||
Unrecognized compensation costs | $ 1,122 | $ 1,122 | $ 1,300 | |||||
Intrinsic value of options exercised | $ 2,400 | |||||||
Exercised (in shares) | 1,424,622 | 0 | ||||||
Option vested in fair value | $ 6,600 | |||||||
Options | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Expiration term | 10 years | |||||||
Options | Exercise Price Range One | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Options granted (in shares) | 336,557 | |||||||
Granted (in dollars per share) | $ 0.001 | |||||||
Options | Exercise Price Range Two | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Options granted (in shares) | 66,029 | |||||||
Granted (in dollars per share) | $ 2 | |||||||
Options | Employees and Consultants | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Options granted (in shares) | 1,828,128 | |||||||
Options | Employees, Directors and Consultants | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Expiration term | 10 years | |||||||
Options granted (in shares) | 1,707,326 | |||||||
Granted (in dollars per share) | $ 2 | |||||||
Vesting period | 4 years | |||||||
Investment Agreement | Options | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Maximum aggregate number of shares under grant | 458,316 | 175,292 | ||||||
Maximum percentage of shares to be granted | 15% | |||||||
Expiration term | 10 years | 10 years | ||||||
2021 Plan | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Options granted (in shares) | 2,275,000 | 0 | 0 | |||||
Percentage of outstanding shares | 4% | |||||||
2021 Plan | Options | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Options granted (in shares) | 402,586 |
INCOME TAXES - Loss from operat
INCOME TAXES - Loss from operations before income taxes (Details) $ in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2021 USN ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2020 USN ($) | |
INCOME TAXES | ||||||||
United States | $ (5,039) | |||||||
Foreign | (12,087) | $ (23,133) | ||||||
Loss before income taxes | $ (3,701) | $ (2,401) | $ (6,463) | $ (11,767) | $ (17,126) | $ (17,126) | $ (23,133) | $ (23,133) |
INCOME TAXES - Reconciliation o
INCOME TAXES - Reconciliation of effective tax rate (Details) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Reconciliation of the statutory income tax rate to effective tax rate | ||
Taxes at domestic rate | 21% | 19% |
Non-US statutory rates | (0.80%) | |
Permanent items | (7.30%) | (1.90%) |
Change in valuation allowance | (22.40%) | (9.40%) |
Loss on conversion of note and associated interest | (8.4) | |
Statutory Rate Change | 9.60% | |
Other | (0.10%) | 0.70% |
Effective tax rate |
INCOME TAXES - Deferred tax ass
INCOME TAXES - Deferred tax assets and liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred tax assets/(liabilities): | ||
Net operating loss carryforwards | $ 7,506 | $ 3,931 |
Property plant and equipment | (190) | (129) |
Other | 229 | 14 |
Total | 7,545 | 3,816 |
Valuation allowance | (7,545) | (3,816) |
Net operating loss carryforwards | 30,674 | $ 20,691 |
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | $ 0 |
SELLING, GENERAL AND ADMINIST_3
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | ||||||
Salaries and benefits | $ 504 | $ 507 | $ 1,005 | $ 4,242 | $ 5,366 | $ 908 |
Rent and property tax (benefit)/expense | (12) | 3 | 16 | 16 | 24 | 62 |
Insurance | 165 | 172 | 331 | 253 | 486 | |
Utilities | 1 | 1 | 2 | 2 | 4 | 1 |
Sales and marketing | 247 | 83 | 434 | 105 | 749 | 96 |
Legal and professional fees | 449 | 569 | 738 | 691 | 1,132 | 625 |
Other selling, general, and administrative expenses | 16 | 10 | 85 | 19 | 308 | 15 |
Total | $ 1,370 | $ 1,345 | $ 2,611 | $ 5,328 | $ 8,069 | $ 1,707 |
DEFINED CONTRIBUTION PENSION (D
DEFINED CONTRIBUTION PENSION (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
DEFINED CONTRIBUTION PENSION | |||
Amounts owed to the pension scheme | $ 0 | $ 0 | $ 0 |
DEFINED CONTRIBUTION PENSION -
DEFINED CONTRIBUTION PENSION - Pension cost (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
DEFINED CONTRIBUTION PENSION | ||||||
Total pension cost | $ 39 | $ 33 | $ 80 | $ 65 | $ 140 | $ 114 |
Research and development | ||||||
DEFINED CONTRIBUTION PENSION | ||||||
Total pension cost | 26 | 24 | 53 | 48 | 98 | 83 |
Selling, general and administrative | ||||||
DEFINED CONTRIBUTION PENSION | ||||||
Total pension cost | $ 13 | $ 9 | $ 27 | $ 17 | $ 42 | $ 31 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||
Jan. 27, 2022 $ / shares shares | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2021 USN ($) | Dec. 31, 2020 USN ($) | |
Related Party Transaction [Line Items] | |||||||||
Notes Payable | $ 47,500 | $ 20,000 | |||||||
Accounts payable and accrued expenses [Member] | |||||||||
Related Party Transaction [Line Items] | |||||||||
Related party payable | $ 18 | $ 18 | $ 18 | $ 0 | |||||
Selling, general and administrative | |||||||||
Related Party Transaction [Line Items] | |||||||||
Related party expenses | $ 29 | $ 18 | $ 47 | $ 25 | 65 | $ 7 | |||
Owner | Securities Exchange | |||||||||
Related Party Transaction [Line Items] | |||||||||
Reimbursement expenses incurred | 66 | ||||||||
Related party payable | 0 | ||||||||
Family member of a Director | Consulting services | |||||||||
Related Party Transaction [Line Items] | |||||||||
Reimbursement expenses incurred | 35 | ||||||||
Related party payable | $ 0 | ||||||||
Octopus Share Purchase [Member] | |||||||||
Related Party Transaction [Line Items] | |||||||||
Sale of Stock, Number of Shares Issued in Transaction | shares | 1,000,000 | ||||||||
Sale of Stock, Price Per Share | $ / shares | $ 2 |
SUBSEQUENT EVENTS (Details)
SUBSEQUENT EVENTS (Details) - $ / shares | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||
Jan. 27, 2022 | Jan. 01, 2022 | Feb. 23, 2021 | Jul. 31, 2022 | Feb. 28, 2022 | Jun. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Jan. 24, 2020 | |
Subsequent Event [Line Items] | ||||||||||
Options granted (in shares) | 2,109,912 | 1,828,128 | ||||||||
Options vesting term | 8 years 9 months 21 days | 9 years 3 months 21 days | ||||||||
Expiration term | 10 years | 10 years | ||||||||
Options exercise price | $ 1.807011 | |||||||||
2021 Plan | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Options granted (in shares) | 2,275,000 | 0 | 0 | |||||||
Percentage of outstanding shares | 4% | |||||||||
Subsequent events | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Options vesting term | 4 years | |||||||||
Expiration term | 10 years | |||||||||
Options exercise price | $ 2 | $ 2 | ||||||||
Issuance of common stock (in shares) | 1,000,000 | |||||||||
Issuance of common shares to vendor (in shares) | 12,500 | |||||||||
Subsequent events | 2021 Plan | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Number of shares increased | 1,022,172 | |||||||||
Reserved for future issuance | 3,297,172 | |||||||||
Percentage of outstanding shares | 4% | |||||||||
Subsequent events | Enterprise Management Incentive Options | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Options granted (in shares) | 225,700 | |||||||||
Subsequent events | ISO Options | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Options granted (in shares) | 150,000 | |||||||||
Subsequent events | NQSO Options | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Options granted (in shares) | 92,300 |
Condensed Consolidated Balanc_3
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 |
Current assets: | |||||||
Cash and cash equivalents | $ 7,757 | $ 12,226 | $ 764 | ||||
Accounts receivable | 4 | 18 | |||||
Research and development tax credit receivable | 1,505 | 1,070 | 982 | ||||
Prepaid expenses and other current assets | 1,815 | 802 | 259 | ||||
Total current assets | 11,081 | 14,098 | 2,023 | ||||
Property, plant equipment, net of accumulated depreciation of $1,090 and $1,102 | 677 | 802 | 682 | ||||
Right-of-use assets, net | 549 | 154 | 236 | ||||
Other assets | 6 | 6 | 8 | ||||
Total assets | 12,313 | 15,060 | 2,949 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Accounts payable and accrued expenses | 1,190 | 1,423 | 861 | ||||
Current lease liabilities | 208 | 87 | 217 | ||||
Total current liabilities | 1,398 | 1,510 | 1,078 | ||||
Non-current lease liabilities | 320 | 28 | 20 | ||||
Total liabilities | 1,718 | 1,538 | 1,098 | ||||
Commitments and contingencies (Note 8) | |||||||
Stockholders' Equity: | |||||||
Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 26,949,282 and 25,554,309 shares issued and outstanding, at June 30, 2022 and December 31, 2021, respectively | 3 | 3 | 1 | ||||
Additional paid-in capital | 92,612 | 89,954 | 61,276 | ||||
Accumulated other comprehensive loss | (485) | (1,363) | (1,480) | ||||
Accumulated deficit | (81,535) | (75,072) | (57,946) | ||||
Total Stockholders' equity | 10,595 | $ 12,897 | 13,522 | $ 18,564 | $ 20,825 | 1,851 | $ (5,083) |
Total Liabilities and Stockholders' Equity | $ 12,313 | $ 15,060 | $ 2,949 |
Condensed Consolidated Balanc_4
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Condensed Consolidated Balance Sheets | |||
Property, plant equipment, net of accumulated depreciation | $ 1,090 | $ 1,102 | $ 908 |
Common shares, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 |
Common Stock, Shares Authorized | 300,000,000 | 300,000,000 | 300,000,000 |
Common Stock, Shares Issued | 26,949,282 | 25,554,309 | 13,627,887 |
Common Stock, Shares Outstanding | 26,949,282 | 25,554,309 | 13,627,887 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Operations and Comprehensive Loss $ in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||
Jun. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2022 USN ($) shares | Mar. 31, 2022 USD ($) | Jun. 30, 2021 USD ($) $ / shares shares | Jun. 30, 2021 USN ($) shares | Mar. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2022 USN ($) shares | Jun. 30, 2021 USD ($) $ / shares shares | Jun. 30, 2021 USN ($) shares | Dec. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2021 USN ($) shares | Dec. 31, 2020 USD ($) $ / shares shares | Dec. 31, 2020 USN ($) shares | |
Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||
Revenue | $ 4 | $ 34 | $ 18 | $ 94 | ||||||||||
Cost of revenue | 2 | 25 | 8 | 55 | ||||||||||
Gross profit | 2 | 9 | 10 | 39 | ||||||||||
Other operating income | 294 | $ 256 | 578 | $ 688 | 1,285 | 1,437 | ||||||||
Operating Expenses: | ||||||||||||||
Research and development | 1,344 | 1,355 | 2,802 | 5,369 | 8,199 | 4,319 | ||||||||
Selling, general and administrative | 1,370 | 1,345 | 2,611 | 5,328 | 8,069 | 1,707 | ||||||||
Transaction expenses | 16 | 1,329 | 1,329 | $ 1,329 | ||||||||||
Total operating expenses | 2,714 | 2,716 | 5,413 | 12,026 | 17,597 | 6,026 | ||||||||
Loss from operations | (2,418) | (2,460) | (4,826) | (11,338) | (16,302) | (4,550) | ||||||||
Non-operating (Expense)/Income | ||||||||||||||
(Loss)/Gain on foreign currency transactions | (1,284) | $ (1,284) | 57 | $ (57) | (1,638) | $ (1,638) | (412) | $ (412) | (808) | |||||
Other income | 1 | |||||||||||||
Interest expense | (19) | (19) | (6,835) | |||||||||||
Interest income | 1 | 2 | 1 | 2 | 3 | 3 | ||||||||
Change in fair value of derivative asset | (6,282) | |||||||||||||
Loss on conversion of convertible notes payable | (5,470) | |||||||||||||
Total non-operating (expense)/income | (1,283) | 59 | (1,637) | (429) | (824) | (18,583) | ||||||||
Loss before income taxes | (3,701) | (2,401) | (6,463) | (11,767) | (17,126) | $ (17,126) | (23,133) | $ (23,133) | ||||||
Net loss | (3,701) | $ (2,762) | (2,401) | $ (9,366) | (6,463) | (11,767) | (17,126) | (23,133) | ||||||
Other comprehensive loss: | ||||||||||||||
Foreign currency translation | 722 | $ 156 | 15 | $ 17 | 878 | 33 | 117 | (284) | ||||||
Total comprehensive loss | $ (2,979) | $ (2,386) | $ (5,585) | $ (11,734) | $ (17,009) | $ (23,417) | ||||||||
Basic net loss per common share | $ / shares | $ (0.13) | $ (0.09) | $ (0.23) | $ (0.52) | $ (0.68) | $ (1.80) | ||||||||
Diluted net loss per common share | $ / shares | $ (0.13) | $ (0.09) | $ (0.23) | $ (0.52) | $ (0.68) | $ (1.80) | ||||||||
Basic weighted average shares outstanding | shares | 28,751,365 | 28,751,365 | 27,066,385 | 27,066,385 | 28,595,550 | 28,595,550 | 22,733,033 | 22,733,033 | 25,233,384 | 25,233,384 | 12,821,748 | 12,821,748 | ||
Diluted weighted average shares outstanding | shares | 28,751,365 | 28,751,365 | 27,066,385 | 27,066,385 | 28,595,550 | 28,595,550 | 22,733,033 | 22,733,033 | 25,233,384 | 25,233,384 | 12,821,748 | 12,821,748 |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Common stock | Additional Paid-in Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | Total |
Beginning Balance at Dec. 31, 2019 | $ 30,926 | $ (1,196) | $ (34,813) | $ (5,083) | |
Beginning Balance (in shares) at Dec. 31, 2019 | 2,183,885 | ||||
Issuance of common shares due to exercise of stock-options (in shares) | 0 | ||||
Foreign currency translation adjustment | (284) | $ (284) | |||
Net loss | (23,133) | (23,133) | |||
Issuance of common stock | 4,592 | 4,592 | |||
Issuance of common stock (in shares) | 2,548,877 | ||||
Conversion of notes and interest | $ 1 | 25,758 | 25,759 | ||
Conversion of notes and interest (in shares) | 8,895,125 | ||||
Ending Balance at Dec. 31, 2020 | $ 1 | 61,276 | (1,480) | (57,946) | 1,851 |
Ending Balance (in shares) at Dec. 31, 2020 | 13,627,887 | ||||
Issuance of common shares due to exercise of stock-options | $ 1 | 19 | 20 | ||
Issuance of common shares due to exercise of stock-options (in shares) | 1,404,813 | ||||
Stock-based compensation expense | 6,020 | 6,020 | |||
Repurchase of common stock (in shares) | (2,307,700) | ||||
Effect of reverse capitalization (in shares) | 2,500,000 | ||||
Issuance of common shares to vendor | 99 | 99 | |||
Issuance of common shares to vendor (in shares) | 50,000 | ||||
Issuance of common stock and warrants in private placement | $ 1 | 24,637 | 24,638 | ||
Issuance of common stock and warrants in private placement (in shares) | 10,162,000 | ||||
Issuance costs related to common stock and warrants in private placement | (2,454) | (2,454) | |||
Foreign currency translation adjustment | 17 | 17 | |||
Net loss | (9,366) | (9,366) | |||
Ending Balance at Mar. 31, 2021 | $ 3 | 89,597 | (1,463) | (67,312) | 20,825 |
Ending Balance (in shares) at Mar. 31, 2021 | 25,437,000 | ||||
Beginning Balance at Dec. 31, 2020 | $ 1 | 61,276 | (1,480) | (57,946) | 1,851 |
Beginning Balance (in shares) at Dec. 31, 2020 | 13,627,887 | ||||
Issuance costs related to common stock and warrants in private placement | (2,454) | ||||
Foreign currency translation adjustment | 33 | ||||
Net loss | (11,767) | ||||
Ending Balance at Jun. 30, 2021 | $ 3 | 89,722 | (1,448) | (69,713) | 18,564 |
Ending Balance (in shares) at Jun. 30, 2021 | 25,462,000 | ||||
Beginning Balance at Dec. 31, 2020 | $ 1 | 61,276 | (1,480) | (57,946) | 1,851 |
Beginning Balance (in shares) at Dec. 31, 2020 | 13,627,887 | ||||
Issuance of common shares due to exercise of stock-options | $ 1 | 19 | $ 20 | ||
Issuance of common shares due to exercise of stock-options (in shares) | 1,424,622 | 1,424,622 | |||
Stock-based compensation expense | 6,196 | $ 6,196 | |||
Repurchase of common stock (in shares) | (2,307,700) | ||||
Effect of reverse capitalization (in shares) | 2,500,000 | ||||
Issuance of common shares to vendor | 280 | 280 | |||
Issuance of common shares to vendor (in shares) | 147,500 | ||||
Issuance of common stock and warrants in private placement | $ 1 | 24,637 | 24,638 | ||
Issuance of common stock and warrants in private placement (in shares) | 10,162,000 | ||||
Issuance costs related to common stock and warrants in private placement | (2,454) | (2,454) | |||
Foreign currency translation adjustment | 117 | 117 | |||
Net loss | (17,126) | (17,126) | |||
Ending Balance at Dec. 31, 2021 | $ 3 | 89,954 | (1,363) | (75,072) | 13,522 |
Ending Balance (in shares) at Dec. 31, 2021 | 25,554,309 | ||||
Beginning Balance at Mar. 31, 2021 | $ 3 | 89,597 | (1,463) | (67,312) | 20,825 |
Beginning Balance (in shares) at Mar. 31, 2021 | 25,437,000 | ||||
Stock-based compensation expense | 75 | 75 | |||
Issuance of common shares to vendor | 50 | 50 | |||
Issuance of common shares to vendor (in shares) | 25,000 | ||||
Foreign currency translation adjustment | 15 | 15 | |||
Net loss | (2,401) | (2,401) | |||
Ending Balance at Jun. 30, 2021 | $ 3 | 89,722 | (1,448) | (69,713) | 18,564 |
Ending Balance (in shares) at Jun. 30, 2021 | 25,462,000 | ||||
Beginning Balance at Dec. 31, 2021 | $ 3 | 89,954 | (1,363) | (75,072) | 13,522 |
Beginning Balance (in shares) at Dec. 31, 2021 | 25,554,309 | ||||
Stock-based compensation expense | 98 | 98 | |||
Issuance of common shares to vendor | 43 | 43 | |||
Issuance of common shares to vendor (in shares) | 12,500 | ||||
Issuance of common stock in private placement | 2,000 | 2,000 | |||
Issuance of common stock in private placement (in shares) | 1,000,000 | ||||
Issuance costs related to common stock and warrants in private placement | (160) | (160) | |||
Foreign currency translation adjustment | 156 | 156 | |||
Net loss | (2,762) | (2,762) | |||
Ending Balance at Mar. 31, 2022 | $ 3 | 91,935 | (1,207) | (77,834) | 12,897 |
Ending Balance (in shares) at Mar. 31, 2022 | 26,566,809 | ||||
Beginning Balance at Dec. 31, 2021 | $ 3 | 89,954 | (1,363) | (75,072) | 13,522 |
Beginning Balance (in shares) at Dec. 31, 2021 | 25,554,309 | ||||
Issuance costs related to common stock and warrants in private placement | (170) | ||||
Foreign currency translation adjustment | 878 | ||||
Net loss | (6,463) | ||||
Ending Balance at Jun. 30, 2022 | $ 3 | 92,612 | (485) | (81,535) | 10,595 |
Ending Balance (in shares) at Jun. 30, 2022 | 26,949,282 | ||||
Beginning Balance at Mar. 31, 2022 | $ 3 | 91,935 | (1,207) | (77,834) | 12,897 |
Beginning Balance (in shares) at Mar. 31, 2022 | 26,566,809 | ||||
Stock-based compensation expense | 97 | 97 | |||
Issuance of common shares to vendor | 590 | 590 | |||
Issuance of common shares to vendor (in shares) | 382,473 | ||||
Issuance costs related to common stock and warrants in private placement | (10) | (10) | |||
Foreign currency translation adjustment | 722 | 722 | |||
Net loss | (3,701) | (3,701) | |||
Ending Balance at Jun. 30, 2022 | $ 3 | $ 92,612 | $ (485) | $ (81,535) | $ 10,595 |
Ending Balance (in shares) at Jun. 30, 2022 | 26,949,282 |
Condensed Consolidated Statem_6
Condensed Consolidated Statements of Cash Flows $ in Thousands, $ in Thousands | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 USN ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2021 USN ($) | Dec. 31, 2020 USD ($) | |
Cash flows from operating activities: | ||||||
Net loss | $ (6,463) | $ (11,767) | $ (23,133) | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation | 105 | 95 | 197 | |||
Common shares issued to vendor for services | 633 | 107 | ||||
Amortization of right of use asset | 131 | 96 | 176 | |||
Stock-based compensation | 195 | 6,095 | ||||
Loss on foreign currency transactions | 1,638 | 412 | ||||
Non-cash interest expense | 6,835 | |||||
Change in fair value of embedded conversion feature | 6,282 | |||||
Loss on conversion of convertible notes payable | 5,470 | |||||
Change in operating assets and liabilities: | ||||||
Accounts receivable, net | (6) | 19 | (17) | |||
Research & development tax credit receivable | (578) | (499) | 551 | |||
Prepaid expenses and other current assets | (1,057) | (901) | (70) | |||
Accounts payable and accrued expenses | (134) | 435 | (214) | |||
Lease liabilities | (115) | (120) | (157) | |||
Other assets | (1) | (2) | ||||
Net cash used in operating activities | (5,651) | (6,029) | (4,082) | |||
Cash flows from investing activities: | ||||||
Purchases of property, plant and equipment | (58) | (121) | (118) | |||
Net cash used by investing activities | (58) | (121) | (118) | |||
Cash flows from financing activities: | ||||||
Proceeds from term loan payable | 738 | |||||
Repayment of term loan payable | (738) | |||||
Proceeds from the issuance of common stock | 4,592 | |||||
Proceeds from the issuance of common stock and warrants in private placement | 24,638 | |||||
Proceeds from the issuance of common stock in private placement | 2,000 | |||||
Payment of issuance costs | (170) | (2,454) | ||||
Proceeds from the exercise of stock options | 20 | |||||
Net cash provided by financing activities | 1,830 | 22,204 | 4,592 | |||
Effect of exchange rate changes on cash | (590) | (387) | (40) | |||
Net change in cash | (4,469) | 15,667 | 352 | |||
Cash, beginning of period | 12,226 | 764 | $ 764 | 412 | ||
Cash, end of period | 7,757 | 16,431 | 12,226 | 764 | ||
Supplemental disclosure of cash and non-cash investing and financing activities | ||||||
Cash paid for interest | 19 | |||||
Right of use asset and lease liability additions | 539 | 86 | 136 | |||
Conversion of debt and accrued interest into common shares | 25,759 | |||||
As restated | ||||||
Cash flows from operating activities: | ||||||
Net loss | (17,126) | |||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation | 209 | |||||
Common shares issued to vendor for services | 263 | |||||
Amortization of right of use asset | 234 | |||||
Stock-based compensation | 6,196 | |||||
Loss on foreign currency transactions | 808 | |||||
Change in operating assets and liabilities: | ||||||
Accounts receivable, net | 19 | |||||
Research & development tax credit receivable | (104) | |||||
Prepaid expenses and other current assets | (532) | |||||
Accounts payable and accrued expenses | 579 | |||||
Lease liabilities | (276) | |||||
Other assets | 2 | |||||
Net cash used in operating activities | $ (6,029) | (9,728) | $ (9,728) | |||
Cash flows from investing activities: | ||||||
Purchases of property, plant and equipment | (341) | |||||
Net cash used by investing activities | (341) | |||||
Cash flows from financing activities: | ||||||
Proceeds from term loan payable | 738 | |||||
Repayment of term loan payable | (738) | |||||
Proceeds from the issuance of common stock in private placement | 24,638 | |||||
Payment of issuance costs | (2,454) | |||||
Proceeds from the exercise of stock options | 20 | |||||
Net cash provided by financing activities | 22,204 | |||||
Effect of exchange rate changes on cash | $ (387) | (673) | $ (673) | |||
Net change in cash | 11,462 | |||||
Cash, beginning of period | $ 12,226 | $ 764 | 764 | |||
Cash, end of period | 12,226 | $ 764 | ||||
Supplemental disclosure of cash and non-cash investing and financing activities | ||||||
Cash paid for interest | 19 | |||||
Right of use asset and lease liability additions | $ 136 |
BUSINESS AND BASIS OF PREPARA_2
BUSINESS AND BASIS OF PREPARATION | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
BUSINESS AND BASIS OF PREPARATION | ||
BUSINESS AND BASIS OF PREPARATION | 1. BUSINESS AND BASIS OF PREPARATION SmartKem Inc. (“SmartKem” or the “Company”) a Delaware corporation, formerly known as Parasol Investments Corporation (“Parasol”), was formed on May 13, 2020 and is the successor, as discussed below, of SmartKem Limited, which was formed under the Laws of England and Wales. The Company was founded as a “shell” company registered under the Exchange Act, with no specific business plan or purpose until it began operating the business of SmartKem Limited following the closing of the Exchange described below. SmartKem is seeking to reshape the world of electronics with a revolutionary semiconductor platform that enables a new generation of displays, sensors and logic. SmartKem’s patented TRUFLEX ® Restatement of previously filed financial statements The Company has determined that it made an error in the presentation and accounting of its consolidated statement of cash flows in the Company’s annual and interim consolidated financial statements during 2021 and 2022. The management of the company has assessed its accounting policies as well as the presentation and accounting for the gain and loss on foreign currency and has concluded that it was necessary to restate its previously issued financial statements for the correction of this error related to incorrect classification of gain and loss on foreign currency in effect of exchange rate changes on cash instead of including such non-cash unrealized gains and losses in cash flows from operating activities. The effect of this error was to overstate net cash used in operating activities and effect of exchange rate changes on cash by $412 thousand for the six months ended June 30, 2021, respectively. The errors and the required restatement had no effect on the Company’s cash flows from investing activities, financing activities, net changes in cash or cash and cash equivalents as of June 30, 2021 and had no impact on the Company’s consolidated balance sheet, statements of operations and comprehensive loss and statements of stockholders’ equity as of and for the three- and six-month periods ended June 30, 2021. The changes are presented below (in thousands): For the Six Months Ended June 30, 2021 Net cash used in operating activities as previously reported $ (6,441) Adjustment for (Loss)/Gain on foreign currency transactions 412 Net cash used in operating activities as restated $ (6,029) Effect of exchange rate changes on cash as previously reported $ 25 Adjustment for (Gain)/Loss on foreign currency transactions (412) Effect of exchange rate changes on cash as restated $ (387) Basis for Presentation These unaudited interim condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting and are presented in thousands, except number of shares and per share data. Accordingly, certain notes or other information that are normally required by U.S. GAAP have been omitted if they substantially duplicate the disclosures contained in the Company’s annual audited consolidated financial statements. Accordingly, the unaudited interim condensed consolidated financial statements should be read in connection with the Company’s audited financial statements and related notes as of and for the year ended December 31, 2021. The accompanying interim condensed consolidated financial statements are unaudited; however, in the opinion of management, they include all normal and recurring adjustments necessary for a fair presentation of the Company’s unaudited interim condensed consolidated financial statements for the periods presented. Results of operations reported for interim periods are not necessarily indicative of results for the entire year. Comprehensive loss of all periods presented is comprised primarily of net loss and foreign currency translation adjustments. Going Concern The accompanying unaudited interim condensed consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the ordinary course of business. Since inception, we have incurred recurring losses including net losses of $3.7 million and $6.5 million for the three and six months ended June 30, 2022, respectively. As of June 30, 2022 we had an accumulated deficit of $81.5 million. The Company’s cash as of June 30, 2022 was $7.8 million. We anticipate operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, further development of our technology and products and expenses related to the commercialization of our products. Management believes that the Company’s existing cash as of June 30, 2022 will be sufficient to fund the operations of the Company through to April 2023 and that the Company will require additional capital to continue its operations and research and development activity thereafter. There can be no assurance, however, that such financing will be available when needed, if at all, or on acceptable terms and conditions. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including the market demand for the Company’s products, the quality of product development efforts, management of working capital, and the continuation of normal payment terms and conditions for purchase of services. In order to address its capital needs, including its planned research and development activities and other expenditures, the Company is assessing options for financing our working capital requirements through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Adequate financing opportunities might not be available to the Company, when and if needed, on acceptable terms or at all. If the Company is unable to obtain additional financing in sufficient amounts or on acceptable terms, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs and product portfolio expansion, which could adversely affect its operating results or business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. After considering the uncertainties, management consider it is appropriate to continue to adopt the going concern basis in preparing the consolidated financial statements. The accompanying unaudited interim condensed consolidated financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. Reverse Recapitalization On February 23, 2021 Parasol entered into a Securities Exchange Agreement (“the Exchange Agreement”), with SmartKem Limited. Pursuant to the Exchange Agreement all of the equity interests in SmartKem Limited, except certain deferred shares which had no economic or voting rights (the “Deferred Shares”) and which were purchased by Parasol for an aggregate purchase price of $1.40, were exchanged for shares of Parasol common stock, par value $0.0001 per share (“common stock”), and SmartKem Limited became a wholly owned subsidiary of Parasol (the “Exchange”). As a result of the Exchange, Parasol acquired the business of SmartKem Limited, and continues as the existing business operations of SmartKem Limited as a public reporting company under the name SmartKem, Inc. Under ASC 805, Business Combinations, SmartKem Limited was deemed the accounting acquirer based on the following predominate factors: Parasol was created as a “shell” company to effect a business combination and had no operations, the former shareholders of SmartKem Limited own more than a majority of the outstanding voting stock of the Company, the Company’s board of directors and management consists of the former board of directors and management of SmartKem Limited, SmartKem Limited was the largest entity by assets at the time of the Exchange, and the principal operating location of the Company is SmartKem Limited’s premises which are located in Manchester, United Kingdom. The Exchange was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with U.S. GAAP. Under this method of accounting, Parasol was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Exchange was treated as the equivalent of SmartKem Limited issuing stock for the net assets of Parasol, accompanied by a recapitalization. The net assets of Parasol are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities, and results of operations prior to the Exchange are those of SmartKem Limited. Reported shares and earnings per share available to holders of the Company’s common stock, prior to the Exchange, have been retroactively restated as shares reflecting the exchange ratios established in the Exchange. At the closing of the Exchange (the “Closing”), each SmartKem Limited ordinary share issued and outstanding immediately prior to the Closing (other than the Deferred Shares) was exchanged for 0.0111907 of a share of the Company’s common stock and each SmartKem Limited A ordinary share issued and outstanding immediately prior to the Closing was exchanged for 0.0676668 of a share of the Company’s common stock, with the maximum number of shares of our common stock issuable to the former holders of SmartKem Limited’s ordinary shares and A ordinary shares equal to 12,725,000. This includes enterprise management incentive options to purchase 124,497,910 SmartKem Limited ordinary shares (the “SmartKem Limited EMI Options”) issued and outstanding immediately prior to the Closing that were accelerated and exercised by the holders thereof for a like number of ordinary shares and exchanged for shares of the Company’s common stock pursuant to the Exchange. In aggregate 1,127,720,477 SmartKem Limited shares were exchanged for 12,725,000 of the Company’s common stock, an average exchange ratio of 0.011283825. Immediately prior to the Closing, an aggregate of 2,500,000 shares of the Company’s common stock owned by the stockholders of Parasol prior to the Exchange were forfeited and cancelled (the “Stock Forfeiture”). The consolidated entity presented is referred to herein as “SmartKem”, “we”, “us”, “our”, or the “Company”, as the context requires and unless otherwise noted. | 1. BUSINESS AND LIQUIDITY Restatement of previously issued financial statements The Company has determined that it made an error in the presentation and accounting of its consolidated statement of cash flows in the Company’s annual and interim consolidated financial statements during 2021 and 2022. The management of the company has assessed its accounting policies as well as the presentation and accounting for the gain and loss on foreign currency and has concluded that it was necessary to restate its previously issued financial statements for the correction of this error related to incorrect classification of gain and loss on foreign currency in effect of exchange rate changes on cash instead of including such non-cash unrealized gains and losses in cash flows from operating activities. The effect of this error was to overstate net cash used in operating activities and effect of exchange rate changes on cash by $808 thousand for the year ended December 31, 2021. The errors and the required restatement had no effect on the Company’s cash flows from investing activities, financing activities, net changes in cash or cash and cash equivalents as of December 31, 2021 and had no impact on the Company’s consolidated balance sheet, the Company’s consolidated statements of operations and comprehensive loss and stockholders’ equity as of and for year ended December 31, 2021. The changes are presented below (in thousands): For the year ended December 31, 2021 Net cash used in operating activities as previously reported $ (10,536) Adjustment for Loss/(Gain) on foreign currency transactions 808 Net cash used in operating activities as restated $ (9,728) Effect of exchange rate changes on cash as previously reported $ 135 Adjustment for (Gain)/Loss on foreign currency transactions (808) Effect of exchange rate changes on cash as restated $ (673) Organization & Reverse Recapitalization SmartKem Inc. (“SmartKem” or the “Company”) a Delaware corporation, formerly known as Parasol Investments Corporation (“Parasol”), was formed on May 13, 2020 and is the successor, as discussed below, of SmartKem Limited, which was formed under the Laws of England and Wales. The Company was founded as a “shell” company registered under the Exchange Act, with no specific business plan or purpose until it began operating the business of SmartKem Limited following the closing of the Exchange described below. On February 23, 2021 Parasol entered into a Securities Exchange Agreement (“the Exchange Agreement”), with SmartKem Limited. Pursuant to the Exchange Agreement all of the equity interests in SmartKem Limited, except certain deferred shares which had no economic or voting rights (the “Deferred Shares”) and which were purchased by Parasol for an aggregate purchase price of $1.40, were exchanged for shares of Parasol common stock, par value $0.0001 per share (“common stock”), and SmartKem Limited became a wholly owned subsidiary of Parasol (the “Exchange”). As a result of the Exchange, Parasol legally acquired the business of SmartKem Limited, and continues as the existing business operations of SmartKem Limited as a public reporting company under the name SmartKem, Inc. Under ASC 805, Business Combinations, SmartKem Limited was deemed the accounting acquirer based on the following predominate factors: Parasol was created as a “shell” company to effect a business combination and had no operations, the former shareholders of SmartKem Limited own more than a majority of the outstanding voting stock of the Company, the Company’s board of directors and management consists of the former board of directors and management of SmartKem Limited, SmartKem Limited was the largest entity by assets at the time of the Exchange, and the principal operating location of the Company is SmartKem Limited’s premises which are located in Manchester, United Kingdom. The Exchange was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with accounting principles generally accepted in the United States of America (“US GAAP”). Under this method of accounting, Parasol was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Exchange was treated as the equivalent of SmartKem Limited issuing stock for the net assets of Parasol, accompanied by a recapitalization. The net assets of Parasol are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities, and results of operations prior to the Exchange are those of SmartKem Limited. Reported shares and earnings per share available to holders of the Company’s common stock, prior to the Exchange, have been retroactively restated as shares reflecting the exchange ratios established in the Exchange. At the closing of the Exchange (the “Closing”), each SmartKem Limited ordinary share issued and outstanding immediately prior to the Closing (other than the Deferred Shares) was exchanged for 0.0111907 of a share of the Company’s common stock and each SmartKem Limited A ordinary share issued and outstanding immediately prior to the Closing was exchanged for 0.0676668 of a share of the Company’s common stock, with the maximum number of shares of our common stock issuable to the former holders of SmartKem Limited’s ordinary shares and A ordinary shares equal to 12,725,000. This includes enterprise management incentive options to purchase 124,497,910 SmartKem Limited ordinary shares (the “SmartKem Limited EMI Options”) issued and outstanding immediately prior to the Closing that were accelerated and exercised by the holders thereof for a like number of ordinary shares and exchanged for shares of the Company’s common stock pursuant to the Exchange. In aggregate 1,127,720,477 SmartKem Ltd shares were exchanged for 12,725,000 of the Company’s common stock, an average exchange ratio of 0.011283825. Immediately prior to the Closing, an aggregate of 2,500,000 shares of the Company’s common stock owned by the stockholders of Parasol prior to the Exchange were forfeited and cancelled (the “Stock Forfeiture”). Business SmartKem, Inc. is seeking to reshape the world of electronics with a revolutionary semiconductor platform that enables a new generation of displays, sensors and logic. SmartKem’s patented TRUFLEX ® COVID-19 Pandemic In March 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic (the “Pandemic”). The Pandemic has had a widespread and detrimental effect on the global economy and has adversely impacted the Company’s business and results of operations. The Company has experienced travel bans, states of emergency, quarantines, lockdowns, “shelter in place” orders, business restrictions and shutdowns in the countries where it operates. The Company’s containment measures have impacted its day-to-day operations and disrupted its business. Because the severity, magnitude and duration of the Pandemic and its economic consequences are highly uncertain, rapidly changing and difficult to predict, the ultimate impact of the Pandemic on the Company’s business, financial condition and results of operations is currently unknown. The additional costs incurred by the Company related to COVID-19 for the year ended December 31, 2021 were deemed to be immaterial to the consolidated financial statements. The Company anticipates there may be additional costs relating to the Pandemic incurred in the upcoming months that will be attributable to fiscal year 2022 and thereafter. These costs are not expected to be material. The consolidated entity presented is referred to herein as “SmartKem”, “we”, “us”, “our”, or the “Company”, as the context requires and unless otherwise noted. |
SUMMARY OF SIGNIFICANT ACCOUN_6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of SmartKem, Inc. and its wholly-owned subsidiaries, SmartKem Delaware, Inc. and SmartKem Limited. The Company does not have any nonconsolidated subsidiaries. All intercompany balances and transactions have been eliminated on consolidation, including unrealized gains and losses on transactions between the companies. The Company's formerly wholly-owned subsidiary, SmartKem Delaware Inc. was dissolved on May 13, 2021. Comprehensive loss Comprehensive loss of all periods presented is comprised primarily of net loss and foreign currency translation adjustments. Management’s Use of Estimates The preparation of interim condensed consolidated financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company’s unaudited interim condensed consolidated financial statements relates to the valuation of common share, fair value of share options, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. As of June 30, 2022 and December 31, 2021, the Company did not have any cash equivalents. Accounts Receivable Accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of non-collection. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required. There was no allowance for doubtful accounts recorded as of June 30, 2022 and December 31, 2021. Impairment of Long-Lived Assets Management continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. If the carrying amount is greater than the undiscounted cash flows, the carrying amount of the asset is reduced to the asset’s fair value. An impairment loss is recognized immediately as an operating expense in the condensed consolidated statements of operations. Reversal of previously recorded impairment losses are prohibited. As of June 30, 2022 and December 31, 2021, Company’s management believed that no revision to the remaining useful lives or impairment of the Company’s long-lived assets was required. Warrants The accounting treatment of warrants issued is determined pursuant to the guidance provided by ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging Leases Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the unaudited condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. The Company has elected not to present short-term leases as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the Company’s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments. Revenue The Company applies the provisions of ASC 606 Revenue from Contracts with Customers The Company’s current contracts with customers do not contain significant estimates or judgments. All of the Company’s revenue contains a single performance obligation that is recognized upon fulfilment of the sales order. The Company derives its revenues primarily from sales of TRUFLEX ® Other Operating Income The Company’s other operating income is related to government grant incentives received for qualifying research and development projects, and research and development tax credits related to the United Kingdom’s Research and Development Expenditure Credit scheme, which is a government tax incentive designed to reward innovative companies for investing in research and development. Such incentives are recorded as other income when it is probable the amounts are collectible and can be reasonably estimated. For the three months ended June 30, 2022 and 2021, the Company recorded grant income and research & development tax credits of $294 thousand and $256 thousand, respectively, and $578 thousand and $688 thousand for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, and December 31, 2021, the Company had receivables related to research & development tax credits for payments not yet received of $1,505 thousand and $1,070 thousand, respectively. Share-based compensation All share-based payments, including grants of stock options, are measured based on the fair value of the share-based awards at the grant date and recognized over their respective vesting periods. Outstanding options generally expire 10 years after the grant date. The Company has issued options that vest based on service requirements and options become exercisable when service requirements are met. Due to the Exchange, all options outstanding immediately prior to the event with a performance obligation requirement became vested and exercisable. The estimated fair value of stock options at the grant date is determined using the Black-Scholes pricing model. The Black-Scholes option pricing model requires inputs such as the fair value of common stock on date of grant, expected term, expected volatility, dividend yield, and risk-free interest rate. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The Company records forfeitures when they occur. Functional Currency and Operations Prior to the Exchange, SmartKem Limited’s (“the predecessor’s”) functional currency was the British Pound Sterling (“GBP”), and the consolidated financial statements were presented in United States dollars (“USD”). The predecessor’s functional currency was the respective local currency of the primary economic environment in which an entity’s operations are conducted. The predecessor translated the financial statements into the presentation currency using exchanges rates in effect on the balance sheet date for assets and liabilities and average exchanges rates for the period for statement of operations accounts, with the difference recognized in accumulated other comprehensive income /(loss). From the date of the Exchange forward, the Company’s functional currency is the U.S. dollar (“USD”). The functional currency of the Company’s foreign operation is the respective local currency. Assets and liabilities of foreign operation denominated in local currencies are translated at the spot rate in effect at the applicable reporting date. The condensed consolidated statements of operations and comprehensive loss are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized gain/loss is recognized as foreign currency translation as a component of other comprehensive income. Foreign Currency Transactions The company measures foreign currency denominated monetary assets and liabilities using exchange rates in effect at the end for the period. Transaction gains and losses are included in net loss. Foreign exchange losses, primarily driven by foreign exchange revaluation of our dollar borrowings held by non-dollar group undertakings, were $1,284 thousand and $1,638 thousand for the three- and six-month periods ended June 30, 2022, respectively. Foreign exchange gains were $57 thousand and foreign exchanges losses were $412 thousand for the three-and six-month periods ended June 30, 2021, respectively. Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. As of June 30, 2022 and December 31, 2021, there were no accruals for uncertain tax positions. Contingent Liabilities A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of June 30, 2022, the Company does not expect that such matters will have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows. Offering Costs Direct and incremental legal and accounting costs associated with the Company’s issuance of common stock and warrants are deferred and classified as a component of other assets on the condensed consolidated balance sheet until completion of the issuance. Upon completion of the issuance, deferred offering costs are reclassified from other assets to equity and recorded against the net proceeds received in the issuance. For the six months ended June 30, 2022 and 2021 respectively, $170 thousand and $2,454 thousand of offering costs were recorded in additional paid-in capital. No offering costs were deferred as of both June 30, 2022 and December 31, 2021. Segment Information The Company has determined that it operates and reports in one segment Basic and Diluted Loss Per Share Basic and diluted net loss per share is determined by dividing net loss by the weighted average ordinary shares outstanding during the period. For all periods presented with a net loss, the shares underlying the ordinary share options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per share are the same for periods with a net loss. The loss per share information in these unaudited interim condensed consolidated financial statements is reflected and calculated as if the Company had existed since January 1, 2020. Accordingly, loss per share for all periods was calculated based on the number of shares retroactively adjusted for the exchange ratio determined in the reverse recapitalization (see also note 1). The Company has 2,168,000 pre-funded common stock warrants outstanding as of June 30, 2022, which became exercisable on April 24, 2021 based on terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $0.01, these shares are considered outstanding common shares and included in computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions were met on April 24, 2021. The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: June 30, 2022 2021 Options 1,937,382 1,596,562 Warrants 985,533 985,533 Total 2,922,915 2,582,095 Recent Accounting Pronouncements Adopted In May 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2021-04, Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity Classified Written Call Options In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) Recent Accounting Pronouncements Not Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments: Credit Losses (Topic 326) Reclassifications Certain amounts in prior periods' interim condensed consolidated financial statements have been reclassified to conform to the current period’s presentation. | 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis for Presentation These consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and accounting principles generally accepted in the United States of America ( “US GAAP”) as defined by the Financial Accounting Standards Board (FASB) within the FASB Accounting Standards Codification (“ASC”) and are presented in thousands, except number of shares and per share data . Going Concern The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities, and commitments in the ordinary course of business. Since inception, we have incurred recurring losses including net losses of $17.1 million and $23.1 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $75.1 million. We anticipate operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, further development of our technology and products and expenses related to the commercialization of our products. We expect that our cash and cash equivalents of $12.2 million as of December 31, 2021 will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the issuance date of these consolidated financial statements through the first quarter of 2023. It is possible this period could be shortened if there are any significant increases in planned spending or development programs or more rapid progress of development programs than anticipated. Our future viability is dependent on our ability to raise additional capital to fund our operations. In the long-term, we will need to obtain additional funds to satisfy our operational needs and to fund our sales and marketing efforts, research and development expenditures, and business development activities. Until such time, if ever, as we can generate sufficient cash through revenue, we expect to finance our working capital requirements through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. There can be no assurance however that such financing will be available in sufficient amounts, when and if needed, on acceptable terms or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including the market demand for the Company’s products and services, the quality of product development efforts, management of working capital, and continuation of normal payment terms and conditions for purchase of services. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows for operations, then the Company will need to raise additional funding to continue as a going concern. Basis of Consolidation The consolidated financial statements include the accounts of SmartKem, Inc. and its wholly-owned subsidiaries, SmartKem Delaware, Inc. and SmartKem Limited. The Company does not have any nonconsolidated subsidiaries. All intercompany balances and transactions have been eliminated on consolidation, including unrealized gains and losses on transactions between the companies. The Company's formerly wholly-owned subsidiary, SmartKem Delaware Inc. was dissolved on May 13, 2021. Comprehensive loss Comprehensive loss of all periods presented is comprised primarily of net loss and foreign currency translation adjustments. Management’s Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relates to the valuation of common share, fair value of share options, fair value of embedded conversion features in the convertible notes, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Certain Risk and Uncertainties The Company’s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the growth stage, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements. See Item 1a of this Form 10-K/A for a fuller discussion of the Company’s risk factors. The Company has access under a framework agreement to equipment which is used in the manufacturing of demonstrator products employing the Company’s inks. If the Company lost access to this fabrication facility, it would materially and adversely affect the Company’s ability to manufacture prototypes and demonstration products for potential customers. The loss of this access could significantly impede the Company’s ability to engage in product development and process improvement activities. Alternative providers of similar services exist, but would take effort and time to bring into the Company’s operations. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. As of December 31, 2021 and 2020, the Company did not have any cash equivalents. Accounts Receivable Accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of non-collection. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required. There was no allowance for doubtful accounts recorded as of December 31, 2021 and 2020. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. Property, Plant and Equipment Property, plant and equipment is stated at cost, less accumulated depreciation. Maintenance and repairs are expensed when incurred. Additions and improvements that extend the economic useful life of the asset are capitalized and depreciated over the remaining useful lives of the assets. The cost and accumulated depreciation of assets sold or retired are removed from the respective accounts, and any resulting gain or loss is reflected in current earnings. Depreciation and amortization are provided using the accelerated declining balance method in amounts considered to be sufficient to amortize the cost of the assets to operations over their estimated useful lives. Property, plant and equipment is depreciated at 25 percent of net book value on an annual basis, resulting in an estimated useful life of approximately 15 years. Impairment of Long-Lived Assets Management continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. If the carrying amount is greater than the undiscounted cash flows, the carrying amount of the asset is reduced to the asset’s fair value. An impairment loss is recognized immediately as an operating expense in the consolidated statements of operations. Reversal of previously recorded impairment losses are prohibited. As of December 31, 2021 and 2020, Company’s management believed that no revision to the remaining useful lives or impairment of the Company’s long-lived assets was required. Derivative Asset for Embedded Conversion Features The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates convertible notes to determine if those contracts or embedded components of those contracts qualify as derivatives to be accounted for separately. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The result of this accounting treatment is that the fair value of the embedded derivative is recorded as a liability and marked-to-market each balance sheet date, with the change in fair value recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The fair value of the embedded conversion features are estimated using a Monte Carlo simulation model, in which possible outcomes and their values are simulated repeatedly and randomly. Under the Monte Carlo method the Company estimated the fair value of the convertible notes conversion feature at the time of issuance and subsequent remeasurement dates, utilizing the with-and without method, where the value of the derivative feature is the difference in values between a note simulated with the embedded conversion feature and the value of the same note simulated without the embedded conversion feature. Estimating fair values of embedded conversion features requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. Fair Value of Financial Instruments ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2021 and 2020. The carrying value of the Company’s cash, accounts receivable, other receivables, prepaid expenses and other current assets, accounts payable and accrued expenses approximate fair value because of the short-term maturity of these financial instruments. The carrying value of derivative asset is displayed at fair value. See Note 8 for additional information regarding fair value measurements. Convertible Notes The Company accounts for its convertible notes in accordance with ASC 470-20, Debt with Conversion and Other Options Debt discount created by the bifurcation of embedded feature in the convertible notes are reflected as a reduction to the related debt liability. The discount is amortized to interest expense over the term of the debt using the effective-interest method. Warrants The accounting treatment of warrants issued is determined pursuant to the guidance provided by ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging Leases Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the consolidated balance sheets as of December 31, 2021 and 2020. The Company has elected not to present short-term leases as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the Company’s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments. Revenue The Company applies the provisions of ASC 606, Revenue from Contracts with Customers The Company’s current contracts with customers do not contain significant estimates or judgments. All of the Company’s revenue contains a single performance obligation that is recognized upon fulfilment of the sales order. The Company derives its revenues primarily from sales of demonstrator units to customers evaluating organic semiconductor technology. The transaction price is stated in each customer agreement and is allocated to a single performance obligation. Revenue is recognized upon shipment of each demonstrator, at a point in time. The Company does not have any significant financing components as payment is received at or shortly after the point of sale. Costs incurred to obtain a contract will be expensed as incurred when the amortization period is less than a year. Research and Development Expenses The Company expenses research and development costs as incurred. Research and development costs include salaries, employee benefit costs, direct project costs, supplies and other related costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. Patent and Licensing Costs Patent and licensing costs are expensed as incurred because their realization is uncertain. These costs are classified as research and development expenses in the accompanying consolidated statements of operations and comprehensive loss. Other Operating Income The Company’s other operating income is related to government grant incentives received for qualifying research and development projects, and research and development tax credits related to the United Kingdom’s Research and Development Expenditure Credit scheme, which is a government tax incentive designed to reward innovative companies for investing in research and development. Such incentives are recorded as other income when it is probable the amounts are collectible and can be reasonably estimated. For the year ended December 31, 2021 and 2020, the Company recorded grant income and research & development tax credits of $1,285 thousand and $1,437 thousand, respectively, which are recorded as other operating income in the accompanying consolidated statements of operations. As of December 31, 2021, and December 31, 2020, the Company had receivables related to research & development tax credits for payments not yet received of $1,070 thousand and $982 thousand, respectively. Ordinary Shares Valuation Due to the absence of an active market for the Company’s ordinary shares, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its ordinary shares. In determining the exercise prices for options to be issued, the estimated fair value of the Company’s ordinary shares on each grant date was estimated based upon a variety of factors, including: ● the issuance prices of ordinary shares; ● the rights and preferences of preferred shareholders; ● the progress of the Company’s research and development programs; ● the Company’s stage of development and business strategy; ● external market conditions affecting the technology industry and trends within the technology industry; ● the Company’s financial position, including cash on hand; ● the Company’s historical and forecasted performance and operating results; ● the lack of active public market for the Company’s ordinary shares; ● the likelihood of achieving a liquidity event, such as a securities offering, initial public offering or a sale of the Company’s shares. Significant changes to the key assumptions underlying the factors used could result in different fair values of ordinary shares at each valuation date. Ordinary shares are classified in shareholders’ equity and represent issued share capital. Share-based compensation All share-based payments, including grants of stock options, are measured based on the fair value of the share-based awards at the grant date and recognized over their respective vesting periods. Outstanding options generally expire 10 years after the grant date. The Company has issued options that vest based on service requirements and issued options that vest based on performance requirements. Options become exercisable when service requirements are met. In the case of performance based options, options become exercisable when there is a liquidity event, such as a change in control or sale or admission (listing as a public company or initial public offering (“IPO”)), and the employee, or consultant, must be providing services to the Company at the time of the event. Due to the Exchange, all options outstanding immediately prior to the event with a performance obligation requirement became vested and exercisable. Non-cash stock-based compensation expense for the year ended December 31, 2021 was The estimated fair value of stock options at the grant date is determined using the Black-Scholes pricing model. The Black-Scholes option pricing model requires inputs such as the fair value of common stock on date of grant, expected term, expected volatility, dividend yield, and risk-free interest rate. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The Company records forfeitures when they occur. Functional Currency and Operations Prior to the Exchange, SmartKem Limited’s (“the predecessor’s”) functional currency was the British Pound Sterling (“GBP”), and the consolidated financial statements were presented in United States dollars (“USD”). The predecessor’s functional currency was the respective local currency of the primary economic environment in which an entity’s operations are conducted. The predecessor translated the consolidated financial statements into the presentation currency using exchanges rates in effect on the balance sheet date for assets and liabilities and average exchanges rates for the period for statement of operations accounts, with the difference recognized in accumulated other comprehensive income/ (loss). The Company’s functional currency is the U.S. dollar (“USD”). The functional currency of the Company’s foreign operation is the respective local currency. Assets and liabilities of foreign operations denominated in local currencies are translated at the spot rate in effect at the applicable reporting date. The consolidated statements of operations and comprehensive loss are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized gain/loss is recognized as foreign currency translation as a component of other comprehensive income. Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. As of December 31, 2021 and 2020, there were no material uncertain tax positions. Contingent Liabilities A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of December 31, 2021, the Company does not expect that such matters will have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows. Offering Costs Direct and incremental legal and accounting costs associated with the Company’s issuance of common stock and warrants are deferred and classified as a component of other assets on the consolidated balance sheet until completion of the issuance. Upon completion of the issuance, deferred offering costs are reclassified from other assets to equity in additional paid-in capital and recorded against the net proceeds received in the issuance. The deferred offering costs incurred as of December 31, 2020 were immaterial and no offering costs were capitalized. For the year ended December 31, 2021 $2,454 thousand of offering costs were recorded in additional paid-in capital. For the year ended December 31, 2021, $1.329 million of direct and incremental costs associated with the Exchange were recorded as Transaction Expenses in the Consolidated Statement of Operations and Comprehensive Loss. Segment Information The Company has determined that it operates and reports in one segment Basic and Diluted Loss Per Share Basic and diluted net loss per share is determined by dividing net loss by the weighted average ordinary shares outstanding during the period. For all periods presented with a net loss, the shares underlying the ordinary share options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per share are the same for periods with a net loss. The loss per share information in these consolidated financial statements is reflected and calculated as if the Company had existed since January 1, 2020. Accordingly, loss per share for all periods was calculated based on the number of shares retroactively adjusted for the exchange ratio determined in the reverse recapitalization (see also note 1). The Company has 2,168,000 pre-funded common stock warrants outstanding as of December 31, 2021, which became exercisable on April 23, 2021 based on terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $0.01, these shares are considered outstanding common shares and included in computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions were met on April 23, 2021. The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: December 31, 2021 2020 Options 1,953,882 1,810,749 Warrants 985,533 — Total 2,939,415 1,810,749 Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments: Credit Losses (Topic 326) annual and interim periods beginning after December 15, 2022. Management is currently evaluating the impact of these changes on the consolidated financial statements. In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40). The amendments in this update affect all entities that issue freestanding written call options (for example warrants) that are classified in equity. Specifically, the amendments affect those entities when a freestanding equity-classified written call option is modified or exchanged and remains equity classified after the modification or exchange. The amendments that relate to the recognition and measurement of EPS for certain modifications or exchanges of freestanding equity-classified written call options affect entities that present EPS in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Management is currently evaluating the impact of this guidance but does not expect this update to have a material impact on the Company's consolidated financial statements. In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance. The amendments in this update affect all business entities that account for a transaction with a government by applying a grant or contribution accounting model by analogy to other accounting guidance. The amendments in this Update require annual disclosures about: (1) Information about the nature of the transactions and the related accounting policy used to account for the transactions; (2) The line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and (3) Significant terms and conditions of the transactions, including commitments and contingencies. The amendments in this update are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. Management is currently evaluating the impact of this guidance but does not expect this update to have a material impact on the Company's consolidated financial statements. Reclassifications Certain amounts in prior years' consolidated financial statements have been recast and reclassified to conform to the current year's presentation |
PREPAID EXPENSES AND OTHER CU_4
PREPAID EXPENSES AND OTHER CURRENT ASSETS | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
PREPAID EXPENSES AND OTHER CURRENT ASSETS | ||
PREPAID EXPENSES AND OTHER CURRENT ASSETS | 3. PREPAID EXPENSES AND OTHER CURRENT ASSETS: Prepaid expenses and other current assets consist of the following: June 30, December 31, 2022 2021 Prepaid service charges and property taxes $ 83 $ 58 Prepaid utilities 31 51 Prepaid insurance 633 412 Prepaid administrative expenses 55 63 Prepaid technical fees 212 141 Prepaid consulting fees 629 27 VAT receivable 141 50 Other Receivable and other prepaid expenses 31 — Total prepaid expenses and other current assets $ 1,815 $ 802 As of June 30, 2022 and December 31, 2021, there was $191 thousand and $217 thousand respectively, of non-current prepaid insurance related to directors’ and officers’ liability insurance that was included in the amounts above. | 3. PREPAID EXPENSES AND OTHER CURRENT ASSETS: Prepaid expenses and other current assets consist of the following: December 31, 2021 2020 Prepaid rent $ 58 $ 65 Prepaid utilities 51 30 Prepaid insurance 412 41 Prepaid administrative expenses 63 61 Prepaid technical fees 141 8 Prepaid consulting fees 27 — VAT receivable 50 54 Total prepaid expenses and other current assets $ 802 $ 259 As of December 31, 2021 and 2020, there was $217 thousand and $0 , respectively, of non-current prepaid insurance related to directors’ and officers’ liability insurance that was included in the amounts above. |
PROPERTY, PLANT AND EQUIPMENT_3
PROPERTY, PLANT AND EQUIPMENT | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
PROPERTY, PLANT AND EQUIPMENT | ||
PROPERTY, PLANT AND EQUIPMENT | 4. PROPERTY, PLANT AND EQUIPMENT: Property, plant and equipment consist of the following: June 30, December 31, 2022 2021 Plant and equipment $ 1,523 $ 1,633 Furniture and fixtures 220 245 Computer hardware and software 24 26 1,767 1,904 Less: Accumulated depreciation (1,090) (1,102) Property, plant and equipment, net $ 677 $ 802 Depreciation expense was $51 thousand and $47 thousand for the three months ended June 30, 2022 and 2021, respectively, and $105 thousand and $95 thousand for the six months ended June 30, 2022 and 2021, respectively and is classified as research and development expense. | 4. PROPERTY, PLANT AND EQUIPMENT: Property, plant and equipment consist of the following: December 31, 2021 2020 Plant and equipment $ 1,633 $ 1,316 Furniture and fixtures 245 248 Computer hardware and software 26 26 1,904 1,590 Less: Accumulated depreciation (1,102) (908) Property, plant and equipment, net $ 802 $ 682 Depreciation expense was $209 thousand and $197 thousand for the year ended December 31, 2021 and 2020, respectively, and is classified as research and development expense. |
ACCOUNTS PAYABLE AND ACCRUED _4
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | ||
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | 5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES: Accounts payable and accrued expenses consist of the following: June 30, December 31, 2022 2021 Accounts payable $ 457 $ 510 Accrued expenses – lab refurbishments 118 131 Accrued expenses – technical fees 58 66 Accrued expenses – variable rent & utilities 9 20 Accrued expenses – audit & accounting fees 167 191 Accrued expenses – other 67 112 Credit card liabilities 34 10 Payroll and social security liabilities 280 383 Total accounts payable and accrued expenses $ 1,190 $ 1,423 | 5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES: Accounts payable and accrued expenses consist of the following: December 31, 2021 2020 Accounts payable $ 510 $ 227 Accrued expenses – lab refurbishments 131 132 Accrued expenses – technical fees 66 45 Accrued expenses – variable rent & utilities 20 67 Accrued expenses – audit & accounting fees 191 250 Accrued expenses – other 112 6 Credit card liabilities 10 6 Payroll and social security liabilities 383 128 Total accounts payable and accrued expenses $ 1,423 $ 861 |
LEASES_2
LEASES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
LEASES | ||
LEASES | 6. LEASES: The Company has operating leases consisting of office space, lab space, and equipment with remaining lease terms of 1 to 3 years, subject to certain renewal options as applicable. In April 2022, the Company renewed its lease for research & development, engineering, testing and corporate offices in Manchester. The renewed lease term expires in 2025 with an option for the Company to end the lease in 2024. There was no sublease rental income for the three and six months ended June 30, 2022 and 2021. The Company is not the lessor in any lease agreement, and no related party transactions for lease arrangements have occurred. The table below presents certain information related to the lease costs for the Company’s operating and finance leases for the periods ended: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Operating lease cost $ 68 $ 52 $ 131 $ 99 Short-term lease cost 2 13 4 26 Variable lease cost 41 64 95 98 Total lease cost $ 111 $ 129 $ 230 $ 223 The total lease cost is included in the unaudited condensed consolidated statements of operations as follows: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 105 $ 120 $ 218 $ 207 Selling, general and administrative 6 9 12 16 Total lease cost $ 111 $ 129 $ 230 $ 223 Right of use lease assets and lease liabilities for our operating leases were recorded in the unaudited condensed consolidated balance sheet as follows: June 30, December 31, 2022 2021 Assets Operating lease right of use assets $ 549 $ 154 Total lease assets $ 549 $ 154 Liabilities Current liabilities: Operating lease liability – current portion $ 208 $ 87 Noncurrent liabilities: Operating lease liability, net of current portion 320 28 Total lease liabilities $ 528 $ 115 The Company had no right of use lease assets and lease liabilities for financing leases as of June 30, 2022 and December 31, 2021. The table below presents certain information related to the cash flows for the Company’s operating leases for the periods ended: For the Six Months Ended June 30, 2022 2021 Operating cash outflows from operating leases $ 115 $ 120 Supplemental non-cash amounts of operating lease liabilities arising from obtaining right of use assets $ 539 $ 86 The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s operating and finance leases as of the period ended: For the Six Months Ended June 30, 2022 2021 Weighted average remaining lease term (in years) – operating leases 2.66 1.10 Weighted average discount rate – operating leases 7.64 % 6.12 % Undiscounted operating lease liabilities as of June 30, 2022, by year and in the aggregate, having non-cancelable lease terms in excess of one year were as follows: As of June 30, 2022 2022 $ 137 2023 220 2024 219 2025 9 2026 — Thereafter — Total undiscounted lease payments 585 Less imputed interest (57) Total net lease liabilities $ 528 | 6. LEASES: The Company has operating leases consisting of office space, lab space, and equipment with remaining lease terms of 1 There was no sublease rental income for the year ended December 31, 2021 and 2020. The Company is not the lessor in any lease agreement, and no related party transactions for lease arrangements have occurred. The table below presents certain information related to the lease costs for the Company’s operating and finance leases for the periods ended: For the Year Ended December 31, 2021 2020 Operating lease cost $ 225 $ 175 Short-term lease cost 32 48 Variable lease cost 140 401 Total lease cost $ 397 $ 624 The total lease cost is included in the consolidated statements of operations as follows: For the Year Ended December 31, 2021 2020 Research and development $ 373 $ 562 Selling, general and administrative 24 62 Total lease cost $ 397 $ 624 Right of use lease assets and lease liabilities for our operating leases were recorded in the consolidated balance sheets as follows: December 31, 2021 2020 Assets Operating lease right of use assets $ 154 $ 236 Total lease assets $ 154 $ 236 Liabilities Current liabilities: Operating lease liability – current portion $ 87 $ 217 Noncurrent liabilities: Operating lease liability, net of current portion 28 20 Total lease liabilities $ 115 $ 237 The Company had no right of use lease assets and lease liabilities The table below presents certain information related to the cash flows for the Company’s operating leases for the periods ended: For the Year Ended December 31, 2021 2020 Operating cash outflows from operating leases $ 276 $ 157 Supplemental non-cash amounts of operating lease liabilities arising from obtaining right of use assets $ 136 $ — The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s operating and finance leases as of the period ended: For the Year Ended December 31, 2021 2020 Weighted average remaining lease term (in years) – operating leases 1.40 1.35 Weighted average discount rate – operating leases 6.07 % 6.30 % Undiscounted operating lease liabilities as of December 31, 2021, by year and in the aggregate, having non-cancelable lease terms in excess of one year were as follows: As of December 31, 2021 2022 $ 93 2023 22 2024 7 2025 — 2026 — Thereafter — Total undiscounted lease payments 122 Less future minimum short-term lease payments (3) Less imputed interest (4) Total net lease liabilities $ 115 |
NOTES PAYABLE
NOTES PAYABLE | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
CONVERTIBLE NOTES AND NOTES PAYABLE. | ||
NOTES PAYABLE | 7. NOTES PAYABLE: On January 26, 2021, the Company entered into a term loan facility agreement for the amount of $739 thousand. The funds were available to be drawn on from the effective date of the agreement through January 27, 2021. The Company drew down the full loan amount on January 26, 2021. The Company’s research and development tax credit was to be utilized as collateral. The Lender was to be paid immediately following payment of research and development tax credit from the United Kingdom’s HM Revenue and Customs. The final repayment was due six months from the agreement date, if the loan and any interest was not repaid in full prior to this date. The loan carried a monthly interest rate of 1.25%. The interest accrued daily and compounded monthly on the monthly anniversary of the draw down date of the loan. The Company repaid the note payable in full on March 2, 2021. For six months ended June 30, 2021, the Company incurred an effective interest rate of 26.20% relating to notes payable. The interest expense recognized based on the debt’s effective interest rate for six months ended June 30, 2021, was $19 thousand. There were no notes payable outstanding during the six months ended June 30, 2022 and no associated interest expense during the period. | 7. CONVERTIBLE NOTES AND NOTES PAYABLE: Convertible Notes The activity for the Company’s convertible notes during the years ended December 31, 2021 and 2020 was as follows: For the Year Ended December 31, 2021 2020 Balance, beginning of year $ — $ 7,280 Amortization of debt discount — 25 Extinguishment of debt discount — 6,767 Loss on conversion of note — 9,344 Conversion of notes to equity — (23,630) Foreign currency translation — 214 Balance, end of year $ — $ — On January 24, 2020, a Qualified Financing Event (as defined below) occurred when the Company received cumulative investment proceeds in excess of $4,600 thousand from the sale and issuance of common shares. The fair value of the Company’s common shares were $1.807011 per share. The 2018 BASF Venture Capital and Entrepreneurs Fund L.P. Notes (as defined below), 2018 Octopus Investment Limited Notes (as defined below), and the 2019 Octopus, EF, and Other Notes (as defined below) in the aggregate principal amount of $11,796 thousand were converted into 8,159,977 of common shares (at the discounted price of $1.45 per share), and the related unpaid and accrued interest totaling $1,063 thousand were also converted into 735,148 of A Ordinary common shares of the Company (at the discounted price of $1.45 per share). The Company recognized a loss on conversion of $5,470 thousand for the year ended December 31, 2020 related to the conversion of notes measured as the difference in carrying value of debt and accrued interest and the fair value of shares converted on the conversion date. As a result of the conversion, the Company also recognized the unamortized debt discount related to the beneficial conversion feature of $6,767 thousand as interest expense for the year ended December 31, 2020. For the year ended December 31, 2020, the Company incurred an effective interest rate of 13.5% relating to convertible notes. There were no convertible notes outstanding as of December 31, 2021 and 2020. There was interest expense recognized based on the debt’s stated interest for the year ended December 31, 2021 and 2020 of zero and $43 thousand, respectively, relating to convertible notes. Additional interest expense related to the amortization of debt issuance cost was zero and $25 thousand for the year ended December 31, 2021 and 2020, respectively, for convertible notes. Loss on the conversion of notes is included on the consolidated statements of operations and other comprehensive loss as loss on conversion of convertible notes payable. The amount displayed in the statements of operations and other comprehensive loss for the year ended December 31, 2020 is inclusive of the loss on notes in the amount of $9,344 thousand, loss on accrued interest in the amount of $1,046 thousand and offset by the gain on the extinguishment of derivative liability in the amount of $4,920 thousand (Note 8). 2018 BASF Venture Capital and Entrepreneurs Fund L.P. Notes On April 18, 2018, the Company entered into a convertible note agreement (the “2018 BASF Venture Capital and Entrepreneurs Fund L.P. Notes”), with BASF Venture Capital (“BASF”) and Entrepreneurs Fund L.P. (“EF”) with an aggregate principal of $5,862 thousand. The 2018 BASF/EF Convertible Note was issued in three separate tranches on April 18, 2018, July 20, 2018 December 28, 2018 The 2018 BASF Venture Capital and Entrepreneurs Fund L.P. Notes and accrued but unpaid interest were convertible into the common share based on (i) fund raising at a price paid per Senior Share equal to the price paid per Senior Share by the investors on a Fund Raising at a discount to the per share price in the Fund Raising, (ii) sale of the company at a price per Senior Share of $16.39, or (iii) listing of the company on a publicly traded market at a price per Senior Share of $16.39. The principal amount shall accrue interest at a rate of 8% per annum, from the Issue Date up until the first anniversary of the Issue Date. Interest shall accrue on the principal amount at a rate of 15% per annum from, and including, the first anniversary of the Issue Date up until the notes are (i) converted, cancelled, repaid or redeemed or (ii) the longstop date. Accrued interest was to be calculated on the basis of a 365-day year for the actual number of days elapsed. 2018 Octopus Notes On July 20, 2018 the Company entered into a convertible note agreement (the “2018 Octopus Investment Limited Notes”) with Octopus Investment Limited (“Octopus”) with an aggregate nominal amount of $2,622 thousand. The 2018 Octopus Convertible Note was issued in two separate tranches on July 20, 2018 and December 28, 2018 The 2018 Octopus Notes and accrued but unpaid interest were convertible into the common shares based on (i) fund raising at a price paid per Senior Share equal to the price paid per Senior Share by the investors on a Fund Raising at a discount, (ii) sale of the company at a price per Senior Share of $15.10, or (iii) listing of the company on a publicly traded market at a price per Senior Share of $15.10. The principal amount shall accrue interest at a rate of 8% per annum, from the Issue Date up until the first anniversary of the Issue Date. Interest shall accrue on the principal amount at a rate of 12% per annum from, and including, the first anniversary of the Issue Date up until the notes are (i) converted, cancelled, repaid or redeemed or (ii) the longstop date. Accrued interest was to be calculated on the basis of a 365-day year for the actual number of days elapsed. 2019 Octopus, EF, and Other Notes On June 26, 2019 the Company entered into a convertible note agreement (the “2019 Octopus, EF, and Other Notes”) with Octopus, EF, and various private investors with an aggregate nominal amount of $3,681 thousand. The 2019 Octopus Convertible Note was issued in two separate tranches on June 26, 2019 and September 23, 2019 The 2018 Octopus, EF, and Other Notes and accrued but unpaid interest were convertible into the common shares based on (i) fund raising at a price paid per Senior Share equal to the price paid per Senior Share by the investors on a Fund Raising at a discount, (ii) sale of the company at a price per Senior Share of $0.001861, (iii) listing of the company on a publicly traded market at a price per Senior Share of $14.61, or (ii) any date following the first anniversary of the date the of the Instrument at a price per Senior Share of $11.19. The principal amount shall accrue interest at a rate of 10% per annum, from the Issue Date up until the notes are (i) converted, cancelled, repaid or redeemed or (ii) the longstop date. Accrued interest was to be calculated on the basis of a 365-day year for the actual number of days elapsed. The issuance of convertible notes with a beneficial redemption feature resulted in a debt discount of $2,608 thousand. Notes Payable On January 26, 2021, the Company entered into a term loan facility agreement for the amount of $738 Customs. The final repayment was due six months from the agreement date, if the loan and any interest was not repaid in full prior to this date. The loan carried a monthly interest rate of 1.25%. The interest accrued daily and compounded monthly on the monthly anniversary of the draw down date of the loan. For year ended December 31, 2021, the Company incurred an effective interest rate of 26.20% relating to notes payable. There were no notes payable outstanding during for the year ended December 31, 2020. The interest expense recognized based on the debt’s effective interest rate for year ended December 31, 2021 and 2020, was $19 thousand and zero, respectively, relating to notes payable. The Company repaid the note payable in full on March 2, 2021. There were no notes payable outstanding as of December 31, 2021 and 2020. |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
COMMITMENTS AND CONTINGENCIES. | ||
COMMITMENTS AND CONTINGENCIES | 8. COMMITMENTS AND CONTINGENCIES: Legal proceedings In the normal course of business, the Company may become involved in legal disputes regarding various litigation matters. In the opinion of management, any potential liabilities resulting from such claims would not have a material effect on the financial statements. Capital expenditure commitments and unconditional purchase obligations contracted for but not yet incurred as of June 30, 2022, totaled $1,087 thousand and primarily consists of purchase commitments in the normal course of business for research & development services, communications infrastructure and administrative services. | 9. COMMITMENTS AND CONTINGENCIES: Legal proceedings In the normal course of business, the Company may become involved in legal disputes regarding various litigation matters. In the opinion of management, any potential liabilities resulting from such claims would not have a material effect on the consolidated financial statements. Capital expenditure commitments contracted for but not yet incurred totaled $1,422 thousand and primarily consists of purchase commitments in the normal course of business for research & development services, communications infrastructure and administrative services. |
STOCKHOLDERS' EQUITY_2
STOCKHOLDERS' EQUITY | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
STOCKHOLDERS' EQUITY | ||
STOCKHOLDERS' EQUITY | 9. STOCKHOLDERS’ EQUITY: Common Stock Voting Rights Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. The Company’s amended and restated certificate of incorporation and the Company’s amended and restated bylaws do not provide for cumulative voting rights. The holders of one-third of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. Dividends The Company has never paid any cash dividends to shareholders and do not anticipate paying any cash dividends to shareholders in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our board of directors and will be dependent upon financial condition, results of operations, capital requirements and such other factors as the board of directors deems relevant. Market Information Quotations on our common stock on the OTC Market Group’s OTCQB ® Common shares issued to vendor for services On May 27, 2022, the Company issued 22,473 shares of common stock as payment for investor relations services. On June 29, 2022, the Company issued 360,000 shares of common stock as payment for a one-year internet advertising contract. Preferred Stock The Company currently has no shares of preferred stock outstanding, and the Company has no present plan to issue any shares of preferred stock. The board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. Common Stock Warrants On February 23, 2021, a total of 985,533 fully vested common stock warrants were issued to a vendor for financial advisory services provided in connection with the sale of the Company’s common stock. The common stock warrants are exercisable at a per share price of $2.00 until they expire on February 23, 2026. During the six months ended June 30, 2022 and 2021, respectively, no warrants issued to vendors for financial advisory services were exercised. The grant date fair value for these warrants of $0.91 per warrant for a total fair value of $896 thousand, was determined using the Black-Scholes options valuation model. The Company recorded the warrants at fair value, as both an increase and decrease in additional paid-in capital during the six months ended June 30, 2021. There were no warrants issued during the three and six months ended June 30, 2022. A summary of the Company’s warrants to purchase common stock activity is as follows: Weighted- Average Weighted- Remaining Average Contractual Number of Exercise Term Shares Price (Years) Warrants outstanding at January 1, 2022 985,533 $ 2.00 4.15 Exercised — — — Forfeited or Expired — — — Granted — — — Warrants outstanding at June 30, 2022 985,533 $ 2.00 3.65 On February 23, 2021, a total of 2,168,000 pre-funded common stock warrants were issued to investors with an exercise price of $0.01 per share for total proceeds to the Company of $4,314 thousand. During the three and six months ended June 30, 2022, no warrants A summary of the Company’s pre-funded warrants to purchase common stock activity is as follows: Weighted- Average Number of Exercise Shares Price Pre-funded warrants outstanding at January 1, 2022 2,168,000 $ 0.01 Exercised — — Forfeited or Expired — — Granted — Pre-funded warrants outstanding at June 30, 2022 2,168,000 $ 0.01 The grant date fair value of common stock warrants is determined using the Black Scholes option-pricing model. There was no public trading market for our shares before February 2022 and the Company estimates its expected stock volatility based on historical volatility of publicly traded peer companies. The Company did not issue any warrants in the six months ended June 30, 2022. | 10. STOCKHOLDERS’ EQUITY: Common Stock Voting Rights Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. The Company’s amended and restated certificate of incorporation and the Company’s amended and restated bylaws do not provide for cumulative voting rights. The holders of one-third of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. Dividends The Company has never paid any cash dividends to shareholders and do not anticipate paying any cash dividends to shareholders in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our board of directors and will be dependent upon financial condition, results of operations, capital requirements and such other factors as the board of directors deems relevant. Market Information Quotations on our common stock on the OTC Market Group’s OTCQB ® Preferred Stock The Company currently has no shares of preferred stock outstanding, and the Company has no present plan to issue any shares of preferred stock. The board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. Common Stock Warrants On February 23, 2021, a total of 985,533 fully vested common stock warrants were issued to a vendor for financial advisory services provided in connection with the sale of the Company’s common stock . The common stock warrants are exercisable at a per share price of $2.00 until they expire on February 23, 2026. During the year ended December 31, 2021, no warrants issued to vendors for financial advisory services were exercised. The grant date fair value for these warrants of $0.91 per warrant for a total fair value of $896 thousand, was determined using the Black-Scholes options valuation model. The Company recorded the warrants at fair value, as both an increase and decrease in additional paid-in capital during the year ended December 31, 2021. A summary of the Company’s warrants to purchase common stock activity is as follows: Weighted- Average Weighted- Remaining Average Contractual Number of Exercise Term Shares Price (Years) Warrants outstanding at January 1, 2021 — $ — — Exercised — — — Forfeited or Expired — — — Granted 985,533 2.00 5.00 Warrants outstanding at December 31, 2021 985,533 $ 2.00 4.15 On February 23, 2021, a total of 2,168,000 pre-funded common stock warrants were issued to investors with an exercise price of $0.01 per share for total proceeds to the Company of $4,314 thousand. During the year ended December 31, 2021, no warrants issued to investors were exercised. The grant date fair value for these warrants of $1.99 is based on the stock price at issuance date of $2.00 less the exercise price of $0.01. The pre-funded common stock warrants have no expiration date and terminate upon exercise. A summary of the Company’s pre-funded warrants to purchase common stock activity is as follows: Weighted- Average Number of Exercise Shares Price Pre-funded warrants outstanding at January 1, 2021 — $ — Exercised — — Forfeited or Expired — — Granted 2,168,000 0.01 Pre-funded warrants outstanding at December 31, 2021 2,168,000 $ 0.01 The grant date fair value of common stock warrants is determined using the Black-Scholes option-pricing model. There was no public trading market for our shares before February 2022 and the Company estimates its expected stock volatility based on historical volatility of publicly traded peer companies. The following assumptions were used during the year ended December 31, 2021: Year Ended December 31, 2021 Expected term (years) 5 years Risk-free interest rate 0.60% Expected volatility 54% Expected dividend yield 0% There were no common stock warrants issued during the year ended December 31, 2020. |
SHARE-BASED COMPENSATION_2
SHARE-BASED COMPENSATION | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SHARE-BASED COMPENSATION | ||
SHARE-BASED COMPENSATION | 10. SHARE-BASED COMPENSATION: Prior to the Exchange discussed in Note 1, SmartKem Limited had stock option plans. SmartKem Limited had issued Enterprise Management Incentive options (“EMI Options”) and non-tax-advantaged options (“Unapproved Options”) to eligible employees, officers, non-employee directors and other individual service providers as a means for them to develop a sense of proprietorship and personal involvement in the development and financial success of SmartKem Limited. The options generally expired the Company at the time of the event. As of December 31, 2020, there were 1,810,749 options outstanding. These options were either exercised or cancelled as a result of the reverse merger and recapitalization. On February 23, 2021, the Company approved the 2021 Equity Incentive Plan (“2021 Plan”), in which a maximum aggregate number of shares of common stock that may be issued under the 2021 Plan is 2,275,000 shares. Subject to the adjustment provisions of the 2021 Plan, the number of shares of the Company’s common stock available for issuance under the 2021 Plan will also include an annual increase on the first day of each fiscal year beginning with 2022 fiscal year and ending on the Company’s 2031 fiscal year in an amount equal to the least of: 1) 2,275,000 shares of the Company’s common stock; 2) four percent (4%) of the outstanding shares of the Company’s common stock on the last day of the immediately preceding fiscal year; or 3) such number of shares of the Company’s common stock as the administrator may determine. As a result of the reverse merger and recapitalization, an aggregate of 402,586 options were issued during February 2021 under the 2021 Plan in consideration for the cancellation of the SmartKem Limited options that were outstanding. Of these options, 336,557 had an exercise price of $0.001 per share and 66,029 had an exercise price of $2.00 per share and all expire on the ten year anniversary of the grant date. These options were fully vested on the grant date. No options were awarded during the three and six months ended June 30, 2022. Determining the appropriate fair value of share-based awards requires the input of subjective assumptions, including the fair value of the Company’s common shares, and for share options, the expected life of the option, and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its share option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involves inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, the share-based compensation expense could be materially different for future awards. In the absence of a public trading market of the common share, on each grant date, the Company develops an estimate of the fair value of the common shares underlying the option grants. The Company estimated the fair value of the common shares by referencing arms-length transactions inclusive of the common shares underlying which occurred on or near the valuation date(s). From February 2022, the Company’s common shares are publicly traded and the Company will no longer have to estimate the fair value of the common share, rather the value will be determined based on quoted market prices. The Company determined the fair value of common share using methodologies, approaches and assumptions consistent with the AICPA Practice Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation and based in part on input from an independent third-party valuation firm. The Company estimates its expected volatility by using a combination of historical share price volatilities of similar companies within our industry. The risk-free interest rate assumption is based on observed interest rates for the appropriate term of the Company’s options on a grant date. The expected option term assumption is the contractual term, as the service period is implied under the practical expedient since the Company does not have sufficient exercise history to estimate expected term of its historical option awards. The following table reflects share activity under the share option plans for six months ended June, 2022: Weighted- Average Weighted- Remaining Weighted- Aggregate Average Contractual Average Intrinsic Number of Exercise Term Fair Value at Value Shares Price (Years) Grant Date (in thousands) Options outstanding at January 1, 2022 1,953,882 $ 1.72323 9.31 $ 1.12355 Exercised — — Cancelled — — Forfeited (16,500) 2.00000 Granted — — Options outstanding at June 30, 2022 1,937,382 $ 1.72087 8.81 $ 1.12553 Options exercisable at June 30, 2022 708,624 $ 1.23685 8.71 $ 541 Vested and expected to vest after June 30, 2022 1,937,382 $ 1.72087 8.81 $ 541 As of June 30, 2022, there were 708,624 exercisable options outstanding. Stock-based compensation, including stock options and warrants is included in the unaudited interim condensed consolidated statements of operations as follows: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 38 $ 24 $ 78 $ 2,931 Selling, general and administrative 59 51 117 3,164 Total $ 97 $ 75 $ 195 $ 6,095 Total compensation cost related to non-vested stock option awards not yet recognized as of June 30, 2022 was $1,122 thousand and will be recognized on a straight-line basis through the end of the vesting periods in September 2025. The amount of future stock option compensation expense could be affected by any future option grants or by any forfeitures. | 11. SHARE-BASED COMPENSATION: Prior to the Exchange discussed in Note 1, SmartKem Limited had stock option plans. SmartKem Limited stock options discussed below have been retroactively restated as options reflecting the exchange ratios established in the Exchange. SmartKem Limited had issued Enterprise Management Incentive options (“EMI Options”) and non-tax-advantaged options ( “Unapproved Options”) to eligible employees, officers, non-employee directors and other individual service providers as a means for them to develop a sense of proprietorship and personal involvement in the development and financial success of SmartKem Limited and to encourage them to devote their best efforts to the business of SmartKem Limited, thereby advancing the interests of SmartKem Limited and its shareholders. Options were issued to certain employees and service providers under the investment agreement dated July 15, 2014, which provided for the grant of up to 175,292 options. On December 14, 2018, the Company entered into a written resolution, which allowed SmartKem Limited to grant up to 458,316 options. SmartKem Limited adopted a new Investment Agreement (the “Agreement”) dated January 24, 2020, SmartKem Limited, by means of the Agreement, seeks to retain the services of such eligible persons and to provide incentives for such persons to exert maximum efforts for the success of SmartKem Limited. The Agreement commenced on the January 24, 2020 and the Agreement is administered by Board of Directors. The maximum aggregate number of shares of common shares which may be issued under all Awards granted to Participants under the Agreement shall be 15% of SmartKem Limited’s issued capital shares. In the event of a termination of continuous service (other than as a result of a change of control, as defined in the Agreement), unvested share options generally shall terminate and, with regard to vested share options, the exercise period shall be the lesser of the original expiration date or six months from the date continuous service terminates. The Company has granted these share option awards to employees and consultants. Outstanding options generally expire 10 years after the grant date. Options are subject to vesting and, grantees become fully vested and exercisable when there is a liquidity event, such as a change in control or sale or admission (listing as a public company or initial public offering (“IPO”)), and the employee, or consultant, must be providing services to the Company at the time of the event. During the year ended December 31, 2020, the Company granted 1,828,128 SmartKem Limited share options to employees and consultants. These options were either exercised or cancelled as a result of the reverse merger and recapitalization. On February 23, 2021, the Company approved the 2021 Equity Incentive Plan (“2021 Plan”), in which a maximum aggregate number of shares of common stock that may be issued under the 2021 Plan is 2,275,000 shares. Subject to the adjustment provisions of the 2021 Plan, the number of shares of the Company’s common stock available for issuance under the 2021 Plan will also include an annual increase on the first day of each fiscal year beginning with 2022 fiscal year and ending on the Company’s 2031 fiscal year in an amount equal to the least of: 1) 2,275,000 shares of the Company’s common stock; 2) four percent (4%) of the outstanding shares of the Company’s common stock on the last day of the immediately preceding fiscal year; or 3) such number of shares of the Company’s common stock as the administrator may determine. As a result of the reverse merger and recapitalization, an aggregate of 402,586 options were issued during February 2021 under the 2021 Plan in consideration for the cancellation of the SmartKem Limited options that were outstanding. Of these options, 336,557 had an exercise price of $0.001 per share and 66,029 had an exercise price of $2.00 per share and all expire on the ten year anniversary of the grant date. These options were fully vested on the grant date. During the year ended December 31, 2021, the Company has issued a further 1,707,326 options for employees, directors and consultants. The options vest over a period of four years, have an exercise price of $2.00 per share and expire on the ten year anniversary of the grant date. Determining the appropriate fair value of share-based awards requires the input of subjective assumptions, including the fair value of the Company’s common shares, and for share options, the expected life of the option, and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its share option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involves inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, the share-based compensation expense could be materially different for future awards. Options granted under the 2021 Plan for year ended December 31, 2021 were valued using the Black-Scholes option-pricing model with the following assumptions: Year Ended December 31, 2021 December 31, 2020 Expected term (years) 5 years – 6 years 0.46 years Risk-free interest rate 0.3% – 1.2% (0.7%) – 0.2% Expected volatility 54% – 58% 58% Expected dividend yield 0% 0% In the absence of a public trading market of the common share, on each grant date, the Company develops an estimate of the fair value of the common shares underlying the option grants. The Company estimated the fair value of the common shares by referencing arms-length transactions inclusive of the common shares underlying which occurred on or near the valuation date(s). From February 2022, the Company’s common shares are publicly traded and the Company will no longer have to estimate the fair value of the common share, rather the value will be determined based on quoted market prices. The Company determined the fair value of common share using methodologies, approaches and assumptions consistent with the AICPA Practice Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation and based in part on input from an independent third-party valuation firm. The Company estimates its expected volatility by using a combination of historical share price volatilities of similar companies within our industry. The risk-free interest rate assumption is based on observed interest rates for the appropriate term of the Company’s options on a grant date. The expected option term assumption is the contractual term, as the service period is implied under the practical expedient since the Company does not have sufficient exercise history to estimate expected term of its historical option awards. The following table reflects share activity under the share option plans for the years ended December 31, 2021 and 2020: Weighted- Average Weighted- Remaining Weighted- Aggregate Average Contractual Average Intrinsic Number of Exercise Term Fair Value at Value Shares Price (Years) Grant Date (in thousands) Options outstanding at January 1, 2020 160,317 1.18311 7.31 8.57245 Exercised — — Cancelled (86,967) 0.65226 Forfeited (90,729) 1.25578 Granted 1,828,128 0.05051 Options outstanding at December 31, 2020 1,810,749 $ 0.06143 9.70 $ 3.46867 $ Exercised (1,424,622) 0.01447 Cancelled (405,936) 0.06452 Forfeited (136,221) 0.00100 Granted 2,109,912 1.68113 Options outstanding at December 31, 2021 1,953,882 $ 1.72323 9.31 $ 1.12355 $ 465 Options exercisable at December 31, 2021 336,556 $ 0.39318 9.15 $ 465 Vested and expected to vest after December 31, 2021 1,953,882 $ 1.72323 9.31 $ 465 The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of our common shares at the end of the year for those options that had exercise prices lower than the fair value of our common shares. The aggregate intrinsic value of options exercised during the years ended December 31, 2021 was $2.4 million. No options were exercised in the year end December 31, 2020. The total fair value of options vesting in the year to December 31, 2021 was $6.6 million. No options vested in the year to December 31, 2020. The weighted-average grant-date fair value per share option granted for the year ended December 31, 2021 and 2020 was $1.14. and $0.04 respectively. Stock-based compensation, including stock options and warrants is included in the consolidated statements of operations as follows: For the Year Ended December 31, 2021 2020 Research and development $ 2,982 $ — Selling, general and administrative 3,214 — Total $ 6,196 $ — As of December 31, 2021 there was $1.3 million of compensation cost related to non-vested stock option awards not yet recognized that will be recognized on a straight-line basis through the end of the vesting periods in September 2025. The amount of future stock option compensation expense could be affected by any future option grants or by any forfeitures. |
SELLING, GENERAL AND ADMINIST_4
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | ||
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | 11. SELLING, GENERAL AND ADMINISTRATIVE EXPENSES: Selling, general and administrative expenses are comprised of the following items: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Salaries and benefits $ 504 $ 507 $ 1,005 $ 4,242 Rent and property tax (benefit)/expense (12) 3 16 16 Insurance 165 172 331 253 Utilities 1 1 2 2 Sales and marketing 247 83 434 105 Legal and professional fees 449 569 738 691 Other selling, general, and administrative expenses 16 10 85 19 Total $ 1,370 $ 1,345 $ 2,611 $ 5,328 | 13. SELLING, GENERAL AND ADMINISTRATIVE EXPENSES: Selling, general and administrative expenses are comprised of the following items: For the Years End December 31, 2021 2020 Salaries and benefits $ 5,366 $ 908 Rent and property tax expense 24 62 Insurance 486 — Utilities 4 1 Sales and marketing 749 96 Legal and professional fees 1,132 625 Other selling, general, and administrative expenses 308 15 Total $ 8,069 $ 1,707 |
DEFINED CONTRIBUTION PENSION_2
DEFINED CONTRIBUTION PENSION | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
DEFINED CONTRIBUTION PENSION | ||
DEFINED CONTRIBUTION PENSION | 12. DEFINED CONTRIBUTION PENSION: The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund. Pension cost is included in the unaudited interim condensed consolidated statements of operations as follows: For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 26 $ 24 $ 53 $ 48 Selling, general and administrative 13 9 27 17 Total pension cost $ 39 $ 33 $ 80 $ 65 As of June 30, 2022 and December 31, 2021 there were no amounts owed to the pension scheme. | 14. DEFINED CONTRIBUTION PENSION: The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund. Pension cost is included in the consolidated statements of operations as follows: For the Years End December 31, 2021 2020 Research and development $ 98 $ 83 Selling, general and administrative 42 31 Total pension cost $ 140 $ 114 As of December 31, 2021 and December 31, 2020 there were no amounts owed to the pension scheme. |
RELATED PARTY TRANSACTIONS_2
RELATED PARTY TRANSACTIONS | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
RELATED PARTY TRANSACTIONS | ||
RELATED PARTY TRANSACTIONS | 13. RELATED PARTY TRANSACTIONS: In addition to transactions and balances related share-based compensation to officers and directors, the Company incurred expenses of $29 thousand and $18 thousand, for the three months ended June 30, 2022 and 2021, respectively, and $47 thousand and $25 thousand, for the six months ended June 30, 2022 and 2021 due to reimbursement of expenses and compensation for members of the Board of Directors. These expenses are recorded in selling, general & administrative in the unaudited interim condensed consolidated statements of operations. As of both June 30, 2022 and December 31, 2021, there was $18 thousand payable to members of the Board of Directors that are recorded in accounts payable and accrued expenses on the unaudited interim condensed consolidated balance sheets. Octopus Share Purchase On January 27, 2022, we sold an aggregate of 1,000,000 shares of our common stock at a purchase price of $2.00 per share to Octopus Titan VCT plc and Octopus Investments Nominees Limited in accordance with the Letter Agreement, dated as of February 23, 2021, between the Company and Octopus Titan VCT plc and certain related parties. | 15. RELATED PARTY TRANSACTIONS: On May 14, 2020, the Company issued a promissory note (the “Note”) to a stockholder of the Company pursuant to which the Company agreed to repay the sum of any and all amounts advanced to the Company, on or before the date that the Company consummated a business combination with a private company or reverse takeover transaction or other transaction after which the Company would cease to be a shell company. The Note was non-interest bearing unless an event of default occurred. As of December 31, 2020, the amount due under the note payable was $20,000 . The maximum amount due under the note payable in the year ended December 31, 2021, was Prior to the closing of the Exchange, we used the office space and equipment of our management at no cost. In addition to transactions and balances related share-based compensation to officers and directors, the Company incurred expenses of $65 thousand and $7 thousand, for the year ended December 31, 2021 and 2020, respectively, due to reimbursement of expenses and compensation for members of the Board of Directors. These expenses are recorded in selling, general & administrative in the consolidated statements of operations. As of December 31, 2021 and December 31, 2020, there was $18 thousand and zero, respectively, payable to members of the Board of Directors that are recorded in accounts payable and accrued expenses on the consolidated balance sheets. During the year ended December 31, 2021, the Company reimbursed an owner for legal fees and other expenses as a result of the Exchange (see Note 1). The reimbursement of these fees for services resulted in an expense of $66 thousand for the year ended December 31, 2021 and there was zero payable as of December 31, 2021. The Company obtained consulting services from an individual who is a family member of a Director of the Company. The consulting services resulted in an expense of $35 thousand for the year ended December 31, 2021 and there was zero payable as of December 31, 2021. |
SUBSEQUENT EVENTS_2
SUBSEQUENT EVENTS | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SUBSEQUENT EVENTS. | ||
SUBSEQUENT EVENTS | 14. SUBSEQUENT EVENTS: During July 2022, the Company issued a further 225,700 EMI options, 150,000 ISO options and 92,300 NQSO options to employees and directors under the 2021 plan. The options vest over a period of four years, expire on the ten | 16. SUBSEQUENT EVENTS: Under the adjustment provisions of the 2021 Plan, on January 1, 2022 the number of shares of the Company’s common stock available for issuance under the 2021 Plan was increased by 1,022,172 or four percent (4%) of the total number of shares of Common Stock outstanding on December 31, 2021. After giving effect to the Evergreen Increase, the total number of shares of Common Stock that may be issued under Plan will be 3,297,172. On January 27, 2022, we sold 1,000,000 shares of our common stock at a purchase price of $2.00 per share to Octopus Investors in accordance with the Octopus Letter Agreement, dated as of February 23, 2021, among the Company and Octopus Titan VCT plc and certain related parties. In February 2022, 12,500 shares of our common stock were issued to a vendor in consideration for services to be provided. Quotations on our common stock on the OTC Market Group’s OTCQB ® |
SUMMARY OF SIGNIFICANT ACCOUN_7
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
Restatement of previously filed financial statements | Restatement of previously issued financial statements The Company has determined that it made an error in the presentation and accounting of its consolidated statement of cash flows in the Company’s annual and interim consolidated financial statements during 2021 and 2022. The management of the company has assessed its accounting policies as well as the presentation and accounting for the gain and loss on foreign currency and has concluded that it was necessary to restate its previously issued financial statements for the correction of this error related to incorrect classification of gain and loss on foreign currency in effect of exchange rate changes on cash instead of including such non-cash unrealized gains and losses in cash flows from operating activities. The effect of this error was to overstate net cash used in operating activities and effect of exchange rate changes on cash by $808 thousand for the year ended December 31, 2021. The errors and the required restatement had no effect on the Company’s cash flows from investing activities, financing activities, net changes in cash or cash and cash equivalents as of December 31, 2021 and had no impact on the Company’s consolidated balance sheet, the Company’s consolidated statements of operations and comprehensive loss and stockholders’ equity as of and for year ended December 31, 2021. The changes are presented below (in thousands): For the year ended December 31, 2021 Net cash used in operating activities as previously reported $ (10,536) Adjustment for Loss/(Gain) on foreign currency transactions 808 Net cash used in operating activities as restated $ (9,728) Effect of exchange rate changes on cash as previously reported $ 135 Adjustment for (Gain)/Loss on foreign currency transactions (808) Effect of exchange rate changes on cash as restated $ (673) | |
Basis of Consolidation | Basis of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of SmartKem, Inc. and its wholly-owned subsidiaries, SmartKem Delaware, Inc. and SmartKem Limited. The Company does not have any nonconsolidated subsidiaries. All intercompany balances and transactions have been eliminated on consolidation, including unrealized gains and losses on transactions between the companies. The Company's formerly wholly-owned subsidiary, SmartKem Delaware Inc. was dissolved on May 13, 2021. | Basis of Consolidation The consolidated financial statements include the accounts of SmartKem, Inc. and its wholly-owned subsidiaries, SmartKem Delaware, Inc. and SmartKem Limited. The Company does not have any nonconsolidated subsidiaries. All intercompany balances and transactions have been eliminated on consolidation, including unrealized gains and losses on transactions between the companies. The Company's formerly wholly-owned subsidiary, SmartKem Delaware Inc. was dissolved on May 13, 2021. |
Comprehensive loss | Comprehensive loss Comprehensive loss of all periods presented is comprised primarily of net loss and foreign currency translation adjustments. | Comprehensive loss Comprehensive loss of all periods presented is comprised primarily of net loss and foreign currency translation adjustments. |
Management's Use of Estimates | Management’s Use of Estimates The preparation of interim condensed consolidated financial statements in conformity U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company’s unaudited interim condensed consolidated financial statements relates to the valuation of common share, fair value of share options, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates. | Management’s Use of Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relates to the valuation of common share, fair value of share options, fair value of embedded conversion features in the convertible notes, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. As of June 30, 2022 and December 31, 2021, the Company did not have any cash equivalents. | Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. As of December 31, 2021 and 2020, the Company did not have any cash equivalents. |
Accounts Receivable | Accounts Receivable Accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of non-collection. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required. There was no allowance for doubtful accounts recorded as of June 30, 2022 and December 31, 2021. | Accounts Receivable Accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. These receivables have historically been paid timely. Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of non-collection. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required. There was no allowance for doubtful accounts recorded as of December 31, 2021 and 2020. |
Impairment of Long-Lived Assets | Impairment of Long-Lived Assets Management continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. If the carrying amount is greater than the undiscounted cash flows, the carrying amount of the asset is reduced to the asset’s fair value. An impairment loss is recognized immediately as an operating expense in the condensed consolidated statements of operations. Reversal of previously recorded impairment losses are prohibited. As of June 30, 2022 and December 31, 2021, Company’s management believed that no revision to the remaining useful lives or impairment of the Company’s long-lived assets was required. | Impairment of Long-Lived Assets Management continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. If the carrying amount is greater than the undiscounted cash flows, the carrying amount of the asset is reduced to the asset’s fair value. An impairment loss is recognized immediately as an operating expense in the consolidated statements of operations. Reversal of previously recorded impairment losses are prohibited. As of December 31, 2021 and 2020, Company’s management believed that no revision to the remaining useful lives or impairment of the Company’s long-lived assets was required. |
Warrants | Warrants The accounting treatment of warrants issued is determined pursuant to the guidance provided by ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging | Warrants The accounting treatment of warrants issued is determined pursuant to the guidance provided by ASC 480, Distinguishing Liabilities from Equity Derivatives and Hedging |
Leases | Leases Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the unaudited condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. The Company has elected not to present short-term leases as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the Company’s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments. | Leases Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease obligation on the consolidated balance sheets as of December 31, 2021 and 2020. The Company has elected not to present short-term leases as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the Company’s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments. |
Revenue | Revenue The Company applies the provisions of ASC 606 Revenue from Contracts with Customers The Company’s current contracts with customers do not contain significant estimates or judgments. All of the Company’s revenue contains a single performance obligation that is recognized upon fulfilment of the sales order. The Company derives its revenues primarily from sales of TRUFLEX ® | Revenue The Company applies the provisions of ASC 606, Revenue from Contracts with Customers The Company’s current contracts with customers do not contain significant estimates or judgments. All of the Company’s revenue contains a single performance obligation that is recognized upon fulfilment of the sales order. The Company derives its revenues primarily from sales of demonstrator units to customers evaluating organic semiconductor technology. The transaction price is stated in each customer agreement and is allocated to a single performance obligation. Revenue is recognized upon shipment of each demonstrator, at a point in time. The Company does not have any significant financing components as payment is received at or shortly after the point of sale. Costs incurred to obtain a contract will be expensed as incurred when the amortization period is less than a year. |
Other Operating Income | Other Operating Income The Company’s other operating income is related to government grant incentives received for qualifying research and development projects, and research and development tax credits related to the United Kingdom’s Research and Development Expenditure Credit scheme, which is a government tax incentive designed to reward innovative companies for investing in research and development. Such incentives are recorded as other income when it is probable the amounts are collectible and can be reasonably estimated. For the three months ended June 30, 2022 and 2021, the Company recorded grant income and research & development tax credits of $294 thousand and $256 thousand, respectively, and $578 thousand and $688 thousand for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, and December 31, 2021, the Company had receivables related to research & development tax credits for payments not yet received of $1,505 thousand and $1,070 thousand, respectively. | Other Operating Income The Company’s other operating income is related to government grant incentives received for qualifying research and development projects, and research and development tax credits related to the United Kingdom’s Research and Development Expenditure Credit scheme, which is a government tax incentive designed to reward innovative companies for investing in research and development. Such incentives are recorded as other income when it is probable the amounts are collectible and can be reasonably estimated. For the year ended December 31, 2021 and 2020, the Company recorded grant income and research & development tax credits of $1,285 thousand and $1,437 thousand, respectively, which are recorded as other operating income in the accompanying consolidated statements of operations. As of December 31, 2021, and December 31, 2020, the Company had receivables related to research & development tax credits for payments not yet received of $1,070 thousand and $982 thousand, respectively. |
Share-based compensation | Share-based compensation All share-based payments, including grants of stock options, are measured based on the fair value of the share-based awards at the grant date and recognized over their respective vesting periods. Outstanding options generally expire 10 years after the grant date. The Company has issued options that vest based on service requirements and options become exercisable when service requirements are met. Due to the Exchange, all options outstanding immediately prior to the event with a performance obligation requirement became vested and exercisable. The estimated fair value of stock options at the grant date is determined using the Black-Scholes pricing model. The Black-Scholes option pricing model requires inputs such as the fair value of common stock on date of grant, expected term, expected volatility, dividend yield, and risk-free interest rate. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The Company records forfeitures when they occur. | Share-based compensation All share-based payments, including grants of stock options, are measured based on the fair value of the share-based awards at the grant date and recognized over their respective vesting periods. Outstanding options generally expire 10 years after the grant date. The Company has issued options that vest based on service requirements and issued options that vest based on performance requirements. Options become exercisable when service requirements are met. In the case of performance based options, options become exercisable when there is a liquidity event, such as a change in control or sale or admission (listing as a public company or initial public offering (“IPO”)), and the employee, or consultant, must be providing services to the Company at the time of the event. Due to the Exchange, all options outstanding immediately prior to the event with a performance obligation requirement became vested and exercisable. Non-cash stock-based compensation expense for the year ended December 31, 2021 was The estimated fair value of stock options at the grant date is determined using the Black-Scholes pricing model. The Black-Scholes option pricing model requires inputs such as the fair value of common stock on date of grant, expected term, expected volatility, dividend yield, and risk-free interest rate. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The Company records forfeitures when they occur. |
Functional Currency and Operations | Functional Currency and Operations Prior to the Exchange, SmartKem Limited’s (“the predecessor’s”) functional currency was the British Pound Sterling (“GBP”), and the consolidated financial statements were presented in United States dollars (“USD”). The predecessor’s functional currency was the respective local currency of the primary economic environment in which an entity’s operations are conducted. The predecessor translated the financial statements into the presentation currency using exchanges rates in effect on the balance sheet date for assets and liabilities and average exchanges rates for the period for statement of operations accounts, with the difference recognized in accumulated other comprehensive income /(loss). From the date of the Exchange forward, the Company’s functional currency is the U.S. dollar (“USD”). The functional currency of the Company’s foreign operation is the respective local currency. Assets and liabilities of foreign operation denominated in local currencies are translated at the spot rate in effect at the applicable reporting date. The condensed consolidated statements of operations and comprehensive loss are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized gain/loss is recognized as foreign currency translation as a component of other comprehensive income. | Functional Currency and Operations Prior to the Exchange, SmartKem Limited’s (“the predecessor’s”) functional currency was the British Pound Sterling (“GBP”), and the consolidated financial statements were presented in United States dollars (“USD”). The predecessor’s functional currency was the respective local currency of the primary economic environment in which an entity’s operations are conducted. The predecessor translated the consolidated financial statements into the presentation currency using exchanges rates in effect on the balance sheet date for assets and liabilities and average exchanges rates for the period for statement of operations accounts, with the difference recognized in accumulated other comprehensive income/ (loss). The Company’s functional currency is the U.S. dollar (“USD”). The functional currency of the Company’s foreign operation is the respective local currency. Assets and liabilities of foreign operations denominated in local currencies are translated at the spot rate in effect at the applicable reporting date. The consolidated statements of operations and comprehensive loss are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized gain/loss is recognized as foreign currency translation as a component of other comprehensive income. |
Foreign Currency Transactions | Foreign Currency Transactions The company measures foreign currency denominated monetary assets and liabilities using exchange rates in effect at the end for the period. Transaction gains and losses are included in net loss. Foreign exchange losses, primarily driven by foreign exchange revaluation of our dollar borrowings held by non-dollar group undertakings, were $1,284 thousand and $1,638 thousand for the three- and six-month periods ended June 30, 2022, respectively. Foreign exchange gains were $57 thousand and foreign exchanges losses were $412 thousand for the three-and six-month periods ended June 30, 2021, respectively. | |
Income Taxes | Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. As of June 30, 2022 and December 31, 2021, there were no accruals for uncertain tax positions. | Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. As of December 31, 2021 and 2020, there were no material uncertain tax positions. |
Contingent Liabilities | Contingent Liabilities A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of June 30, 2022, the Company does not expect that such matters will have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows. | Contingent Liabilities A provision for contingent liabilities is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is a party to certain litigation and disputes arising in the normal course of business. As of December 31, 2021, the Company does not expect that such matters will have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows. |
Offering Costs | Offering Costs Direct and incremental legal and accounting costs associated with the Company’s issuance of common stock and warrants are deferred and classified as a component of other assets on the condensed consolidated balance sheet until completion of the issuance. Upon completion of the issuance, deferred offering costs are reclassified from other assets to equity and recorded against the net proceeds received in the issuance. For the six months ended June 30, 2022 and 2021 respectively, $170 thousand and $2,454 thousand of offering costs were recorded in additional paid-in capital. No offering costs were deferred as of both June 30, 2022 and December 31, 2021. | Offering Costs Direct and incremental legal and accounting costs associated with the Company’s issuance of common stock and warrants are deferred and classified as a component of other assets on the consolidated balance sheet until completion of the issuance. Upon completion of the issuance, deferred offering costs are reclassified from other assets to equity in additional paid-in capital and recorded against the net proceeds received in the issuance. The deferred offering costs incurred as of December 31, 2020 were immaterial and no offering costs were capitalized. For the year ended December 31, 2021 $2,454 thousand of offering costs were recorded in additional paid-in capital. For the year ended December 31, 2021, $1.329 million of direct and incremental costs associated with the Exchange were recorded as Transaction Expenses in the Consolidated Statement of Operations and Comprehensive Loss. |
Segment Information | Segment Information The Company has determined that it operates and reports in one segment | Segment Information The Company has determined that it operates and reports in one segment |
Basic and Diluted Loss Per Share | Basic and Diluted Loss Per Share Basic and diluted net loss per share is determined by dividing net loss by the weighted average ordinary shares outstanding during the period. For all periods presented with a net loss, the shares underlying the ordinary share options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per share are the same for periods with a net loss. The loss per share information in these unaudited interim condensed consolidated financial statements is reflected and calculated as if the Company had existed since January 1, 2020. Accordingly, loss per share for all periods was calculated based on the number of shares retroactively adjusted for the exchange ratio determined in the reverse recapitalization (see also note 1). The Company has 2,168,000 pre-funded common stock warrants outstanding as of June 30, 2022, which became exercisable on April 24, 2021 based on terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $0.01, these shares are considered outstanding common shares and included in computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions were met on April 24, 2021. The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: June 30, 2022 2021 Options 1,937,382 1,596,562 Warrants 985,533 985,533 Total 2,922,915 2,582,095 | Basic and Diluted Loss Per Share Basic and diluted net loss per share is determined by dividing net loss by the weighted average ordinary shares outstanding during the period. For all periods presented with a net loss, the shares underlying the ordinary share options and warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per share are the same for periods with a net loss. The loss per share information in these consolidated financial statements is reflected and calculated as if the Company had existed since January 1, 2020. Accordingly, loss per share for all periods was calculated based on the number of shares retroactively adjusted for the exchange ratio determined in the reverse recapitalization (see also note 1). The Company has 2,168,000 pre-funded common stock warrants outstanding as of December 31, 2021, which became exercisable on April 23, 2021 based on terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $0.01, these shares are considered outstanding common shares and included in computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions were met on April 23, 2021. The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: December 31, 2021 2020 Options 1,953,882 1,810,749 Warrants 985,533 — Total 2,939,415 1,810,749 |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Adopted In May 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2021-04, Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity Classified Written Call Options In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) Recent Accounting Pronouncements Not Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments: Credit Losses (Topic 326) | Recent Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments: Credit Losses (Topic 326) annual and interim periods beginning after December 15, 2022. Management is currently evaluating the impact of these changes on the consolidated financial statements. In May 2021, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40). The amendments in this update affect all entities that issue freestanding written call options (for example warrants) that are classified in equity. Specifically, the amendments affect those entities when a freestanding equity-classified written call option is modified or exchanged and remains equity classified after the modification or exchange. The amendments that relate to the recognition and measurement of EPS for certain modifications or exchanges of freestanding equity-classified written call options affect entities that present EPS in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Management is currently evaluating the impact of this guidance but does not expect this update to have a material impact on the Company's consolidated financial statements. In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance. The amendments in this update affect all business entities that account for a transaction with a government by applying a grant or contribution accounting model by analogy to other accounting guidance. The amendments in this Update require annual disclosures about: (1) Information about the nature of the transactions and the related accounting policy used to account for the transactions; (2) The line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item; and (3) Significant terms and conditions of the transactions, including commitments and contingencies. The amendments in this update are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. Management is currently evaluating the impact of this guidance but does not expect this update to have a material impact on the Company's consolidated financial statements. |
Reclassifications | Reclassifications Certain amounts in prior periods' interim condensed consolidated financial statements have been reclassified to conform to the current period’s presentation. | Reclassifications Certain amounts in prior years' consolidated financial statements have been recast and reclassified to conform to the current year's presentation |
Basis for Preparation | Basis for Presentation These consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and accounting principles generally accepted in the United States of America ( “US GAAP”) as defined by the Financial Accounting Standards Board (FASB) within the FASB Accounting Standards Codification (“ASC”) and are presented in thousands, except number of shares and per share data . | |
Going Concern | Going Concern The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities, and commitments in the ordinary course of business. Since inception, we have incurred recurring losses including net losses of $17.1 million and $23.1 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $75.1 million. We anticipate operating losses to continue for the foreseeable future due to, among other things, costs related to research funding, further development of our technology and products and expenses related to the commercialization of our products. We expect that our cash and cash equivalents of $12.2 million as of December 31, 2021 will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the issuance date of these consolidated financial statements through the first quarter of 2023. It is possible this period could be shortened if there are any significant increases in planned spending or development programs or more rapid progress of development programs than anticipated. Our future viability is dependent on our ability to raise additional capital to fund our operations. In the long-term, we will need to obtain additional funds to satisfy our operational needs and to fund our sales and marketing efforts, research and development expenditures, and business development activities. Until such time, if ever, as we can generate sufficient cash through revenue, we expect to finance our working capital requirements through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. There can be no assurance however that such financing will be available in sufficient amounts, when and if needed, on acceptable terms or at all. The precise amount and timing of the funding needs cannot be determined accurately at this time, and will depend on a number of factors, including the market demand for the Company’s products and services, the quality of product development efforts, management of working capital, and continuation of normal payment terms and conditions for purchase of services. If the Company is unable to substantially increase revenues, reduce expenditures, or otherwise generate cash flows for operations, then the Company will need to raise additional funding to continue as a going concern. | |
Certain Risk and Uncertainties | Certain Risk and Uncertainties The Company’s activities are subject to significant risks and uncertainties including the risk of failure to secure additional funding to properly execute the Company’s business plan. The Company is subject to risks that are common to companies in the growth stage, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, reliance on third party manufacturers, protection of proprietary technology, and compliance with regulatory requirements. See Item 1a of this Form 10-K/A for a fuller discussion of the Company’s risk factors. The Company has access under a framework agreement to equipment which is used in the manufacturing of demonstrator products employing the Company’s inks. If the Company lost access to this fabrication facility, it would materially and adversely affect the Company’s ability to manufacture prototypes and demonstration products for potential customers. The loss of this access could significantly impede the Company’s ability to engage in product development and process improvement activities. Alternative providers of similar services exist, but would take effort and time to bring into the Company’s operations. | |
Concentrations of Credit Risk | Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. Periodically, the Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses in these deposits. | |
Property, Plant and Equipment | Property, Plant and Equipment Property, plant and equipment is stated at cost, less accumulated depreciation. Maintenance and repairs are expensed when incurred. Additions and improvements that extend the economic useful life of the asset are capitalized and depreciated over the remaining useful lives of the assets. The cost and accumulated depreciation of assets sold or retired are removed from the respective accounts, and any resulting gain or loss is reflected in current earnings. Depreciation and amortization are provided using the accelerated declining balance method in amounts considered to be sufficient to amortize the cost of the assets to operations over their estimated useful lives. Property, plant and equipment is depreciated at 25 percent of net book value on an annual basis, resulting in an estimated useful life of approximately 15 years. | |
Derivative Asset for Embedded Conversion Features | Derivative Asset for Embedded Conversion Features The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates convertible notes to determine if those contracts or embedded components of those contracts qualify as derivatives to be accounted for separately. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The result of this accounting treatment is that the fair value of the embedded derivative is recorded as a liability and marked-to-market each balance sheet date, with the change in fair value recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. The fair value of the embedded conversion features are estimated using a Monte Carlo simulation model, in which possible outcomes and their values are simulated repeatedly and randomly. Under the Monte Carlo method the Company estimated the fair value of the convertible notes conversion feature at the time of issuance and subsequent remeasurement dates, utilizing the with-and without method, where the value of the derivative feature is the difference in values between a note simulated with the embedded conversion feature and the value of the same note simulated without the embedded conversion feature. Estimating fair values of embedded conversion features requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. | |
Fair Value of Financial Instruments | Fair Value of Financial Instruments ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended December 31, 2021 and 2020. The carrying value of the Company’s cash, accounts receivable, other receivables, prepaid expenses and other current assets, accounts payable and accrued expenses approximate fair value because of the short-term maturity of these financial instruments. The carrying value of derivative asset is displayed at fair value. See Note 8 for additional information regarding fair value measurements. | |
Convertible Notes | Convertible Notes The Company accounts for its convertible notes in accordance with ASC 470-20, Debt with Conversion and Other Options Debt discount created by the bifurcation of embedded feature in the convertible notes are reflected as a reduction to the related debt liability. The discount is amortized to interest expense over the term of the debt using the effective-interest method. | |
Research and Development Expenses | Research and Development Expenses The Company expenses research and development costs as incurred. Research and development costs include salaries, employee benefit costs, direct project costs, supplies and other related costs. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. | |
Patent and Licensing Costs | Patent and Licensing Costs Patent and licensing costs are expensed as incurred because their realization is uncertain. These costs are classified as research and development expenses in the accompanying consolidated statements of operations and comprehensive loss. | |
Ordinary Shares Valuation | Ordinary Shares Valuation Due to the absence of an active market for the Company’s ordinary shares, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its ordinary shares. In determining the exercise prices for options to be issued, the estimated fair value of the Company’s ordinary shares on each grant date was estimated based upon a variety of factors, including: ● the issuance prices of ordinary shares; ● the rights and preferences of preferred shareholders; ● the progress of the Company’s research and development programs; ● the Company’s stage of development and business strategy; ● external market conditions affecting the technology industry and trends within the technology industry; ● the Company’s financial position, including cash on hand; ● the Company’s historical and forecasted performance and operating results; ● the lack of active public market for the Company’s ordinary shares; ● the likelihood of achieving a liquidity event, such as a securities offering, initial public offering or a sale of the Company’s shares. Significant changes to the key assumptions underlying the factors used could result in different fair values of ordinary shares at each valuation date. Ordinary shares are classified in shareholders’ equity and represent issued share capital. |
Business and Liquidity (Table_2
Business and Liquidity (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
BUSINESS AND BASIS OF PREPARATION | ||
Restatement Of Previously Filed Financial Statements | For the Six Months Ended June 30, 2021 Net cash used in operating activities as previously reported $ (6,441) Adjustment for (Loss)/Gain on foreign currency transactions 412 Net cash used in operating activities as restated $ (6,029) Effect of exchange rate changes on cash as previously reported $ 25 Adjustment for (Gain)/Loss on foreign currency transactions (412) Effect of exchange rate changes on cash as restated $ (387) | For the year ended December 31, 2021 Net cash used in operating activities as previously reported $ (10,536) Adjustment for Loss/(Gain) on foreign currency transactions 808 Net cash used in operating activities as restated $ (9,728) Effect of exchange rate changes on cash as previously reported $ 135 Adjustment for (Gain)/Loss on foreign currency transactions (808) Effect of exchange rate changes on cash as restated $ (673) |
SUMMARY OF SIGNIFICANT ACCOUN_8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||
Schedule of Antidilutive Securities | June 30, 2022 2021 Options 1,937,382 1,596,562 Warrants 985,533 985,533 Total 2,922,915 2,582,095 | December 31, 2021 2020 Options 1,953,882 1,810,749 Warrants 985,533 — Total 2,939,415 1,810,749 |
PREPAID EXPENSES AND OTHER CU_5
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
PREPAID EXPENSES AND OTHER CURRENT ASSETS | ||
Schedule of Prepaid Expenses and Other Current Assets | June 30, December 31, 2022 2021 Prepaid service charges and property taxes $ 83 $ 58 Prepaid utilities 31 51 Prepaid insurance 633 412 Prepaid administrative expenses 55 63 Prepaid technical fees 212 141 Prepaid consulting fees 629 27 VAT receivable 141 50 Other Receivable and other prepaid expenses 31 — Total prepaid expenses and other current assets $ 1,815 $ 802 | December 31, 2021 2020 Prepaid rent $ 58 $ 65 Prepaid utilities 51 30 Prepaid insurance 412 41 Prepaid administrative expenses 63 61 Prepaid technical fees 141 8 Prepaid consulting fees 27 — VAT receivable 50 54 Total prepaid expenses and other current assets $ 802 $ 259 |
PROPERTY, PLANT AND EQUIPMENT_4
PROPERTY, PLANT AND EQUIPMENT (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
PROPERTY, PLANT AND EQUIPMENT | ||
Schedule of Property, Plant and Equipment | June 30, December 31, 2022 2021 Plant and equipment $ 1,523 $ 1,633 Furniture and fixtures 220 245 Computer hardware and software 24 26 1,767 1,904 Less: Accumulated depreciation (1,090) (1,102) Property, plant and equipment, net $ 677 $ 802 | December 31, 2021 2020 Plant and equipment $ 1,633 $ 1,316 Furniture and fixtures 245 248 Computer hardware and software 26 26 1,904 1,590 Less: Accumulated depreciation (1,102) (908) Property, plant and equipment, net $ 802 $ 682 |
ACCOUNTS PAYABLE AND ACCRUED _5
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | ||
Schedule of Accounts Payable and Accrued Expenses | June 30, December 31, 2022 2021 Accounts payable $ 457 $ 510 Accrued expenses – lab refurbishments 118 131 Accrued expenses – technical fees 58 66 Accrued expenses – variable rent & utilities 9 20 Accrued expenses – audit & accounting fees 167 191 Accrued expenses – other 67 112 Credit card liabilities 34 10 Payroll and social security liabilities 280 383 Total accounts payable and accrued expenses $ 1,190 $ 1,423 | December 31, 2021 2020 Accounts payable $ 510 $ 227 Accrued expenses – lab refurbishments 131 132 Accrued expenses – technical fees 66 45 Accrued expenses – variable rent & utilities 20 67 Accrued expenses – audit & accounting fees 191 250 Accrued expenses – other 112 6 Credit card liabilities 10 6 Payroll and social security liabilities 383 128 Total accounts payable and accrued expenses $ 1,423 $ 861 |
LEASES (Tables)_2
LEASES (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
LEASES | ||
Schedule of Lease Costs | For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Operating lease cost $ 68 $ 52 $ 131 $ 99 Short-term lease cost 2 13 4 26 Variable lease cost 41 64 95 98 Total lease cost $ 111 $ 129 $ 230 $ 223 For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 105 $ 120 $ 218 $ 207 Selling, general and administrative 6 9 12 16 Total lease cost $ 111 $ 129 $ 230 $ 223 | For the Year Ended December 31, 2021 2020 Operating lease cost $ 225 $ 175 Short-term lease cost 32 48 Variable lease cost 140 401 Total lease cost $ 397 $ 624 For the Year Ended December 31, 2021 2020 Research and development $ 373 $ 562 Selling, general and administrative 24 62 Total lease cost $ 397 $ 624 |
Schedule of Operating Lease Assets And Liabilities | June 30, December 31, 2022 2021 Assets Operating lease right of use assets $ 549 $ 154 Total lease assets $ 549 $ 154 Liabilities Current liabilities: Operating lease liability – current portion $ 208 $ 87 Noncurrent liabilities: Operating lease liability, net of current portion 320 28 Total lease liabilities $ 528 $ 115 | December 31, 2021 2020 Assets Operating lease right of use assets $ 154 $ 236 Total lease assets $ 154 $ 236 Liabilities Current liabilities: Operating lease liability – current portion $ 87 $ 217 Noncurrent liabilities: Operating lease liability, net of current portion 28 20 Total lease liabilities $ 115 $ 237 |
Schedule of Operating Lease Cash Flow Information | For the Six Months Ended June 30, 2022 2021 Operating cash outflows from operating leases $ 115 $ 120 Supplemental non-cash amounts of operating lease liabilities arising from obtaining right of use assets $ 539 $ 86 | For the Year Ended December 31, 2021 2020 Operating cash outflows from operating leases $ 276 $ 157 Supplemental non-cash amounts of operating lease liabilities arising from obtaining right of use assets $ 136 $ — |
Schedule of Weighted Average Remaining Lease Term and Weighted Average Discount Rate | For the Six Months Ended June 30, 2022 2021 Weighted average remaining lease term (in years) – operating leases 2.66 1.10 Weighted average discount rate – operating leases 7.64 % 6.12 % | For the Year Ended December 31, 2021 2020 Weighted average remaining lease term (in years) – operating leases 1.40 1.35 Weighted average discount rate – operating leases 6.07 % 6.30 % |
Schedule of Operating Lease, Liability, Maturity | As of June 30, 2022 2022 $ 137 2023 220 2024 219 2025 9 2026 — Thereafter — Total undiscounted lease payments 585 Less imputed interest (57) Total net lease liabilities $ 528 | As of December 31, 2021 2022 $ 93 2023 22 2024 7 2025 — 2026 — Thereafter — Total undiscounted lease payments 122 Less future minimum short-term lease payments (3) Less imputed interest (4) Total net lease liabilities $ 115 |
STOCKHOLDERS' EQUITY (Tables)_2
STOCKHOLDERS' EQUITY (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Common Stock Warrants | ||
Schedule of Warrants | Weighted- Average Weighted- Remaining Average Contractual Number of Exercise Term Shares Price (Years) Warrants outstanding at January 1, 2022 985,533 $ 2.00 4.15 Exercised — — — Forfeited or Expired — — — Granted — — — Warrants outstanding at June 30, 2022 985,533 $ 2.00 3.65 | Weighted- Average Weighted- Remaining Average Contractual Number of Exercise Term Shares Price (Years) Warrants outstanding at January 1, 2021 — $ — — Exercised — — — Forfeited or Expired — — — Granted 985,533 2.00 5.00 Warrants outstanding at December 31, 2021 985,533 $ 2.00 4.15 |
Schedule of Fair Value of Common Stock Warrants Assumptions | Year Ended December 31, 2021 Expected term (years) 5 years Risk-free interest rate 0.60% Expected volatility 54% Expected dividend yield 0% | |
Pre Funded Warrants | ||
Schedule of Warrants | Weighted- Average Number of Exercise Shares Price Pre-funded warrants outstanding at January 1, 2022 2,168,000 $ 0.01 Exercised — — Forfeited or Expired — — Granted — Pre-funded warrants outstanding at June 30, 2022 2,168,000 $ 0.01 | Weighted- Average Number of Exercise Shares Price Pre-funded warrants outstanding at January 1, 2021 — $ — Exercised — — Forfeited or Expired — — Granted 2,168,000 0.01 Pre-funded warrants outstanding at December 31, 2021 2,168,000 $ 0.01 |
SHARE-BASED COMPENSATION (Tab_2
SHARE-BASED COMPENSATION (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SHARE-BASED COMPENSATION | ||
Schedule of Black Scholes option-pricing model with assumptions used | Year Ended December 31, 2021 December 31, 2020 Expected term (years) 5 years – 6 years 0.46 years Risk-free interest rate 0.3% – 1.2% (0.7%) – 0.2% Expected volatility 54% – 58% 58% Expected dividend yield 0% 0% | |
Summary of non-vested share option activity under the share option plans | Weighted- Average Weighted- Remaining Weighted- Aggregate Average Contractual Average Intrinsic Number of Exercise Term Fair Value at Value Shares Price (Years) Grant Date (in thousands) Options outstanding at January 1, 2022 1,953,882 $ 1.72323 9.31 $ 1.12355 Exercised — — Cancelled — — Forfeited (16,500) 2.00000 Granted — — Options outstanding at June 30, 2022 1,937,382 $ 1.72087 8.81 $ 1.12553 Options exercisable at June 30, 2022 708,624 $ 1.23685 8.71 $ 541 Vested and expected to vest after June 30, 2022 1,937,382 $ 1.72087 8.81 $ 541 | Weighted- Average Weighted- Remaining Weighted- Aggregate Average Contractual Average Intrinsic Number of Exercise Term Fair Value at Value Shares Price (Years) Grant Date (in thousands) Options outstanding at January 1, 2020 160,317 1.18311 7.31 8.57245 Exercised — — Cancelled (86,967) 0.65226 Forfeited (90,729) 1.25578 Granted 1,828,128 0.05051 Options outstanding at December 31, 2020 1,810,749 $ 0.06143 9.70 $ 3.46867 $ Exercised (1,424,622) 0.01447 Cancelled (405,936) 0.06452 Forfeited (136,221) 0.00100 Granted 2,109,912 1.68113 Options outstanding at December 31, 2021 1,953,882 $ 1.72323 9.31 $ 1.12355 $ 465 Options exercisable at December 31, 2021 336,556 $ 0.39318 9.15 $ 465 Vested and expected to vest after December 31, 2021 1,953,882 $ 1.72323 9.31 $ 465 |
Schedule of stock-based compensation | For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 38 $ 24 $ 78 $ 2,931 Selling, general and administrative 59 51 117 3,164 Total $ 97 $ 75 $ 195 $ 6,095 | For the Year Ended December 31, 2021 2020 Research and development $ 2,982 $ — Selling, general and administrative 3,214 — Total $ 6,196 $ — |
SELLING, GENERAL AND ADMINIST_5
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | ||
Schedule of Selling, general and administrative expenses | For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Salaries and benefits $ 504 $ 507 $ 1,005 $ 4,242 Rent and property tax (benefit)/expense (12) 3 16 16 Insurance 165 172 331 253 Utilities 1 1 2 2 Sales and marketing 247 83 434 105 Legal and professional fees 449 569 738 691 Other selling, general, and administrative expenses 16 10 85 19 Total $ 1,370 $ 1,345 $ 2,611 $ 5,328 | For the Years End December 31, 2021 2020 Salaries and benefits $ 5,366 $ 908 Rent and property tax expense 24 62 Insurance 486 — Utilities 4 1 Sales and marketing 749 96 Legal and professional fees 1,132 625 Other selling, general, and administrative expenses 308 15 Total $ 8,069 $ 1,707 |
DEFINED CONTRIBUTION PENSION _2
DEFINED CONTRIBUTION PENSION (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
DEFINED CONTRIBUTION PENSION | ||
Schedule of pension cost | For the Three Months Ended June 30, For the Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 26 $ 24 $ 53 $ 48 Selling, general and administrative 13 9 27 17 Total pension cost $ 39 $ 33 $ 80 $ 65 | For the Years End December 31, 2021 2020 Research and development $ 98 $ 83 Selling, general and administrative 42 31 Total pension cost $ 140 $ 114 |
BUSINESS AND BASIS OF PREPARA_3
BUSINESS AND BASIS OF PREPARATION - Going Concern and Reverse Recapitalization (Details) $ / shares in Units, $ in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||
Feb. 23, 2021 $ / shares shares | Jun. 30, 2022 USD ($) patent $ / shares | Jun. 30, 2022 USN ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 USN ($) | Mar. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) patent $ / shares | Jun. 30, 2022 USN ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 USN ($) | Dec. 31, 2021 USD ($) patent $ / shares | Dec. 31, 2021 USN ($) | Dec. 31, 2020 USD ($) $ / shares | |
Net cash used in operating activities | $ (5,651) | $ (6,029) | $ (4,082) | |||||||||||
(Loss)/Gain on foreign currency transactions | $ (1,284) | $ (1,284) | $ 57 | $ (57) | (1,638) | $ (1,638) | (412) | $ (412) | $ (808) | |||||
Effect of exchange rate changes on cash | (590) | (387) | (40) | |||||||||||
Gain (loss) on foreign currency transactions | 1,284 | $ 1,284 | (57) | $ 57 | 1,638 | $ 1,638 | 412 | 412 | 808 | |||||
Net loss | 3,701 | $ 2,762 | $ 2,401 | $ 9,366 | 6,463 | $ 11,767 | 17,126 | 23,133 | ||||||
Accumulated deficit | 81,535 | 81,535 | 75,072 | 57,946 | ||||||||||
Cash and cash equivalents | $ 7,757 | $ 7,757 | $ 12,226 | $ 764 | ||||||||||
Common shares, par value | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||||
Number of issued patents | patent | 120 | 120 | 120 | |||||||||||
As restated | ||||||||||||||
Net cash used in operating activities | (6,029) | $ (9,728) | $ (9,728) | |||||||||||
(Loss)/Gain on foreign currency transactions | 412 | (808) | ||||||||||||
Effect of exchange rate changes on cash | (387) | $ (673) | (673) | |||||||||||
Gain (loss) on foreign currency transactions | (412) | 808 | ||||||||||||
Previously Reported [Member] | ||||||||||||||
Net cash used in operating activities | (6,441) | (10,536) | ||||||||||||
Effect of exchange rate changes on cash | $ 25 | $ 135 | ||||||||||||
Securities Exchange Agreement, Smartkem Limited | ||||||||||||||
Purchase price (in dollars per share) | $ / shares | $ 1.40 | |||||||||||||
Common shares, par value | $ / shares | $ 0.0001 | |||||||||||||
Share exchange ratio | 0.0676668 | |||||||||||||
Securities Exchange Agreement, Smartkem Limited | Common stock A Shares | ||||||||||||||
Share exchange ratio | 0.0111907 | |||||||||||||
Share exchange, number of shares issued or issuable | shares | 12,725,000 | |||||||||||||
Shares exchange, number of shares exchanged | shares | 1,127,720,477 | |||||||||||||
Management incentive options to purchase | shares | 124,497,910 | |||||||||||||
Average share exchange ratio | 0.011283825 | |||||||||||||
Effect of reverse capitalization (in shares) | shares | 2,500,000 |
SUMMARY OF SIGNIFICANT ACCOUN_9
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||
Jun. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2022 USN ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2021 USN ($) | Mar. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) segment $ / shares shares | Jun. 30, 2022 USN ($) segment | Jun. 30, 2021 USD ($) | Jun. 30, 2021 USN ($) | Dec. 31, 2021 USD ($) segment $ / shares shares | Dec. 31, 2020 USD ($) | Feb. 23, 2021 $ / shares | |
Class of Warrant or Right [Line Items] | |||||||||||||
Cash equivalents | $ 0 | $ 0 | $ 0 | $ 0 | |||||||||
Allowance for doubtful accounts | 0 | 0 | $ 0 | 0 | |||||||||
Percentage of depreciated of net book value | 25% | ||||||||||||
Estimated useful life | 15 years | ||||||||||||
Other operating income | 294 | $ 256 | 578 | $ 688 | $ 1,285 | 1,437 | |||||||
Uncertain tax positions | 0 | 0 | 0 | ||||||||||
Research & development tax credits | 1,505 | $ 1,505 | $ 1,070 | 982 | |||||||||
Expiration term | 10 years | 10 years | 10 years | ||||||||||
Deferred offering costs | 0 | $ 0 | $ 0 | $ 0 | |||||||||
Number of operating segments | segment | 1 | 1 | 1 | ||||||||||
Gain (loss) on foreign currency transactions | 1,284 | $ 1,284 | $ (57) | $ 57 | $ 1,638 | $ 1,638 | 412 | $ 412 | $ 808 | ||||
Number of reportable segments | segment | 1 | 1 | 1 | ||||||||||
Offering costs recorded in additional paid-in capital | $ 10 | $ 160 | $ 2,454 | $ 170 | $ 2,454 | $ 2,454 | |||||||
Pre Funded Warrants | |||||||||||||
Class of Warrant or Right [Line Items] | |||||||||||||
Common stock warrants outstanding | shares | 2,168,000 | 2,168,000 | 2,168,000 | ||||||||||
Warrants exercisable price | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 |
SUMMARY OF SIGNIFICANT ACCOU_10
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Dilutive Securities (Details) - shares | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of earnings per share | 2,922,915 | 2,582,095 | 2,939,415 | 1,810,749 |
Options | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of earnings per share | 1,937,382 | 1,596,562 | 1,953,882 | 1,810,749 |
Warrants | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of earnings per share | 985,533 | 985,533 | 985,533 |
PREPAID EXPENSES AND OTHER CU_6
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
PREPAID EXPENSES AND OTHER CURRENT ASSETS | |||
Prepaid service charges and property taxes | $ 83 | $ 58 | |
Prepaid rent | 58 | $ 65 | |
Prepaid utilities | 31 | 51 | 30 |
Prepaid insurance | 633 | 412 | 41 |
Prepaid administrative expenses | 55 | 63 | 61 |
Prepaid technical fees | 212 | 141 | 8 |
Prepaid consulting fees | 629 | 27 | |
VAT receivable | 141 | 50 | 54 |
Other Receivable and other prepaid expenses | 31 | ||
Total prepaid expenses and other current assets | 1,815 | 802 | 259 |
Prepaid Insurance Noncurrent | $ 191 | $ 217 | $ 0 |
PROPERTY, PLANT AND EQUIPMENT_5
PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Line Items] | ||||||
Property, plant and equipment, Gross | $ 1,767 | $ 1,767 | $ 1,904 | $ 1,590 | ||
Less: Accumulated depreciation | (1,090) | (1,090) | (1,102) | (908) | ||
Property, plant and equipment, net | 677 | 677 | 802 | 682 | ||
Depreciation | 105 | $ 95 | 197 | |||
Plant and equipment | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Property, plant and equipment, Gross | 1,523 | 1,523 | 1,633 | 1,316 | ||
Furniture and fixtures | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Property, plant and equipment, Gross | 220 | 220 | 245 | 248 | ||
Computer hardware and software | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Property, plant and equipment, Gross | 24 | 24 | 26 | 26 | ||
Research and development | ||||||
Property, Plant and Equipment [Line Items] | ||||||
Depreciation | $ 51 | $ 47 | $ 105 | $ 95 | $ 209 | $ 197 |
ACCOUNTS PAYABLE AND ACCRUED _6
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
ACCOUNTS PAYABLE AND ACCRUED EXPENSES | |||
Accounts payable | $ 457 | $ 510 | $ 227 |
Accrued expenses - lab refurbishments | 118 | 131 | 132 |
Accrued expenses - technical fees | 58 | 66 | 45 |
Accrued expenses - variable rent & utilities | 9 | 20 | 67 |
Accrued expenses - audit & accounting fees | 167 | 191 | 250 |
Accrued expenses - other | 67 | 112 | 6 |
Credit card liabilities | 34 | 10 | 6 |
Payroll and social security liabilities | 280 | 383 | 128 |
Total accounts payable and accrued expenses | $ 1,190 | $ 1,423 | $ 861 |
LEASES - Lease Costs (Details_2
LEASES - Lease Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Operating lease cost | $ 68 | $ 52 | $ 131 | $ 99 | $ 225 | $ 175 |
Short-term lease cost | 2 | 13 | 4 | 26 | 32 | 48 |
Variable lease cost | 41 | 64 | 95 | 98 | 140 | 401 |
Total lease cost | 111 | 129 | 230 | 223 | 397 | 624 |
Research and development | ||||||
Total lease cost | 105 | 120 | 218 | 207 | 373 | 562 |
Selling, general and administrative | ||||||
Total lease cost | $ 6 | $ 9 | $ 12 | $ 16 | $ 24 | $ 62 |
LEASES - Lease Assets And Lia_2
LEASES - Lease Assets And Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Assets | |||
Operating lease right of use assets | $ 549 | $ 154 | $ 236 |
Total lease assets | 549 | 154 | 236 |
Current liabilities: | |||
Operating lease liability - current portion | 208 | 87 | 217 |
Noncurrent liabilities: | |||
Operating lease liability, net of current portion | 320 | 28 | 20 |
Total lease liabilities | $ 528 | $ 115 | $ 237 |
LEASES - Operating And Financ_2
LEASES - Operating And Finance Leases (Details) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
LEASES | ||||
Operating cash flows from operating leases | $ 115 | $ 120 | $ 276 | $ 157 |
Supplemental non-cash amounts of operating lease liabilities arising from obtaining right of use assets | $ 539 | $ 86 | $ 136 |
LEASES - Weighted Average (De_2
LEASES - Weighted Average (Details) | Jun. 30, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2020 |
LEASES | ||||
Weighted average remaining lease term (in years) - operating leases | 2 years 7 months 28 days | 1 year 4 months 24 days | 1 year 1 month 6 days | 1 year 4 months 6 days |
Weighted average discount rate - operating leases | 7.64% | 6.07% | 6.12% | 6.30% |
LEASES - Undiscounted Operati_2
LEASES - Undiscounted Operating Lease Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Lessee, Operating Lease, Liability, Payment, Due [Abstract] | |||
2022 | $ 137 | ||
2023 | 220 | $ 93 | |
2024 | 219 | 22 | |
2025 | 9 | 7 | |
Total undiscounted lease payments | 585 | 122 | |
Less future minimum short-term lease payments | (3) | ||
Less imputed interest | (57) | (4) | |
Total net lease liabilities | $ 528 | $ 115 | $ 237 |
LEASES - Additional Informati_2
LEASES - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Sublease rental income | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 |
Finance lease, right-of-use assets | 0 | 0 | 0 | |||
Finance lease, liabilities | $ 0 | $ 0 | $ 0 | |||
Minimum | ||||||
Operating leases terms | 1 year | 1 year | 1 year | |||
Maximum | ||||||
Operating leases terms | 3 years | 3 years | 3 years |
NOTES PAYABLE - Additional Info
NOTES PAYABLE - Additional Information (Details) $ / shares in Units, $ in Thousands | 6 Months Ended | 12 Months Ended | |||||||||||
Jan. 26, 2021 USD ($) | Jan. 24, 2020 USD ($) $ / shares shares | Sep. 23, 2019 tranche | Jun. 26, 2019 USD ($) tranche $ / shares | Dec. 28, 2018 tranche | Jul. 20, 2018 USD ($) tranche $ / shares | Apr. 18, 2018 USD ($) tranche $ / shares | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2021 USN ($) | Dec. 31, 2020 USN ($) | |
Debt Instrument [Line Items] | |||||||||||||
Cumulative investment proceeds, excess limit | $ 4,600 | ||||||||||||
Fair value of common shares | $ / shares | $ 1.807011 | ||||||||||||
Aggregate principal, converted | $ 11,796 | ||||||||||||
Conversion of debt, Shares issued | shares | 8,159,977 | ||||||||||||
Discounted price of conversion (in dollars per share) | $ / shares | $ 1.45 | ||||||||||||
Unpaid interest, converted | $ 1,063 | ||||||||||||
Conversion of debt interest, Shares issued | shares | 735,148 | ||||||||||||
Loss on conversion of note | $ 5,470 | ||||||||||||
Unamortized debt discount due to beneficial conversion feature | $ 6,767 | ||||||||||||
Effective interest rate | 13.50% | 13.50% | |||||||||||
Interest expense, stated interest rate | $ 0 | $ 43 | |||||||||||
Amortization of debt issuance cost | 0 | 25 | |||||||||||
Loss on notes | 9,344 | ||||||||||||
Loss on accrued interest | 1,046 | ||||||||||||
Gain on extinguishment of derivative liability | 4,920 | ||||||||||||
Convertible notes | $ 0 | 0 | |||||||||||
Notes payable | $ 47,500 | $ 20,000 | |||||||||||
2018 BASF Venture Capital and Entrepreneurs Fund L.P. Notes | |||||||||||||
Debt Instrument [Line Items] | |||||||||||||
Aggregate principal | $ 5,862 | ||||||||||||
Number of tranches | tranche | 3 | 3 | 3 | ||||||||||
Share price trigger (in dollars per share) | $ / shares | $ 16.39 | ||||||||||||
Accrued interest rate trigger, first anniversary | 8% | ||||||||||||
Accrued interest rate trigger, conversion period | 15% | ||||||||||||
Threshold number of days for interest calculation | 365 days | ||||||||||||
2018 Octopus Notes | |||||||||||||
Debt Instrument [Line Items] | |||||||||||||
Aggregate principal | $ 2,622 | ||||||||||||
Number of tranches | tranche | 2 | 2 | |||||||||||
Share price trigger (in dollars per share) | $ / shares | $ 15.10 | ||||||||||||
Accrued interest rate trigger, first anniversary | 8% | ||||||||||||
Accrued interest rate trigger, conversion period | 12% | ||||||||||||
Threshold number of days for interest calculation | 365 days | ||||||||||||
2019 Octopus, EF, and Other Notes | |||||||||||||
Debt Instrument [Line Items] | |||||||||||||
Aggregate principal | $ 3,681 | ||||||||||||
Number of tranches | tranche | 2 | 2 | |||||||||||
Share price trigger (in dollars per share) | $ / shares | $ 0.001861 | ||||||||||||
Accrued interest rate trigger, conversion period | 10% | ||||||||||||
Threshold number of days for interest calculation | 365 days | ||||||||||||
Debt instrument price per senior share | $ / shares | $ 11.19 | ||||||||||||
Debt discount - bifurcation of redemption feature | $ 2,608 | ||||||||||||
Term Loan Facility Agreement | |||||||||||||
Debt Instrument [Line Items] | |||||||||||||
Effective interest rate | 26.20% | 26.20% | 26.20% | ||||||||||
Aggregate principal | $ 739 | ||||||||||||
Debt term | 6 months | ||||||||||||
Monthly interest rate | 1.25% | ||||||||||||
Notes payable | $ 0 | $ 0 | 0 | ||||||||||
Interest expense of notes payable | $ 0 | $ 19 | $ 19 | $ 0 | |||||||||
Publicly Traded Market | 2019 Octopus, EF, and Other Notes | |||||||||||||
Debt Instrument [Line Items] | |||||||||||||
Share price trigger (in dollars per share) | $ / shares | $ 14.61 |
COMMITMENTS AND CONTINGENCIES_3
COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands, $ in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 USD ($) | Dec. 31, 2021 USN ($) | |
COMMITMENTS AND CONTINGENCIES. | ||
Capital expenditures to be paid in the future | $ 1,087 | $ 1,422 |
STOCKHOLDERS' EQUITY (Details_2
STOCKHOLDERS' EQUITY (Details) | 6 Months Ended | 12 Months Ended | ||
Jun. 29, 2022 shares | May 27, 2022 shares | Jun. 30, 2022 Vote shares | Dec. 31, 2021 Vote shares | |
Class of Stock [Line Items] | ||||
Number of votes, common shares | Vote | 1 | 1 | ||
Preferred shares, outstanding (in shares) | 0 | 0 | ||
Preferred stock available for issuance | 10,000,000 | 10,000,000 | ||
Investor relations services | ||||
Class of Stock [Line Items] | ||||
Issuance of common shares to vendor (in shares) | 22,473 | |||
Internet advertisement contract services | ||||
Class of Stock [Line Items] | ||||
Issuance of common shares to vendor (in shares) | 360,000 |
STOCKHOLDERS' EQUITY - Common_2
STOCKHOLDERS' EQUITY - Common Stock Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Feb. 23, 2021 | Jun. 30, 2022 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Weighted Average Remaining Contractual Term (years) | ||||||
Warrants outstanding at beginning | 5 years | |||||
Warrants outstanding at end | 5 years | |||||
Common Stock Warrants | ||||||
Number of shares | ||||||
Warrants outstanding beginning (in shares) | 985,533 | |||||
Exercised (in shares) | 0 | 0 | 0 | |||
Warrants outstanding at end (in shares) | 985,533 | 985,533 | 985,533 | |||
Weighted-Average Exercise Price | ||||||
Warrants outstanding beginning (in dollars per share) | $ 2 | |||||
Warrants outstanding at end (in dollars per share) | $ 2 | $ 2 | $ 2 | |||
Weighted Average Remaining Contractual Term (years) | ||||||
Warrants outstanding at end | 3 years 7 months 24 days | 3 years 7 months 24 days | ||||
Warrants issued | 985,533 | 0 | 0 | 0 | ||
Warrants exercisable price | $ 2 | $ 0.91 | $ 0.91 | $ 0.91 | ||
Fair value of warrant | $ 896 | $ 896 | $ 896 | |||
Pre Funded Warrants | ||||||
Number of shares | ||||||
Warrants outstanding beginning (in shares) | 2,168,000 | |||||
Granted (in shares) | 2,168,000 | |||||
Warrants outstanding at end (in shares) | 2,168,000 | 2,168,000 | 2,168,000 | |||
Weighted-Average Exercise Price | ||||||
Warrants outstanding beginning (in dollars per share) | $ 0.01 | |||||
Granted (in dollars per share) | $ 0.01 | |||||
Warrants outstanding at end (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | |||
Weighted Average Remaining Contractual Term (years) | ||||||
Warrants issued | 2,168,000 | 0 | 0 | 0 | ||
Warrants exercisable price | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | ||
Fair value of per warrant | 1.99 | 1.99 | ||||
Exercise less amount | $ 2 | $ 2 | ||||
Proceeds from Warrant | $ 4,314 |
SHARE-BASED COMPENSATION - Sh_2
SHARE-BASED COMPENSATION - Share option activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | |
Number of Shares | ||||
Options outstanding at beginning (in shares) | 1,953,882 | 1,810,749 | 160,317 | |
Exercised (in shares) | (1,424,622) | 0 | ||
Cancelled (in shares) | (405,936) | (86,967) | ||
Forfeited (in shares) | (16,500) | (136,221) | (90,729) | |
Granted (in shares) | 2,109,912 | 1,828,128 | ||
Options outstanding at end (in shares) | 1,937,382 | 1,953,882 | 1,810,749 | 160,317 |
Options exercisable (in shares) | 708,624 | 336,556 | ||
Vested and expected to vest (in shares) | 1,937,382 | 1,953,882 | ||
Weighted-Average Exercise Price | ||||
Options outstanding at beginning (in dollars per share) | $ 1.72323 | $ 0.06143 | $ 1.18311 | |
Exercised (in dollars per share) | 0.01447 | |||
Cancelled (in dollars per share) | 0.06452 | 0.65226 | ||
Forfeited (in dollars per share) | 2 | 0.00100 | 1.25578 | |
Granted (in dollars per share) | 1.68113 | 0.05051 | ||
Options outstanding at end (in dollars per share) | 1.72087 | 1.72323 | $ 0.06143 | $ 1.18311 |
Options exercisable (in dollars per share) | 1.23685 | 0.39318 | ||
Vested and expected to vest (in dollars per share) | $ 1.72087 | $ 1.72323 | ||
Weighted-Average Remaining Contractual Term : | ||||
Weighted-Average Remaining Contractual Term (in Years) | 8 years 9 months 21 days | 9 years 3 months 21 days | 9 years 8 months 12 days | 7 years 3 months 21 days |
Options exercisable weighted average remaining contractual term | 8 years 8 months 15 days | 9 years 1 month 24 days | ||
Vested and expected to vest outstanding weighted average remaining contractual term | 8 years 9 months 21 days | 9 years 3 months 21 days | ||
Weighted- Average Fair Value at Grant Date : | ||||
Weighted- Average Fair Value at Grant Date at beginning (in dollars) | $ 1.12355 | $ 3.46867 | $ 8.57245 | |
Weighted- Average Fair Value at Grant Date at end (in dollars) | $ 1.12553 | $ 1.12355 | $ 3.46867 | $ 8.57245 |
Aggregate Intrinsic Value, Options outstanding (in dollars) | $ 465 | |||
Aggregate Intrinsic Value, Options exercisable | $ 541 | 465 | ||
Aggregate Intrinsic Value, Vested and expected to vest | $ 541 | $ 465 |
SHARE-BASED COMPENSATION - St_2
SHARE-BASED COMPENSATION - Stock Based Compensation (Details) $ in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USN ($) | Dec. 31, 2021 USD ($) | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Total | $ 97 | $ 75 | $ 195 | $ 6,095 | $ 6,196 | $ 6,196 |
Research and development | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Total | 38 | 24 | 78 | 2,931 | 2,982 | |
Selling, general and administrative | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Total | $ 59 | $ 51 | $ 117 | $ 3,164 | $ 3,214 |
SHARE-BASED COMPENSATION - Ad_2
SHARE-BASED COMPENSATION - Additional information (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
Feb. 28, 2021 | Feb. 23, 2021 | Jun. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 14, 2018 | Jul. 15, 2014 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Expiration term | 10 years | 10 years | ||||||
Options granted (in shares) | 2,109,912 | 1,828,128 | ||||||
Granted (in dollars per share) | $ 1.68113 | $ 0.05051 | ||||||
Vested shares | 0 | |||||||
Weighted-average grant-date fair value (in dollars per share) | $ 1.14 | $ 0.04 | ||||||
Exercisable options (in shares) | 708,624 | 708,624 | 336,556 | |||||
Unrecognized compensation costs | $ 1,122 | $ 1,122 | $ 1,300 | |||||
Intrinsic value of options exercised | $ 2,400 | |||||||
Exercised (in shares) | 1,424,622 | 0 | ||||||
Option vested in fair value | $ 6,600 | |||||||
Options | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Expiration term | 10 years | |||||||
Options | Exercise Price Range One | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Options granted (in shares) | 336,557 | |||||||
Granted (in dollars per share) | $ 0.001 | |||||||
Options | Exercise Price Range Two | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Options granted (in shares) | 66,029 | |||||||
Granted (in dollars per share) | $ 2 | |||||||
Options | Employees and Consultants | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Options granted (in shares) | 1,828,128 | |||||||
Options | Employees, Directors and Consultants | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Expiration term | 10 years | |||||||
Options granted (in shares) | 1,707,326 | |||||||
Granted (in dollars per share) | $ 2 | |||||||
Vesting period | 4 years | |||||||
Investment Agreement | Options | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Maximum aggregate number of shares under grant | 458,316 | 175,292 | ||||||
Maximum percentage of shares to be granted | 15% | |||||||
Expiration term | 10 years | 10 years | ||||||
2021 Plan | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Options granted (in shares) | 2,275,000 | 0 | 0 | |||||
Percentage of outstanding shares | 4% | |||||||
2021 Plan | Options | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||
Options granted (in shares) | 402,586 |
SELLING, GENERAL AND ADMINIST_6
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | ||||||
Salaries and benefits | $ 504 | $ 507 | $ 1,005 | $ 4,242 | $ 5,366 | $ 908 |
Rent and property tax (benefit)/expense | (12) | 3 | 16 | 16 | 24 | 62 |
Insurance | 165 | 172 | 331 | 253 | 486 | |
Utilities | 1 | 1 | 2 | 2 | 4 | 1 |
Sales and marketing | 247 | 83 | 434 | 105 | 749 | 96 |
Legal and professional fees | 449 | 569 | 738 | 691 | 1,132 | 625 |
Other selling, general, and administrative expenses | 16 | 10 | 85 | 19 | 308 | 15 |
Total | $ 1,370 | $ 1,345 | $ 2,611 | $ 5,328 | $ 8,069 | $ 1,707 |
DEFINED CONTRIBUTION PENSION _3
DEFINED CONTRIBUTION PENSION (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
DEFINED CONTRIBUTION PENSION | |||
Amounts owed to the pension scheme | $ 0 | $ 0 | $ 0 |
DEFINED CONTRIBUTION PENSION _4
DEFINED CONTRIBUTION PENSION - Pension cost (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
DEFINED CONTRIBUTION PENSION | ||||||
Total pension cost | $ 39 | $ 33 | $ 80 | $ 65 | $ 140 | $ 114 |
Research and development | ||||||
DEFINED CONTRIBUTION PENSION | ||||||
Total pension cost | 26 | 24 | 53 | 48 | 98 | 83 |
Selling, general and administrative | ||||||
DEFINED CONTRIBUTION PENSION | ||||||
Total pension cost | $ 13 | $ 9 | $ 27 | $ 17 | $ 42 | $ 31 |
RELATED PARTY TRANSACTIONS (D_2
RELATED PARTY TRANSACTIONS (Details) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||
Jan. 27, 2022 $ / shares shares | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2021 USN ($) | Dec. 31, 2020 USN ($) | |
Related Party Transaction [Line Items] | |||||||||
Notes Payable | $ 47,500 | $ 20,000 | |||||||
Accounts payable and accrued expenses [Member] | |||||||||
Related Party Transaction [Line Items] | |||||||||
Related party payable | $ 18 | $ 18 | $ 18 | $ 0 | |||||
Selling, general and administrative | |||||||||
Related Party Transaction [Line Items] | |||||||||
Related party expenses | $ 29 | $ 18 | $ 47 | $ 25 | 65 | $ 7 | |||
Owner | Securities Exchange | |||||||||
Related Party Transaction [Line Items] | |||||||||
Reimbursement expenses incurred | 66 | ||||||||
Related party payable | 0 | ||||||||
Family member of a Director | Consulting services | |||||||||
Related Party Transaction [Line Items] | |||||||||
Reimbursement expenses incurred | 35 | ||||||||
Related party payable | $ 0 | ||||||||
Octopus Share Purchase [Member] | |||||||||
Related Party Transaction [Line Items] | |||||||||
Sale of Stock, Number of Shares Issued in Transaction | shares | 1,000,000 | ||||||||
Sale of Stock, Price Per Share | $ / shares | $ 2 |
SUBSEQUENT EVENTS (Details)_2
SUBSEQUENT EVENTS (Details) - $ / shares | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||
Jan. 27, 2022 | Jan. 01, 2022 | Feb. 23, 2021 | Jul. 31, 2022 | Feb. 28, 2022 | Jun. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Jan. 24, 2020 | |
Subsequent Event [Line Items] | ||||||||||
Options granted (in shares) | 2,109,912 | 1,828,128 | ||||||||
Options vesting term | 8 years 9 months 21 days | 9 years 3 months 21 days | ||||||||
Expiration term | 10 years | 10 years | ||||||||
Options exercise price | $ 1.807011 | |||||||||
2021 Plan | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Options granted (in shares) | 2,275,000 | 0 | 0 | |||||||
Subsequent events | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Options vesting term | 4 years | |||||||||
Expiration term | 10 years | |||||||||
Options exercise price | $ 2 | $ 2 | ||||||||
Issuance of common stock (in shares) | 1,000,000 | |||||||||
Issuance of common shares to vendor (in shares) | 12,500 | |||||||||
Subsequent events | 2021 Plan | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Number of shares increased | 1,022,172 | |||||||||
Reserved for future issuance | 3,297,172 | |||||||||
Subsequent events | Enterprise Management Incentive Options | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Options granted (in shares) | 225,700 | |||||||||
Subsequent events | ISO Options | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Options granted (in shares) | 150,000 | |||||||||
Subsequent events | NQSO Options | ||||||||||
Subsequent Event [Line Items] | ||||||||||
Options granted (in shares) | 92,300 |